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Abstract 
Introduction 
EGFR, MTOR and COX2 are up regulated in malignant pleural mesothelioma (MPM). In 
this study we aimed to determine the expression of Lipoxygenase enzymes (LOX), absence 
of PTEN protein expression and the cytotoxic effect of EGFR, MTOR and COX2 inhibitors 
in MPM.  
Materials and Methods  
Immunohistochemical analysis was performed in 93 archival MPM tissue samples to 
determine the expression of 5-LOX and 12-LOX and PTEN protein. The COX-2 positive 
cell lines MSTO-211H, NCI-H2052, NCI-H2452 (mesothelioma) and A549 (lung cancer) 
were utilised. All cell lines were tested for EGFR, KRAS and BRAF mutations. Cells were 
incubated with Cetuximab, Gefitinib, Rapamycin, Ku0063794 (MTOR kinase inhibitor) 
and Celecoxib as single agents and in combinations and analysed using the MTS assay.   
Results 
Positive 5-LOX expression was seen in 73% and positive 12-LOX expression was seen in 
83% of MPM samples. PTEN protein expression was absent in 27% of the samples.  A549 
cells had a KRAS missense mutation at codon 12. No other EGFR, KRAS and BRAF 
mutations were identified in any of the cell lines. Cetuximab showed 50% cell growth 
inhibition in MSTO-211H cells at a concentration of 1.6 µM. All other cell lines were 
resistant to Cetuximab. All cell lines were resistant to Gefitinib. Rapamycin and 
Ku0063794 demonstrated 50% cell growth inhibition in NCI-H2052, NCI-H2452 and 
A549. Celecoxib demonstrated 50% cell growth inhibition in all cell lines. Cetuximab and 
Gefitinib were combined in turn with Rapamycin, Ku0063794 and Celecoxib.  Cetuximab 
when combined with Celecoxib (NCI-H2052, NCI-H2452 and A549 cells) and Ku0063794 
(MSTO-211H cells) demonstrated significant growth inhibition.  
Conclusions  
Our study suggests that 5LOX and 12LOX are expressed in the majority and PTEN protein 
expression is absent is a significant proportion of MPM tissue samples.  Inhibition of 
MTOR pathway may be an important therapeutic strategy in patients with MPM.  
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PI3K phosphoinositide-3-kinase 
PIK3CA phosphoinositide-3-kinase catalytic alpha polypeptide 
PIP Phosphatidylinositol phosphate 
PKA Protein kinase A 
PLAGF Placental Growth Factor 
PR Partial response 
PTEN phosphatase and tensin homolog 
RIDEP Repeatedly identified differentially expressed protein 
RNA Ribonucleic acid 
RR Response rate 
SD Stable response 
SDS Sodium dodecyl sulphate 
SEM Standard error of mean 
SSC Side scatter 
SV40 Simian Virus 40 
tBID Truncated BID 
TBS Tris buffered saline 
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TGF-a Transforming Growth Factor alpha 
TKI tyrosine kinase inhibitors 
TNF-R1 Tumour necrosis factor alpha receptors 
TNFα Tumour necrosis factor alpha 
TRAIL TNF related apoptosis-inducing ligand 
TSC Tuberous sclerosis complex 
VEGF Vascular Endothelial Growth Factor 
VEGF Vascular Endothelial Growth Factor Receptor 
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Chapter 1.  Malignant pleural 
mesothelioma 
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1.1 Incidence 
Mesothelium is a single layer of mesothelial cells that line the serosal cavities such as 
pleura, pericardium, peritoneum and tunica vaginalis of testes. Malignant pleural 
mesothelioma (MPM) is a rare, aggressive tumour of the mesothelial cells of the pleura. 
The incidence of MPM is on the rise in most parts of the world including Europe, Australia 
and Asia. In the United States of America the incidence of MPM reached its peak in the 
early to mid 1990’s and is now on a downward trend (Weill, Hughes et al. 2004). Great 
Britain, Australia and Belgium have the highest annual crude incidence rates of 30 cases 
per million population with United States of America and Japan having annual crude 
incidence rates of approximately 9 and 7 cases per million respectively (Figure 1.1) 
(Bianchi and Bianchi 2007). Britain has one of the highest mortality rates from MPM and it 
is predicted that the mortality rates in Britain are likely to peak in 2016 with over 2000 
deaths per year (Tan, Warren et al. 2010). It is estimated that there will have been be over 
60000 predicted deaths from mesothelioma in UK alone from 2007 onwards (Tan, Warren 
et al. 2010). Similar predictions in other parts of Western Europe suggest that the incidence 
of MPM is on the rise (Peto, Decarli et al. 1999).  
In emerging economies such as India and China, the use of asbestos is widespread with 
little or no government regulation. They do not report mesothelioma cases and hence it is 
very difficult to analyse the burden in these countries. A recently published study attempted 
to predict the number of cases of mesothelioma in countries that do not report such cases 
using mathematical models and extrapolating from those countries who do report (Park, 
Takahashi et al. 2011). The authors identified 56 countries who reported data on the use of 
asbestos and mesothelioma frequency and 33 countries who reported data only on the use 
of asbestos, but not on mesothelioma. These 89 countries represented 82.6% of the global 
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population in 2000. Among the countries which reported data for asbestos and 
mesothelioma, the authors found a statistically significant linear relationship between the 
cumulative use of asbestos from 1920 to 1970 and the cumulative deaths from 
mesothelioma from 1984 to 2008. In the 56 countries that recorded data on mesothelioma 
the cumulative asbestos use was 51.2 million metric tons and the total number of 
mesothelioma deaths in the 15 year period was 174,300. Using this data, the authors 
predicted that 14.2 million metric tons of asbestos was used in the 33 countries that did not 
report data on mesothelioma and estimated that 38,900 deaths due to mesothelioma may 
have occurred in this 15 year period. The leading countries in this group were Russia 
(21,300 deaths), Kazakhstan (6,500 deaths), China (5,100 deaths), India (2,200 deaths) and 
Thailand (500 deaths). Despite the ban on the use of asbestos in most developed countries 
the cumulative useage of asbestos has increased from 65 million metric tons in 1970 to 124 
million metric tons currently. Most of the increase in the use of asbestos is likely  from the 
developing countries with the 33 countries that did not report data on mesothelioma 
quadrupling its use in the same period. 
    
4 
 
 
 
Figure 1.1  Incidence of Mesothelioma. Crude Incidence rates of Mesothelioma per 100 million population in Western Europe, 
Australia, USA and Japan. Graph drawn by incorporating data obtained from (Bianchi and Bianchi 2007).  
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1.2 Causes and pathophysiology 
In 80% of cases, MPM can be attributed to asbestos fibre exposure (Carbone, Kratzke et al. 
2002) with a median latency of at least 32 years (Lanphear and Buncher 1992). Simian 
virus 40 (SV40) has also been implicated as one of the other potential causes of MPM (De 
Luca, Baldi et al. 1997; Testa, Carbone et al. 1998; Carbone, Kratzke et al. 2002). Familial 
transmission in an autosomal dominant fashion has been reported in the Cappadocian 
region of Turkey (Roushdy-Hammady, Siegel et al. 2001; Dogan, Baris et al. 2006). 
1.2.1 Asbestos and mesothelioma 
Asbestos is a natural fibrous mineral that is fire, acid, corrosive and stress resistant, flexible 
and durable. These excellent properties of asbestos led to its widespread commercial use for 
more than a century in various industries such as construction, transportation and mining. 
There are two types of asbestos fibres; amphibole (crocidolite, amosite, anthrophyllite, 
tremolite and actinolite) and serpentine (chrysotile).  The exposure of humans to asbestos 
fibres resulted in its harmful effects and was first reported in 1907 by Murray in his report 
to the Departmental Committee, London, among textile workers in Great Britain (Baldi 
2008). Wenger et al (1960) described a case series of 33 patients with histologically proved 
MPM who were associated with the Cape asbestos field (South Africa) due to the probable 
exposure to crocidolite asbestos (Wagner, Sleggs et al. 1960) . Since then, there have been 
numerous reports of the detrimental effects of asbestos and its association with MPM, 
which led to the production and use of asbestos being ‘controlled’ in most parts of the 
world in the second half of 20th Century.  Most of the exposure to asbestos is of 
occupational origin with workers handling raw asbestos. However, MPM is also observed 
in patients with non occupational exposure to asbestos, such as in people living near 
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asbestos factories or end users of asbestos products. Although all commercial asbestos has 
the capacity to induce mesothelioma, the amphibole fibres such as crocidolite, and amosite 
have a higher carcinogenic potential than chrysolite with exposure specific risk of 
mesothelioma being 1:100:500 for chrysotile, amosite and crocidolite respectively 
(Hodgson and Darnton 2000). Various studies have demonstrated a dose response 
relationship between asbestos exposure and mesothelioma with the risk being greatest 
among those heavily exposed to asbestos (Seidman, Selikoff et al. 1986; Hansen, de Klerk 
et al. 1998; Iwatsubo, Pairon et al. 1998). A population based case controlled French study 
demonstrated a significant dose-response relationship between cumulative asbestos 
exposure and occurrence of MPM with the odds ratio increasing from 1.2 (95% CI 0.8-1.8) 
for low exposure category to 8.7 (95% CI 4.1 – 18.5) in the highest exposure category 
(Iwatsubo, Pairon et al. 1998). Peto et al (1982) demonstrated a linear dose respone 
relationship using a mathematical model in which the risk of mesothelioma increased with 
the third and fourth power of time since first exposure in a cohort of  North American 
insulators (Peto, Seidman et al. 1982). Newhouse et al (1985) studied the mortality rates in 
asbestos factory workers (3000 males, 1400 laggers and 700 women) of East London. They 
classified them into four categories depending upon the degree and duration of exposure 
and demonstrated that the mortality from mesothelioma increased according to the severity 
and the duration of exposure (Newhouse, Berry et al. 1985).  An Italian study evaluated the 
latency period of 2544 patients diagnosed with mesothelioma and demonstrated a median 
latency period of 44.6 years with a shorter latency period of 43 years among those patients 
who were occupationally exposed to asbestos and a longer latency period of 48 years 
among those patients non occupational exposure to asbestos (Marinaccio, Binazzi et al. 
2007). This may suggest that a high exposure to asbestos fibres (occupational) may have 
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less latency than low exposure to asbestos fibres (non occupational).  Analysis of 
mesothelioma trends in the United States demonstrated a life time risk of mesothelioma 
among males as approximately 2.1 x 10
-3 
for the 1925 – 1929 birth cohort with a downward 
trend in the incidence of mesothelioma in subsequent cohorts (Price and Ware 2004). 
Among the female population the life time risk of mesothelioma has remained constant at 
approximately 3.6 x 10
-4 
. The high risk  of mesothelioma in males is likely due to a high 
occupational exposure to asbestos in contrast to the low risk in females where the asbestos 
exposure has been mainly environmental or domestic (wives of men exposed to asbestos). 
One of the possible mechanisms of asbestos induced oncogenesis is failure of apoptosis via 
the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway. 
Inhalation of asbestos fibres such as crocidolite causes accumulation of macrophages in the 
lungs, which result in release of Tumour necrosis factor alpha (TNF ). Asbestos fibres also 
induce normal mesothelial cells to release TNFα in an autocrine and paracrine fashion and 
express TNF  receptors (TNF-R1). TNFα then acts on the NF-kB pathway resulting in 
failure of apoptosis. This allows the mesothelial cells that have undergone deoxyribonucleic 
acid (DNA) damage by the asbestos fibres to survive, resulting in increased chances of 
malignant transformation (Figure 1.2) (Yang, Bocchetta et al. 2006; Baldi 2008).  
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Figure 1.2 Pathophysiology of asbestos induced mesothelioma. Inhaled asbestos fibres are 
phagocytosed by the macrophages resulting in the release of TNFα. These fibres induce 
normal mesothelial cells to release TNFα in an autocrine and paracrine fashion and express 
TNF-R1. TNFα then acts on the NF-kB pathway resulting in failure of apoptosis. (Adapted 
from Baldi, A. (2008). Mesothelioma from bench side to clinic. New York, Nova 
Biomedical Books, page 107). 
1.2.2 SV40 and mesothelioma 
SV40 may act as a co-carcinogen along with asbestos fibres resulting in the development of 
malignant mesothelioma (Bocchetta, Di Resta et al. 2000).  SV40 infection of the human 
mesothelial cells results in cell survival. SV40 virus integrates itself into the mesothelial 
cells resulting in expression of SV40 tumour antigens (large antigen Tag; small antigen tag) 
(Bocchetta, Di Resta et al. 2000; Cacciotti, Libener et al. 2001; Yu and Alwine 2002; 
Carbone, Pass et al. 2003) . Cells infected with SV40 virus, when exposed to asbestos 
fibres may result in production of toxic oxygen free radicals and chromosomal aberrations 
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causing malignant transformation (Wang, Jaurand et al. 1987; Broaddus, Yang et al. 1996). 
Cacciotti et al (2005) demonstrated that a mesothelioma cell line (MMP) expressing SV40 
Tag was intrinsically more resistant to apoptosis when exposed to asbestos resulting in cell 
survival. (Cacciotti, Barbone et al. 2005). In the presence of Tag the cell survival was 
mediated through activation of PI3K/AKT pathway (Chapter 3) either independently or in 
response to growth factors such as hepatocyte growth factor in SV40 negative cell lines 
(Broaddus, Yang et al. 1996). 
However, the role of SV40 in MPM remains controversial. Manfredi et al (2005) did a PCR 
based analysis in 69 MPM tissue samples to detect SV40 large T antigen DNA and did not 
identify the gene in any of them arguing against the role of SV40 in MPM (Manfredi, Dong 
et al. 2005). Another similar study failed to demonstrate the presence of SV40 large T 
antigen DNA in 71 MPM tissue samples (Lopez-Rios, Illei et al. 2004). A large population 
in the United States received SV40 contaminated live polio virus during 1955-163. 
Epidemiological studies conducted failed to demonstrate an increased risk of MPM in this 
cohort of population when compared to another similar group of different birth cohort 
(Strickler, Rosenberg et al. 1998). 
1.2.3 Other causes of MPM 
There are various other factors which are known to cause MPM such as radiation therapy, 
erionite exposure and genetic predisposition. MPM is  known to occur as second 
malignancies in patients with primary cancers such as lymphomas and breast cancers who 
have received therapeutic radiation therapy and had a median latency of 4.3 years 
(Cavazza, Travis et al. 1996; Teta, Lau et al. 2007). MPM is found to be endemic in the 
Cappadocia, Turkey, resulting in 50% of the deaths in three small villages (Carbone, Emri 
et al. 2007). Pedigree studies have demonstrated an autosomal dominant pattern of 
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inheritance among the families suffering from MPM. The Cappadocian region is also 
dominated by volcanic rocks having a high concentration of the mineral erionite. The 
houses of the villages are made out of stone taken from the nearby mountains or rivers and 
have a high content of erionite. Exposure to erionite is strongly associated with the 
development of MPM in in vivo studies. MPM was seen in 100% (40/40) rats injected with 
erionite compared with 48% (19/40) of rats injected with asbestos (Zucali, Ceresoli et al. 
2011). The MPM epidemic in the Cappadocian region is likely due to high erionite 
exposure in genetically predisposed individuals.  
1.3 Pathology 
Histologically, MPM can be categorised as epithelioid, sarcomatoid or mixed (biphasic) 
phenotype containing both epithelioid and sarcomatoid elements (Figure 1.3). Epithelioid 
phenotype is associated with better prognosis (Ceresoli, Locati et al. 2001; O'Kane, 
Cawkwell et al. 2005). Immunohistochemical staining of various biomarkers are required to 
distinguish MPM from adenocarcinoma of lung or metastasis from other sites. A consensus 
statement from International Mesothelioma Interest Group recommended that markers 
should have either specificity or sensitivity greater than 80% (Husain, Colby et al. 2009). 
Immunohistochemical staining for pancytokeratin is useful as virtually all mesothelioma 
are positive except some rare sarcomatoid mesothelioma. The International Mesothelioma 
Interest Group recommends that at least two positive markers and two negative markers be 
used in addition to pancytokeratin. Virtually all epithelioid tumours are positive for 
Calretinin and Mesothelin. Keratin 5/6 is expressed in 75% to 100% , Wilms Tumour-1 
protein in 43% to 93% and Podoplanin in 86% to 100% of epithelioid mesothelioma. 
Thyroid transcription factor-1 is not expressed in mesothelioma. Similarly only 2% to 20% 
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of mesotheliomas express MOC-31, BG8 (Lewis-Y blood group), Ber-EP4, CD15 and 
Carcinoembryonic antigen. 
 
 
Figure 1.3 Histological microphotograph (original magnification X 40) of epithelioid, 
sarcomatoid and biphasic mesothelioma. Figure (A) demonstrated hematoxylin-eosin 
staining of epithelioid mesothelioma with clusters of cubiodal shaped epithelial 
mesothelioma cells. Figure (B) demonstrated hematoxylin-eosin staining of sarcomatoid 
mesothelioma with spindle shaped cells lying in a disorganised way. Figure (C) 
demonstrated hematoxylin-eosin staining of biphasic mesothelioma with epithelioid pattern 
in top right and sarcomatoid pattern in the bottom left. Reprinted from Allen TC. 
Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential 
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diagnosis of pleural biopsies. Arch Pathol Lab Med 2005;129:1415-20 with permission 
from Archives of Pathology & Laboratory Medicine. Copyright 2005. College of American 
Pathologists (Allen 2005). 
1.4 Staging 
An ideal staging system of MPM is difficult to define as MPM has an unusual growth 
pattern. It tends to grow along the parietal and visceral pleura invading the surrounding 
structures making it difficult to access the volume and spread of the tumour. In view of this 
many staging systems by various authors such as Butchart, Mattson, Sugarbaker, Chahinian 
have been suggested, but the most common staging system used is based on the TNM 
staging suggested by International Mesothelioma Interest Group (IMIG) (Rusch 1995). 
These are outlined in Table 1.1. 
 
Table 1.1 IMIG TNM staging for malignant pleural mesothelioma. 
Primary Tumour (T) 
T1 
       T1a 
 
        T1b 
Tumour limited to the ipsilateral parietal pleura, including mediastinal and 
diaphragmatic pleura No involvement of the visceral pleura 
Tumour involving the ipsilateral parietal pleura, including mediastinal and 
diaphragmatic pleura 
Scattered foci of tumour also involving the visceral pleura 
T2 Tumour involving each of the ipsilateral pleural surfaces (parietal, mediastinal, 
diaphragmatic, and visceral pleura) with at least one of the following features: 
. Involvement of diaphragmatic muscle 
. Confluent visceral pleural tumour (including the fissures) or extension of 
tumour from visceral pleura into the underlying pulmonary parenchyma 
T3 Describes locally advanced but potentially resectable tumour 
Tumour involving all of the ipsilateral pleural surfaces (parietal, mediastinal, 
diaphragmatic, and visceral pleura) with at least one of the following features: 
. Involvement of the endothoracic fascia 
. Extension into the mediastinal fat 
. Solitary, completely resectable focus of tumour extending into the soft tissues 
of the chest wall 
. Non transmural involvement of the pericardium 
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T4 Describes locally advanced technically unresectable tumour 
Tumour involving all of the ipsilateral pleural surfaces (parietal, mediastinal, 
diaphragmatic, and visceral) with at least one of the following features: 
. Diffuse extension or multifocal masses of tumour in the chest wall, with or 
without associated rib destruction 
. Direct transdiaphragmatic extension of tumour to the peritoneum 
. Direct extension of tumour to the contralateral pleura 
. Direct extension of tumour to one or more mediastinal organs 
. Direct extension of tumour into the spine 
. Tumour extending through to the internal surface of the pericardium with or 
without a pericardial effusion; or tumour involving the myocardium 
Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes 
N2 Metastases in the subcarinal or the ipsilateral mediastinal lymph nodes, 
including the ipsilateral internal mammary nodes 
N3 Metastases in the contralateral mediastinal, contralateral internal mammary, 
ipsilateral, or contralateral supraclavicular lymph nodes 
Metastasis (M) 
MX Presence of distant metastases cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
Stage 
Stage 1a 
Stage 1b 
T1aN0M0 
T1bN0M0 
Stage II T2N0M0 
Stage III Any T3N0 
Any N1M0 
Any N2M0 
Stage IV Any T4 
Any N3 
Any M1 
 
1.5 Prognostic biomarkers 
Identification of prognostic biomarkers may assist clinicians in appropriate prognostic 
evaluation and treatment planning of patients with MPM. One of the earliest studies to 
evaluate the prognostic factors in MPM was the Surveillence, Epidemiology and End 
Results Program review, which evaluated 1,475 patients with MPM and demonstrated that 
age, sex, stage, treatment and geographical area predicted patient survival (Spirtas, 
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Connelly et al. 1988). Various prognostic markers, both clinical and biomarkers have been 
identified in many studies (Ambrogi, Mineo et al. 2012). The CALGB and the EORTC 
groups developed scoring systems to discriminate between good and poor prognostic 
groups in patients receiving systemic treatments (Curran, Sahmoud et al. 1998; Herndon, 
Green et al. 1998). The CALGB group defined six patient groups based on the performance 
status, age, weight loss, chest pain, haemoglobin and WBC levels (Herndon, Green et al. 
1998). The median survival of the six groups (poor to good prognosis) ranged from 1.4 
(95% CI 0.5 – 3.6) months to 13.9 (95% CI 11.1 – 31.4) months and 1 year survival ranged 
from 0 to 63% (95% CI 46% – 77%).   The EORTC group divided patients into two 
prognostic groups depending upon the sex, performance status, histology (probability of 
diagnosis and histological subtype) and WBC count. The median survival of the poor and 
good prognosis groups was  5.5 months and 10.8 months respectively, and 1 year survival 
was 12% (95% CI 4-20) and  40% (95% CI 30-50) respectively (Curran, Sahmoud et al. 
1998). A recent multivariate analysis of an international database of 3101 patients from 15 
centers, developed by the International Association for the Study of Lung Cancer Staging 
Committee showed that age (<50 versus >65 years; HR 1.31, p=0.0006), sex (HR 1.28, 
p=0.0002), TNM staging (stage IV versus I HR 1.86, p= <0.0001), histology ( epithelial 
versus others; HR 1.7, p= <0.001) and the intent of surgery (palliative versus curative; HR 
1.71, p= <0.0001) significantly influenced survival (Rusch, Giroux et al. 2012). Various 
biomarkers have also been analysed as a prognostic biomarkers, but none have been 
successfully translated into clinical practice (Table 1.2) (Ambrogi, Mineo et al. 2012). 
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Table 1.2 Biomarkers associated with poor prognosis in MPM. Adapted and modified from 
(Ambrogi, Mineo et al. 2012) 
Functions Poor prognostic Biomarkers 
Direct relationship Inverse relationships 
Growth Factors COX-2  
 MM2 & MM9  
 EGF  
 VEGF  
 PLGF  
 FGF  
 PDGFR  
 HGF  
Apoptosis Bcl-xL TRAIL 
 PI3K BAX 
 Glucose transporter 1 PTEN loss 
Cell cycle p53 p27 
 MIB-1/Ki67 p27 kip 1 
Others ERK Calretinin 
 NFkβ D2-40 
 ERCC1  
 Aquaporin 1  
Serum Biomarkers MPF Glycoprotein 90K 
 Osteopontin  
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1.6 Treatment options 
1.6.1 Surgery 
The surgical options available to treat MPM are very limited due increased incidence of 
regional and distant recurrence. Due to the nature of its growth and spread pattern, 
obtaining a completely clear (R0) resection margin is extremely difficult. Palliative 
pleurectomy/ decortication (P/D) and extrapulmonary pneumonectomy (EPP) are the 
commonest procedures used for surgically removing the tumour. Video-assisted 
thoracoscopy is also used for diagnostic and palliative purposes. P/D involves removal of 
parietal and visceral pleura, pericardium and diaphragm. EPP involves en block removal of 
parietal and visceral pleura, lung, mediastinal lymph nodes, pericardium, and diaphragm. 
The choice of surgical modality is controversial due to lack of trial data and is dependent of 
the fitness level of patient, co morbidities, extent of disease and availability of 
multimodality treatments such as chemotherapy and radiotherapy (Tsao, Wistuba et al. 
2009). The MARS trial in UK randomised patients to receiving either trimodality treatment 
with induction chemotherapy followed by EPP and radiation therapy versus no EPP 
(Treasure, Lang-Lazdunski et al. 2011). A total of 112 patients were registered and 50 were 
randomised to EPP (n=24) or no EPP (n=26). The hazard ratio for overall survival was 2.75 
(p=0.016) in favour of no EPP group. The median survival in EPP group was 14.4 months 
and in the no EPP group was 19.5 months. The quality of life seemed to be lower in EP 
group (n=12) compared to EPP group (n=19), but this was not statistically significant.  
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1.6.2 Radiotherapy 
Radiotherapy can be used in MPM in adjuvant setting post EPP or prophylactically at the 
surgical manipulation site to prevent local recurrence. A Phase II trial has shown that 
adjuvant radiotherapy (54 Gy) added to EPP results in reduced local recurrence rates and 
improved survival in stage I and II disease (Rusch, Rosenzweig et al. 2001). The potential 
benefit of prophylactic radiotherapy to the procedural sites of surgical pleural manipulation 
is debateable. Currently the Phase III Trial of Prophylactic Irradiation of Tracts in Patients 
with Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention trial 
(PIT) and the Surgical and large bore pleural procedures in malignant pleural mesothelioma 
and radiotherapy trial (SMART) are ongoing in the UK to ascertain the benefits of 
prophylactic tract radiotherapy in MPM. 
1.6.3 Chemotherapy 
Most of the chemotherapy based studies in MPM conducted in the 20
th
 century were often, 
non-randomised Phase II trials with very few patients enrolled into those trials. The 
response rates of single agent chemotherapy rarely exceeded 20%. A meta-analysis of 83 
clinical trials (88 treatment arms) published between 1965 and 2001 was published in 2002 
(Berghmans, Paesmans et al. 2002). Of these 83 trials, 80 were single arm Phase II trials 
and three were randomised Phase II trials.  This study grouped the studies into four groups 
depending upon the treatment arms; Cisplatin based regimes without Doxorubicin (n=20); 
Doxorubicin based regimes without Cisplatin (n=8); Cisplatin plus Doxorubicin (n=6); 
other chemotherapy drug regimes (n=54). The most active single agent was Cisplatin and 
the combination of Cisplatin and Doxorubicin demonstrated the highest response rate 
(28.5%; p=<0.001).  Combination chemotherapy was better than single agent chemotherapy 
(22.6% versus 11.6%; p=<0.001).  
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The current standard for systemic treatment of advanced MPM is combination 
chemotherapy with Cisplatin and Pemetrexed or Raltitrexed (Stahel, Weder et al. 2009). A 
large Phase III trial in 456 patients showed that the combination chemotherapy with 
Cisplatin and Pemetrexed compared to Cisplatin alone had a better response rate (41.3% 
versus 16.7%; p < 0.0001), improved progression free survival (5.7 months versus 3.9 
months; P = 0.001) and median overall survival (12.1 months versus 9.3 months; p = 0.02) 
(Vogelzang, Rusthoven et al. 2003). Therefore this regimen is considered as standard first 
line treatment for advanced MPM in most parts of the world. Administration of Pemetrexed 
has previously been associated with severe, unpredictable and sometimes life threatening 
toxicities such as myelosupression and gastrointestinal toxicity, which occurred as a result 
of Folate deficiency. Pre administration of Folate along with Vitamin B12 during the 
course of Pemetrexed administration significantly reduced the toxicities (Adjei 2004). 
Baseline deficiency of Folate and Vitamin B12 results in increased homocysteine levels. 
Raised pre-treatment homocysteine levels may be a more sensitive measure of functional 
folate status rather than RBC or serum folate levels and may more accurately predict 
toxicities from Pemetrexed (Niyikiza, Baker et al. 2002). The combination of Raltitrexed 
with Cisplatin has also been demonstrated to improve overall survival, when compared 
with Cisplatin alone (11.4 months versus 8.8 months; p = 0.048), in a Phase III randomised 
trial of 250 patients (van Meerbeeck, Gaafar et al. 2005). Raltitrexed and Cisplatin may be 
more cost effective compared to Pemetrexed and Cisplatin with similar efficacy in the first 
line treatment of MPM (Woods, Paracha et al. 2012).  
Currently there is no widely approved salvage regimen after failure of first line treatment 
and all patients are encouraged to enter into clinical trials (Ceresoli, Zucali et al. 2010).  
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1.6.4 Targeted therapy 
1.6.4.1 Epidermal Growth Factor Receptor (EGFR) inhibitors 
The role of EGFR and its inhibition in MPM is discussed in Chapter 2.   
1.6.4.2 PTEN/AKT/MTOR inhibitors 
The role of PTEN/AKT/MTOR and its inhibition in MPM is discussed in Chapter 3.    
1.6.4.3 Vascular Endothelial Growth Factor inhibitor  
Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor 
receptor (VEGFR) plays an important role in tumour angiogenesis (See appendix B for list 
of all drugs and targets for the targeted biological agents used). VEGF combines with Type 
1(Flt-1) and 2(KDR) VEGFR resulting in activation of various intracellular signalling 
pathways giving rise to endothelial cell proliferation and new vessel formation. The 
significant role played by VEGF- VEGFR pathway has made it a major target for the 
development of anti-cancer drugs. The first VEGF inhibitor antibody that has shown 
promising results in clinical trials and has been approved by the FDA and was 
Bevacizumab (Avastin ; Genentech Inc). Bevacizumab is currently used in colorectal 
cancer, non small cell lung cancer, glioblastoma and renal cell cancer. 
VEGF has shown to be expressed in the serum as well as in the tumour samples of MPM 
patients with level of VEGF increasing in advanced disease (Linder, Linder et al. 1998; 
Konig, Tolnay et al. 1999; Ohta, Shridhar et al. 1999; Konig, Tolnay et al. 2000; Aoe, 
Hiraki et al. 2006; Yasumitsu, Tabata et al. 2010). Bevacizumab in combination with 
Erlotinib (OSI-774, Tarceva OSI Pharmaceuticals) did not show any significant 
responses in 24 MPM patients (Jackman, Kindler et al. 2008). Bevacizumab in combination 
with chemotherapy such as Cisplatin and Gemcitabine also did not demonstrate any 
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significant clinical benefit (T. Karrison, H. L. Kindler et al. 2007). However, when 
Bevacizumab was combined with Cisplatin and Pemetrexed in the U.S. Intergroup Phase II 
trial in 45 patients the median overall survival seen was 15.3 months (95% CI, 11.3-23.5) 
which was higher than 12.1 months seen in patients receiving Cisplatin and Pemetrexed in 
the study by Volgelzang et al (2003) (Vogelzang, Rusthoven et al. 2003; S. M. Radaideh 
2010). The French MAPS trial was a randomised Phase II/III multicentre trial involving 
111 patients comparing the addition of   Bevacizumab to Cisplatin and Pemetrexed with 
Cisplatin and Pemetrexed only. There was an improvement in six month disease control 
rate in favour of the Bevacizumab arm (73.5% versus 43.2%; P=0.01) (G. Zalcman, J. 
Margery et al. 2010). 
VEGFR and multi-targeted tyrosine kinase inhibitors such as Vatalanib (PTK787, Bayer & 
Novartis),  Sorafinib (Nexavar , Bayer), Semaxanib (SU5416, SUGEN) and Thalidomide 
have shown limited activity in MPM (Zucali, Ceresoli et al. 2011). A Phase II trial of the 
oral pan-VEGFR tyrosine kinase inhibitor, Cediranib (AZD2171, Astra Zeneca), after 
failure of first line platinum based chemotherapy in 54 patients, demonstrated 9% response 
rate and 34% of patients had stable disease (Garland, Chansky et al. 2011). 
1.6.4.4 Ribonuclease inhibitor 
Ranpirnase (Onconase , Tamir Biotechnology, NJ) is an enzyme that breaks down RNA 
and inhibits protein synthesis. A Phase II trial of Ranpirnase in MPM in 105 patients 
demonstrated partial response in four patients, minimal regression in two patients and 35 
patients had stable disease. The 1 year survival rate was 34.3% and 2 year survival rate was 
21.6% which were higher than that of the historical control (n=337) of 27% and 12% 
respectively (Mikulski, Costanzi et al. 2002). In a larger Phase III randomised 
(unpublished) study Ranpirnase in combination with Doxorubicin was compared to 
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Doxorubicin alone in 413 patients. There was no difference seen in the overall survival 
between the two groups (11.1 versus 10.7 months; HR 1.02, 95% CI 0.82-1.26). However 
in 130 patients who were pretreated with one line of therapy there was a modest survival 
benefit seen (10.5 versus 9 months; HR 1.49, 95% CI 1.02-2.17) (M. Reck, M. Krzakowski 
et al. 2009). 
1.6.4.5 Histone deacetylase inhibitors  
Histones exist in acetylated or deacetylated form catalysed by histone acetyltransferase and 
histone deacetylase (HDAC). Equilibrium between the two forms of the histone is 
maintained by these enzymes. When histone proteins in deacetylated form are combined to 
DNA, the transcription of DNA is significantly inhibited acting as transcription repressors. 
Histone deacetylase inhibitors (HDACi) induce cell apoptosis by expressing genes 
associated with apoptosis and cell cycle arrest (Xu, Parmigiani et al. 2007). Vorinostat 
(Zolinza Merck) is an HDACi approved by FDA for use in patients with cutaneous T-
cell lymphoma. In the largest ever randomised Phase III VANTAGE 014 trial of Vorinostat 
in MPM recruiting 661 patients, Vorinostat was compared to placebo in patients pretreated 
with chemotherapy. This study did not demonstrate any benefit of Vorinostat in MPM with 
median overall survival being  30.7 week in the Vorinostat arm compared to 27.1 weeks in 
placebo arm (p =0.858) (Krug, Kindler et al. 2011). 
The anti-epileptic drug Valproic acid has shown to be an HDACi (Gottlicher, Minucci et al. 
2001). A Phase II trial evaluating the effect of Valproic acid in combination with 
Doxorubicin in pretreated patients demonstrated a modest benefit. The response rate was 
16%, disease control rate was 36% and overall survival was 6.7 months (95% CI 4.9 – 8.5) 
in the cohort of 45 patients enrolled in the study (Scherpereel, Berghmans et al. 2011).  
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1.7 Conclusion 
Over the past decade there has been significant improvement in the treatment of MPM with 
combination chemotherapy with Cisplatin and Pemetrexed or Raltitrexed being the first line 
therapy. Despite there being an impressive 40% response rate the survival is still at best just 
over a year. There are no approved second line chemotherapy regimens.  Current clinical 
trials of targeted treatment options have failed to show any meaningful benefit in MPM 
with maximum response being less than 20%. In particular EGFR, MTOR and VEGF 
inhibitors, which have shown significant activity in other solid tumour types and are 
approved for use by FDA, have failed to impress and change practise in MPM. The largest 
ever MPM clinical trial of 661 patients evaluating the HDACi Vorinostat, did not 
demonstrate any benefit. In view of the poor survival benefit from first-line chemotherapy, 
and the lack of subsequent effective treatment options, there is a need for the development 
of more effective treatment modalities for patients with MPM. 
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Chapter 2.  Targeted Epidermal Growth 
Factor Receptor Therapy in Malignant 
Pleural Mesothelioma – Where do we 
stand? 
 
 
 
Agarwal V, Lind MJ, Cawkwell L. Targeted epidermal growth factor receptor  
therapy in malignant pleural mesothelioma: Where do we stand?  
Cancer treatment reviews 2011;37:533-42. 
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2.1 Epidermal Growth Factor Receptor  
Novel targeted therapies have been successful in other tumour types. One of the most 
commonly studied targets in cancer therapeutics is the epidermal growth factor receptor 
(EGFR). Epidermal growth factor (EGF) was first discovered by Stanley Cohen in 1960 
during his study of nerve growth factor in mouse sub-maxillary glands and subsequently, in 
1975, he confirmed the presence of plasma membrane receptors in human fibroblasts 
(Cohen 1960 March; G. Carpenter 1975). EGFR was isolated in 1982 as a 170 kDa 
transmembrane glycoprotein with an EGF binding site on the extracellular surface (Cohen, 
Ushiro et al. 1982). The structure of EGFR was found to be the human equivalent of the 
mammalian v-erb-B oncogene protein from the avian erythroblastosis virus. Unlike the 
human EGFR, the v-erb-B oncogene protein did not have the extracellular EGF binding 
domain thereby demonstrating that the intracellular domain may play an important role in 
tumourigenesis (Downward, Yarden et al. 1984). EGFR belongs to the human epidermal 
growth factor receptor (HER) family, which has four structurally related receptor tyrosine 
kinases ErbB1 (EGFR), ErbB2 (HER2), ErbB3 and ErbB4 (Salomon, Brandt et al. 1995). 
The EGFR protein consists of 1186 amino acids. The receptor structure consists of 
extracellular, transmembrane and intracellular domains (Figure 2.1). The extracellular 
domain consists of cysteine-rich clusters, which form the ligand-binding domain. Upon 
binding with ligands such as EGF or transforming growth factor alpha (TGF- ), the EGFR 
monomers form homodimers by dimerisation with another EGFR or heterodimers with 
another receptor of the HER family. The intracellular domain has tyrosine kinase activity. 
Dimerisation of the EGFR results in structural rearrangement of the intracellular tyrosine 
kinase domain. Adenosine triphosphate (ATP) is then recruited into the catalytic domain, 
resulting in its auto-phosphorylation. This leads to the activation of a cascade of 
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intracellular signal transduction pathways resulting in cell proliferation, anti-apoptosis, 
invasion and metastasis (Bogdan and Klambt 2001; Hynes and Lane 2005; Citri and 
Yarden 2006). Among a host of various intracellular signalling pathways stimulated by 
EGFR, the major pathways activated are the RAS/RAF/MAPK pathway resulting in cell 
proliferation, metastasis and invasion, and the PI3K/AKT/MTOR pathway resulting in 
inhibition of apoptosis (Ciardiello and Tortora 2008)  (Figure 2.2). 
 
 
 
Figure 2.1  Structure of EGFR. This figure shows the structure of EGFR with the 
extracellular component demonstrating the ligand binding cysteine rich domain, the 
transmembrane domain and the intracellular tyrosine kinase domain.  
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Figure 2.2 EGFR signal transduction pathways. Upon EGFR stimulation by EGF ligands, 
the RAS/RAF/MAPK pathway and the PI3K/AKT/MTOR pathway is activated resulting in 
the transcription of various genes leading to cell proliferation, cell survival, invasion, 
metastasis and angiogenesis. (Adapted from Ciardiello F and Tortora G. N Engl J Med 
2008; 358:1160-1174). 
 
EGFR is physiologically expressed in various epithelial cells such as skin, hair follicles, 
mammary glands, liver and the gastrointestinal tract (Herbst and Shin 2002). It plays an 
important role is normal cellular functions such as proliferation, migration, differentiation 
and cell survival and is essential for embryonic development and tissue homeostasis in 
adults (Wieduwilt and Moasser 2008; Reiss and Saftig 2009). Dysregulation of  EGFR may 
be associated with an oncogenic phenotype. Cancer cells often secrete EGFR ligands 
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initiating an autocrine loop resulting in activation of EGFR and oncogenesis (de Larco and 
Todaro 1978; Yarden and Sliwkowski 2001). Over-expression of EGFR has been seen in a 
number of tumour types including breast, ovarian, glioblastoma, bladder, pancreas, 
prostrate, renal, lung, colon and head and neck (Gullick 1991; Yarden and Sliwkowski 
2001; Herbst and Shin 2002; Holbro and Hynes 2004). EGFR expression in normal cells 
range from 40,000 to 100,000 receptors per cell (Herbst and Shin 2002). In malignant cells 
the number of EGFRs per cell increases significantly; for example in breast cancers up to 2 
million EGFRs per cell have been reported. Various studies have analysed the prognostic 
relevance of EGFR expression with conflicting results. It is currently unclear if expression 
of EGFR necessarily equates to activation of EGFR and neoplastic progression. Expression 
of EGFR may or may not be associated with EGFR gene amplification (Bredel, Pollack et 
al. 1999; Bhargava, Gerald et al. 2005). The EGFR gene is amplified in 
oligodendrogliomas (Fallon et al, 2004), glioblastomas (Marquez et al, 2004), lung 
carcinomas (Baselga and Arteaga, 2005; Giaccone, 2005), gastric carcinomas (Takehana et 
al, 2003), and breast carcinomas (Takehana, Kunitomo et al. 2003; Al-Kuraya, Schraml et 
al. 2004; Fallon, Palmer et al. 2004; Marquez, Wu et al. 2004; Bhargava, Gerald et al. 
2005). Amplification of the EGFR gene may be associated with truncation mutations of the 
EGFR extracellular domain, as seen in gliomas, which result in constitutive activation of 
EGFR and oncogenesis  (Humphrey, Wong et al. 1990; Ekstrand, James et al. 1991; 
Nishikawa, Ji et al. 1994; Pedersen, Meltorn et al. 2001). Mutations in the EGFR TK 
domain may result in constitutive activation of  EGFR and induce carcinogenesis 
(discussed in 2.2.1.1). 
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2.2 Targeted EGFR therapy 
Two classes of EGFR inhibitors have been developed: anti-EGFR monoclonal antibodies 
(mAbs) and small molecule tyrosine kinase inhibitors (TKIs) (See appendix B for list of all 
drugs and targets for the targeted biological agents used). The anti-EGFR mAbs, including 
Cetuximab (IMC-C225, Erbitux ImClone Systems Incorporated) and Panitumumab 
(ABX-EGF, Vectibix mgen), target the extracellular domain of EGFR and compete 
with the ligand for binding, thus reducing tyrosine kinase phosphorylation. The EGFR 
TKIs, including Gefitinib (ZD1839, Iressa AstraZeneca) and Erlotinib, compete with 
ATP and inhibit EGFR auto-phosphorylation (Figure 2.3). EGFR inhibitors currently in 
clinical practice are Erlotinib, Gefitinib, Lapatinib GW572016, Tyverb , 
GlaxoSmithKline) Cetuximab and Panitumumab (Table 2.1).  
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Figure 2.3 Mechanism of action of EGFR inhibitors. This figure shows the action of 
monoclonal antibodies such as Cetuximab at the extracellular domain of EGFR and that of 
tyrosine kinase inhibitor such as Gefitinib at the intracellular domain (Ciardiello and 
Tortora 2008).  
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Table 2.1 EGFR inhibitors in clinical practice. 
Drugs Target Dose Indication 
Erlotinib  
  
EGFR tyrosine 
kinase inhibitor 
150 mg daily 
orally 
 
 
 
NSCLC refractory to 
platinum based chemotherapy 
First line treatment in 
advanced pancreatic cancer in 
combination with 
Gemcitabine 
 
Gefitinib  EGFR tyrosine 
kinase inhibitor 
250 mg daily 
orally 
Licensed as first line therapy 
for advanced stage NSCLC 
with positive EGFR mutation 
 
Lapatinib  Dual EGFR and 
HER2 tyrosine 
kinase inhibitor 
1250 mg daily 
every 3 of 4 
weeks orally 
With Capecitabine in HER2 
Positive advanced or 
metastatic breast cancer 
refractory to Herceptin 
 
Cetuximab  
 
 
 
 
Anti-EGFR 
monoclonal 
antibody 
 
 
 
 
 
 
400 mg/m2 
loading dose 
followed by 
250 mg/m2 
weekly, 
intravenously 
 
 
 
 
In combination with radiation 
for local or locally advanced 
HNSCC or platinum 
refractory metastatic HNSCC 
 In metastatic colorectal 
cancer after failure of 
Oxaliplatin and Irinotecan 
based regimens. 
 
Panitumumab  Anti EGFR 
Monoclonal 
Antibody 
6mg/kg IV 
every 2 weeks 
In metastatic colorectal 
cancer after failure of 
Oxaliplatin and Irinotecan 
based regimens. 
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2.2.1 EGFR in non small cell lung cancer  
Non small cell lung cancer (NSCLC) demonstrates a high frequency of EGFR over-
expression when compared to normal pleura (Rusch, Baselga et al. 1993; Franklin, Veve et 
al. 2002; Hirsch, Varella-Garcia et al. 2003). Nakamura et al (2006) performed a meta-
analysis of the survival impact of EGFR over-expression in NSCLC which included 2972 
patients from 18 studies (Nakamura, Kawasaki et al. 2006). EGFR over-expression was 
seen in 58% squamous carcinomas, 39% adenocarcinomas, 38% large cell carcinomas, and 
32% of a miscellaneous category but EGFR over-expression did not show any significant 
impact on survival (HR 1.14; 95% CI, 0.97 – 1.34; p = 0.103) (Nakamura, Kawasaki et al. 
2006).  
2.2.1.1 Role of TKIs and EGFR gene mutations in NSCLC 
Both Gefitinib and Erlotinib  have shown  a modest response in the order of 8-19% in 
NSCLC (Fukuoka, Yano et al. 2003; Kris, Natale et al. 2003; Perez-Soler, Chachoua et al. 
2004; Shepherd, Rodrigues Pereira et al. 2005; Thatcher, Chang et al. 2005). However it 
was noted that sub-groups of patients (those who were of Asian origin, female or non-
smokers and those with tumours of the adenocarcinoma histological type) had a higher 
likelihood of response to EGFR TKI therapy (Thatcher, Chang et al. 2005). This led to the 
investigation of potential molecular biomarkers of response to EGFR TKI therapy. Lynch 
et al (2004) hypothesised that patients who had a good response to Gefitinib had somatic 
mutations in the EGFR gene and hence sequenced the entire coding region (Lynch, Bell et 
al. 2004). They identified somatic mutations in 8/9 tumours from patients with Gefitinib-
responsive lung cancer but no mutations were identified in any of 7 tumours from patients 
who did not have any response to Gefitinib (p <0.001) (Lynch, Bell et al. 2004). These 
activating mutations in the tyrosine kinase domain were associated with increased kinase 
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activity and conferred susceptibility to TKIs. Paez et al (2004) conducted a genome-wide 
screen of receptor tyrosine kinases and found mutations in the EGFR gene in 15/58 NSCLC 
samples from Gefitinib-naïve patients in Japan and in 1/61 samples from Gefitinib-naïve 
patients in the United States of America (Paez, Janne et al. 2004). They also evaluated 9 
patients who had been treated with Gefitinib and reported that 5/5 tumour samples which 
showed a response to Gefitinib therapy carried a mutation in the EGFR. No mutations were 
found in any of 4 tumours which had not responded to Gefitinib therapy (p = 0.0027) (Paez, 
Janne et al. 2004). It is now known that EGFR gene is located in chromosome region 7p12 
and mutations in NSCLC cluster in exons 18-21, which are within the tyrosine kinase 
domain (Figure 2.4) (Sharma, Bell et al. 2007). Approximately 45% of mutations are in-
frame deletions involving amino acids L746 to A750 in exon 19 and a further 45% of 
mutations create the substitution L858R within exon 21 (Sharma, Bell et al. 2007). The 
remaining mutations mainly occur in exons 18 and 20. These mutations are not found in 
normal lung tissues (Shigematsu, Lin et al. 2005; Chan, Gullick et al. 2006).  
The presence of these activating mutations in the tyrosine kinase domain increases the 
kinase activity and locks the EGFR in a constitutively active state with tumour growth 
dependent on EGFR signalling (Gazdar, Shigematsu et al. 2004; Yun, Boggon et al. 2007). 
TKIs bind more avidly to mutant EGFR compared to wild type due to marked rotational 
change in the tyrosine kinase domain of the mutant receptor, thereby making it more 
responsive to their inhibitory effects (Tracy, Mukohara et al. 2004; Yun, Boggon et al. 
2007).  
Activating mutations in the tyrosine kinase domain (exons 18-21) were shown to be present 
in approximately 10% (25/262) of NSCLC samples in the United States and 30% (122/419) 
in the East Asian population (Pao and Miller 2005). They were found to be more frequent 
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in adenocarcinoma and in tumours from patients who were non-smokers, female, or of 
Asian ethnic origin (Paez, Janne et al. 2004; Pao and Miller 2005; Shigematsu, Lin et al. 
2005). These characteristics were similar to those patients who demonstrated a good 
clinical response to Gefitinib or Erlotinib therapy in Phase III trials (Shepherd, Rodrigues 
Pereira et al. 2005; Thatcher, Chang et al. 2005). A recent meta-analysis of somatic EGFR 
gene mutation as a predictive biomarker for response to single agent TKI therapy in 
NSCLC evaluated data from 59 clinical trials of Erlotinib or Gefitinib therapy. Among the 
3101 patients, 1020 (32.9%) had tumours with an EGFR gene mutation and the analysis 
demonstrated that mutant EGFR was predictive of response to single agent TKI therapy 
(sensitivity 0.78; 95% CI, 0.74 - 0.82; specificity 0.86; 95% CI, 0.82 - 0.89) (Dahabreh, 
Linardou et al.).  
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Figure 2.4  EGFR mutations in NSCLC. This figure demonstrates the structure of EGFR 
gene. The commonest mutations were seen with exons 19 and 21 resulting in activating 
mutations of the TKI domain. (Adapted and modified from (Sharma, Bell et al. 2007). TM= 
transmembrane 
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2.2.1.2 KRAS gene mutations 
KRAS is a GTPase, which lies downstream of the EGFR and activates the 
RAS/RAF/MAPK and PI3K/AKT/MTOR pathways. Mutations in the KRAS gene may 
result in constitutive downstream activation of the EGFR signalling pathways resulting in 
lack of sensitivity to both TKIs and monoclonal antibodies targeting EGFR, both of which 
act upstream of KRAS. KRAS gene is located on chromosome 12p12 and consists of 6 
exons (www.atlasgeneticsoncology.org). KRAS mutations are commonly seen in codon 12 
(GGT) and codon 13 (GGC) of exon 2 and codon 61 (CAA) of exon 3 (van Krieken, Jung 
et al. 2008) (Figure 2.5). Codon 12 and 13 code for glycine and codon 61 codes for 
Glutamine in wild type KRAS. Single point mutations of the bases lead to amino acid 
exchange in the KRAS protein resulting in reduction of Ras GAP GTPase activity. This 
locks the KRAS protein in the active Ras-GTP conformation resulting in KRAS being in a 
constitutively active state (Ellis and Clark 2000). Mutated KRAS occurs in approximately 
20% of NSCLC samples and a meta-analysis of 17 studies (1008 NSCLC patients) where 
Erlotinib or Gefitinib therapy had been used, revealed that response to EGFR TKI treatment 
was highly unlikely if the tumour carried a KRAS mutation (Linardou, Dahabreh et al. 
2008). A recent extended meta-analysis of 22 studies (1470 patients with NSCLC) again 
reported that mutated KRAS was associated with a poor response to EGFR TKI therapy 
(3% response versus 26% response for wild type KRAS) (Qiu, Mao et al. 2010). 
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Figure 2.5 KRAS gene. Numbers in red are codons that may result in missense mutations 
resulting in alteration of the KRAS protein thereby inhibiting the Ras GAP GTPase 
activity. Adapted and modified from (van Krieken, Jung et al. 2008). 
 
2.2.2 Anti-EGFR monoclonal antibody therapy in NSCLC 
Cetuximab has been shown to give a modest response in NSCLC when combined with 
chemotherapy, resulting in small but statistically significant benefit (Robert, Blumenschein 
et al. 2005; Butts, Bodkin et al. 2007; Rosell, Robinet et al. 2008; Ettinger 2010). The large 
FLEX Phase III trial in advanced NSCLC randomised 1125 patients with EGFR-positive 
tumours to either chemotherapy alone (Cisplatin and Vinorelbine) or chemotherapy with 
Cetuximab. The combination arm showed a minimal overall survival benefit (median 11.3 
months versus 10·1 months; p=0.044) (Pirker, Pereira et al. 2009).  
2.2.3 Anti-EGFR monoclonal antibody therapy in colorectal cancer  
In colorectal cancer the response rates with single agent anti-EGFR mAb therapy were a 
modest 9 to 12% however, when combined with chemotherapy, this increased to 
approximately 20% (Cunningham, Humblet et al. 2004; Saltz, Meropol et al. 2004; 
Folprecht, Lutz et al. 2006; Lenz, Van Cutsem et al. 2006; Tabernero, Van Cutsem et al. 
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2007; Van Cutsem, Peeters et al. 2007). Several clinical trials and studies have 
demonstrated that colorectal cancers which carry a mutation in the KRAS oncogene, are 
significantly associated with resistance to anti-EGFR mAb therapy (Cunningham, Humblet 
et al. 2004; Saltz, Meropol et al. 2004; Lenz, Van Cutsem et al. 2006; Van Cutsem, Peeters 
et al. 2007; Karapetis, Khambata-Ford et al. 2008; De Roock, Claes et al. 2010). Mutated 
KRAS is present in approximately 40% of colorectal cancers, is associated with poor 
prognosis and induces resistance to anti-EGFR mAb treatment (either alone or in 
combination with chemotherapy)  (Andreyev, Norman et al. 2001; De Roock, Piessevaux et 
al. 2008; Linardou, Dahabreh et al. 2008). Poor response to anti-EGFR mAb therapy is also 
related to BRAF mutations (Linardou, Dahabreh et al. 2008; Laurent-Puig, Cayre et al. 
2009; Hawkes and Cunningham 2010).  
2.2.4 Predictive biomarkers for targeted EGFR therapy  
The association of EGFR and KRAS gene mutations with response to targeted EGFR 
therapy has been discussed above. Additional gene mutations in the EGFR downstream 
signalling pathways may also lead to resistance to EGFR therapy (Figure 2.6).  
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Figure 2.6  Biomarkers predictive of EGFR resistance. This figure demonstrates the 
biomarkers that lie downstream of EGFR, the mutation of which can result in inducing 
resistance to EGFR inhibitors. PIK3CA encodes for the 110 subunit of PI3K and its 
mutation results in persistent activation of PI3K. PTEN protein enables dephosphorylation 
of PIP3 to PIP2 and the loss of PTEN results in PIP3 remaining in a phosphorylated form 
resulting in persistent activation of the AKT. Mutation of RAS and RAF result in persistent 
activation of the RAS/RAF/MAPK pathway. 
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The BRAF gene is a member of the RAF family of serine/threonine kinases and lies 
downstream of RAS in the RAS/RAF/MAPK pathway. BRAF gene is located on 
chromosome 7q34 and is composed of 18 exons (www.atlasgeneticsoncology.org). All 
activating mutations are seen within the kinase domain and in 90% of the cases thymine is 
substituted with adenine at nucleotide 1799 in exon 15. This leads to valine being 
substituted for by glutamate at codon 600 (V600E) (Davies, Bignell et al. 2002; Yuen, 
Davies et al. 2002; Tan, Liu et al. 2008). The presence of BRAF mutations is associated 
with poor progression-free and overall survival in colorectal cancer and has been associated 
with resistance to anti-EGFR mAb therapy (Di Nicolantonio, Martini et al. 2008; Loupakis, 
Ruzzo et al. 2009; Tol, Nagtegaal et al. 2009; De Roock, Claes et al. 2010).  
Activation of the PI3K protein by phosphorylation leads to downstream activation of AKT 
in the PI3K/AKT/MTOR pathway (Markman, Atzori et al. 2010). The p110  catalytic 
subunit of PI3K is encoded by the PIK3CA gene. Colorectal carcinomas with mutations in 
PIK3CA have been reported to show increased resistance to anti-EGFR mAb therapy 
(Perrone, Lampis et al. 2009; Sartore-Bianchi, Martini et al. 2009; De Roock, Claes et al. 
2010).  
The PTEN tumour suppressor protein antagonises the activity of PI3K in the 
PI3K/AKT/MTOR pathway and inactivation of PTEN may lead to constitutive activation 
of PIK (Zhang and Yu 2010). In colorectal cancers the loss of the PTEN protein is 
associated with increased resistance to EGFR mAbs (Frattini, Saletti et al. 2007; Perrone, 
Lampis et al. 2009; Sartore-Bianchi, Martini et al. 2009). 
Wild type KRAS status is known to be a good predictive biomarker for response to EGFR 
mAbs in metastatic colorectal cancer. However not all wild type tumours respond and the 
additional analysis of mutations in the BRAF, NRAS and PIK3CA genes in tumours 
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demonstrating wild type KRAS was found to improve the prediction of response to 
Cetuximab (De Roock, Claes et al. 2010). It has been suggested that colorectal tumours 
which are “quadruple negative” for mutations in the KRAS, BRAF, PIK3CA and PTEN 
genes would benefit most from EGFR mAb therapy (Bardelli and Siena 2010). 
2.2.5 EGFR over expression in MPM 
EGFR is over-expressed in 44 to 97% of MPM samples as demonstrated by various 
immunohistochemical studies (Table 2.2). Immunohistochemistry is a subjective technique 
and can lack reproducibility due to the use of different antibodies, scoring systems and 
methodologies. Some research groups reported that there was no relationship between 
EGFR over-expression and outcome in patients with MPM (Destro, Ceresoli et al. 2006; 
Okuda, Sasaki et al. 2008; Gaafar, Bahnassy et al. 2010) whilst others have reported that 
EGFR over-expression is associated with improved outcome (Dazzi, Hasleton et al. 1990; 
O'Byrne, Edwards et al. 2004; Edwards, Swinson et al. 2006). However EGFR over-
expression in MPM is seen more commonly in the epithelial histological subtype, which is 
associated with improved patient survival, and EGFR over-expression is not an 
independent prognostic marker (Dazzi, Hasleton et al. 1990; Edwards, Swinson et al. 
2006). 
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Table 2.2 EGFR over expression in MPM by immunohistochemistry 
 
Study Total 
samples 
Histological 
subtype 
Antibody 
used 
Scoring Positive for EGFR 
expression 
Prognos
tic 
marker 
Dazzi et 
al(Dazzi, 
Hasleton 
et al. 
1990) 
34 Epithelial – 16; 
Biphasic – 9; 
Sarcomatoid - 
9 
F4 
monoclonal 
antibody 
Positive - 
greater 
than or 
equal to 
5% 
Total- 23/34 (68%) 
Epithelial -14/16 
(87.5%); Biphasic 
– 2/9 (22%); 
Sarcomatoid - 7/9 
(78%) 
No 
Destro et 
al(Destro
, 
Ceresoli 
et al. 
2006) 
61 Epithelial – 50; 
Biphasic – 9; 
Sarcomatoid - 
2 
EGFrAb-10 
(clone 
111.6) 
(Neomarker
s, Union 
City, CA) 
Negative 
(0-10%); 
Low 
expression 
(11-50%); 
High 
expression 
(>50%) 
Total (Low + high 
expression) – 34/61 
(56%) 
No 
(CALGB 
30101)(
Govinda
n, 
Kratzke 
et al. 
2005) 
28 Not reported EGFr 
antibody 
clone 31G7 
(Zymed 
Laboratorie
s, Inc) 
All 
samples 
were 
scored as 
0+, 1+, 
2+, and 3+ 
Total (2+ and 3+) - 
27/28 (97%) 
No 
Edwards 
et 
al(Edwar
ds, 
Swinson 
et al. 
2006) 
168 Epithelial – 98; 
Biphasic – 37; 
Sarcomatoid - 
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EGFR.113 
(Novocastra 
Laboratorie
s 
Ltd., 
Newcastle, 
UK) 
Positive - 
greater 
than or 
equal to 
5% 
Total – 74/168 
(44%) 
Epithelial -58/98 
(59%); Biphasic – 
13/37 (35%); 
Sarcomatoid – 3/33 
(9%) 
No 
Garland 
et 
al(Garla
nd, 
Rankin 
et al. 
2007) 
57 Not reported EGFr 
antibody 
clone 31G7 
(Zymed 
Laboratorie
s,  
Inc) 
All 
samples 
were 
scored as 
0+, 1+, 
2+, and 3+ 
Total (2+ and 3+) - 
43/57 (75%) 
No 
Rena et 
al (Rena, 
Boldorin
i et al. 
2011) 
83 Epithelial – 57; 
Biphasic – 20; 
Sarcomatoid - 
6 
EGFR 
antibody 
clone H11 
(Dako, 
Denmark) 
All 
samples 
were 
scored as 
0+, 1+, 
2+, and 3+ 
Total – 70/83 
(84%) 
Epithelial -30/57 
(52%); Biphasic – 
8/20 (40%); 
Sarcomatoid – 0/6  
No 
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2.2.6 EGFR TKI therapy in MPM 
Gefitinib inhibits EGF-induced phosphorylation of downstream signal transduction 
pathways and the growth of MPM cells in vitro (Janne, Taffaro et al. 2002). Another EGFR 
TKI, PD153035, was shown to reduce motility and invasion in MPM cell lines (Cole, 
Alleva et al. 2005). Based on the in vitro studies showing activity of EGFR TKIs in MPM 
cells, two Phase II trials were conducted (Table 2.3). The CALGB 30101 Phase II trial 
enrolled 43 chemotherapy-naïve patients with pleural (n = 42) or peritoneal (n = 1) 
mesothelioma and a performance status of 0 - 1. All patients received 500mg Gefitinib once 
a day until disease progression or unacceptable toxicity was observed. The primary end 
point of the study was the percentage of patients who remained alive and progression-free 
three months after the start of Gefitinib treatment. The 3-month progression-free survival 
was 40% (95% CI, 25 - 56%) (Govindan, Kratzke et al. 2005). This was compared with a 
similar historic control group of 337 chemotherapy-naïve patients with malignant 
mesothelioma from the Cancer and Leukemia Group B database, which incorporated 7 
Phase II trials (Herndon, Green et al. 1998). The 3 month failure-free survival rate among 
patients with good performance status (275/337 patients) was approximately 60%. This was 
higher than that seen in the Gefitinib trial (40% progression-free survival at 3 months) and 
the authors therefore concluded that single-agent Gefitinib was not active in malignant 
mesothelioma (Govindan, Kratzke et al. 2005). In the second Phase II trial, 63 
chemotherapy-naïve patients with advanced or recurrent MPM and a performance status of 
0 - 1 were treated with Erlotinib. The primary objective was to measure survival outcomes. 
Thirty-three patients had measurable disease, among which four patients had inadequate 
assessments. There were no responses seen, although 14/33 (42%) had stable disease 
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(Garland, Rankin et al. 2007). The median progression-free survival of 2 months in this 
study was significantly lower than that associated with standard first-line 
Pemetrexed/Cisplatin chemotherapy (5.7 months; 11 (Vogelzang, Rusthoven et al. 2003). 
The authors therefore concluded that single-agent Erlotinib was not effective in MPM.  
In both the studies evaluating Gefitinib and Erlotinib in MPM, the EGFR protein was 
shown to be expressed by immunohistochemistry in the majority of the tissue samples, but 
its expression did not predict response to TKI.  EGFR gene amplification by and mutation 
of the EGFR TKI domain, which have shown to predict response to TKIs, were not 
assessed (Lynch, Bell et al. 2004; Paez, Janne et al. 2004; Hirsch and Witta 2005). 
Furthermore, in both  studies the radiological response was assessed using the Response 
Evaluation Criteria In Solid Tumours (RECIST) criteria. This may have had a significant 
impact on the analysis of the response rates in both studies. Response assessment of tumour 
therapy in MPM is difficult due to the growth pattern of MPM. MPM grows as a 
‘rind’around the pleural surface and hence uni- or bi-dimensional tumor measurement may 
not be suitable for adequate tumor response assessment. The RECIST criteria specify a 
single dimensional measurement of the tumor’s longest diameter and sets thresholds of 
tumour response evaluation (complete response is disappearance of all tumour; partial 
response is reduction by >30% of sum of the longest diameter of all lesions; stable disease 
is reduction <30% and progression <20%; progressive disease as progression by >20% of 
sum of the longest diameter of all lesions) (Therasse, Arbuck et al. 2000). Due to the nature 
of the growth of MPM, the RECIST criteria should be modified from the longest diameter 
to tumour thickness perpendicular to chest wall or mediastinum when evaluating tumour 
response in MPM (Byrne and Nowak 2004). Symptomatic benefit and quality of life data 
was not assessed in either of the trials as it may have contributed to our assessment of 
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clinical benefit to the patients. Both  studies were non randomised, Phase II trials, with 
small patient numbers. The primary end point in the study by Govindan et al was the 
percentage of patients who remained progression free after 3 months and in the study by 
Garland et al was one year survival. These end points were compared with historical 
controls which may not accurately predict the outcome in the same patient population. A 
randomised study comparing the TKI with either best supportive care and assessing 
survival data such as overall survival would have given a better understanding of the 
efficacy of the drug. However, a randomised trial with extensive follow up would have had 
significant cost and resource implications. In both  studies, the TKIs were used as first line 
agents in chemo naive patients. The efficacy of TKIs in combination with chemotherapy or 
as second line treatment has not been assessed.   
 
Table 2.3 Phase II studies showing the response rates and survival analysis of EGFR TKIs 
in malignant mesothelioma. 
 
Response rate  Median 
overall 
survival 
(Months), 
95% CI 
Median 
progression 
free 
survival 
(Months), 
95% CI 
1 year 
survival 
(%), 95% 
CI 
CR PR SD PD 
Gefitinib(
Govindan, 
Kratzke et 
al. 2005) 
1/43 
(2%) 
1/43 
(2%) 
21/43 
(49%) 
15/43 
(35%) 
6.8, (3.5 - 
10.3) 
2.6, (1.5 - 
4.2) 
32, (21 - 50) 
 
Erlotinib 
(Garland, 
Rankin et 
al. 2007) 
0/33  0/33 14/33 
(42%) 
15/33 
(45%) 
10, (5 - 13) 2, (2 - 4) 43, (31-55) 
CR – complete response; PR – partial response; SD – stable disease; PD – progressive 
disease; CI – confidence interval 
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2.2.7 EGFR gene mutations in MPM 
Cortese et al (2006) identified mutations in the tyrosine kinase domain of the EGFR gene in 
19/99 lung adenocarcinoma samples but in none of 66 MPM samples (Cortese, Gowda et 
al. 2006). Similarly, Destro et al (2006) failed to identify exon 18-21 mutations in 16 MPM 
samples (Destro, Ceresoli et al. 2006) and Okuda et al (2008) failed to identify exon 18-21 
mutations in 25 MPM samples from a Japanese population (Okuda, Sasaki et al. 2008). 
Therefore it would be reasonable to extrapolate that the absence of EGFR activating 
mutations in MPM may be one of the causes of resistance to EGFR TKI therapy in MPM. 
2.2.8 KRAS gene mutations in MPM 
A number of studies have explored the presence of KRAS gene mutations in MPM. Metcalf 
et al (1992) screened 20 mesothelioma cell lines for KRAS gene mutations at codons 12, 
13 and 61 and found no mutations (Metcalf, Welsh et al. 1992). Kitamura et al (1998; 
2002) did not identify KRAS mutations in MPM samples from 7 Japanese and 12 
American patients (Kitamura, Araki et al. 1998; Kitamura, Araki et al. 2002). Ni et al 
(2000) also examined 17 mesothelioma samples for KRAS mutations and did not identify 
any mutations (Ni, Liu et al. 2000). 
2.2.9 BRAF gene mutations in MPM 
In MPM, BRAF gene mutations were not present in 53 tumours and 6 cell lines studied 
(Dote, Tsukuda et al. 2004). 
2.2.10 PIK3CA gene mutations in MPM 
Suzuki et al (2009) studied 21 mesothelioma cell lines and did not find any PIK3CA gene 
mutations (Yutaro Suzuki, Hideki Murakami et al. 2009). 
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2.2.11 Loss of PTEN in MPM 
Discussed in detail in section 3.1.1. 
2.3 Cross-talk between EGFR and other pathways 
There is known to be significant cross-talk between the EGFR pathway and other receptor 
signalling pathways. Resistance to EGFR inhibition therapy may be due to the over-
expression of an alternative receptor which compensates for the loss of EGFR function. 
Such “by-pass” mechanisms may therefore account for resistance to EGFR inhibition 
therapy and highlight the possible requirement for multi-receptor blockade therapy. 
Downstream proteins within the EGFR signalling pathway, such as PI3K and AKT 
(Chapter 3) are utilised by other tyrosine kinase receptor growth factor pathways, including 
the c-MET receptor and IGF-1R pathways (Engelman and Janne 2008; Eyzaguirre, Buck et 
al. 2008; Kono, Marshall et al. 2009). In MPM, Jagadeeswaran et al (2006) reported over-
expression of the c-MET protein in 82% of 66 MPM tissue samples and in 0/21 samples of 
normal pleura using immunohistochemistry (Jagadeeswaran, Ma et al. 2006). In 
mesothelioma cell lines, treatment with the small molecule c-MET inhibitor SU11274 lead 
to dose-dependent growth inhibition (Jagadeeswaran, Ma et al. 2006). IGF-1R has been 
shown to be important in the malignant phenotype of MPM (Hoang, Zhang et al. 2004) and 
treatment of mesothelioma cell lines with the IGF-1R inhibitors NVP-AEW541(Novartis) 
and AG1024 resulted in dose-dependent growth inhibition (Whitson, Jacobson et al. 2006; 
Kai, D'Costa et al. 2009). AG1024 was also shown to enhance the cytotoxic effect of 
Cisplatin in mesothelioma cells (Kai, D'Costa et al. 2009).  
Significant cross talk exists between the EGFR and COX-2 pathways (Dannenberg, 
Lippman et al. 2005). COX-2 is an inducible enzyme, which converts Arachidonic acid to 
prostaglandins (PG) and its role in MPM is discussed in detail in Section 4.1.  Increased 
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EGFR stimulation and subsequent activation of intracellular MAPK protein promotes 
transcription of COX-2 which then produces PG including PGE2. PGE2 can trans-activate 
the EGFR, promoting cell proliferation and migration, and also increases the expression of 
amphiregulin which is a ligand of the EGFR (Figure 2.7). The activation of EGFR via the 
COX-2 pathway can form a positive feedback loop resulting in increased production of 
COX-2/PGE2, which in turn trans-activates the EGFR pathway. In MPM, both EGFR and 
COX-2 are frequently over-expressed and, since significant cross-talk exists between the 
two pathways, targeting both of these pathways may form a rationale for treatment. In 
mesothelioma cell lines, treatment with EGFR inhibitors or COX-2 inhibitors leads to 
cytotoxicity (Janne, Taffaro et al. 2002; O'Kane, Eagle et al. 2010) but the in vitro effects 
of combined inhibition, targeting both the EGFR and COX-2 pathways, are as yet 
unknown. Although no clinical studies in MPM have investigated a combination therapy 
with EGFR TKI inhibitors and COX-2 inhibitors, a Phase I study of the COX-2 inhibitor 
Celecoxib (Celebrex  Pfizer) combined with Gefitinib in recurrent or metastatic 
squamous cell carcinoma of the head and neck was well tolerated and had an encouraging 
response rate of 22% (Wirth, Haddad et al. 2005). In NSCLC the combination of Celecoxib 
or COX-2 inhibitor Rofecoxib (Vioxx Merck) with Gefitinib showed good tolerability 
but response rates were comparable to single agent Gefitinib (Gadgeel, Ruckdeschel et al. 
2007; O'Byrne, Danson et al. 2007) Another Phase I study combined Celecoxib with 
Erlotinib in 22 patients with advanced NSCLC and reported a partial response rate of 33% 
(Reckamp, Krysan et al. 2006). 
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Figure 2.7 Activation of EGFR pathway by PGE2. Activation of the EP receptor by 
prostaglandin E2 (PGE2) results in activation of the EGFR via its action on Src. It also 
signals directly through the PI3K/AKT/MTOR network, which is downstream of the 
EGFR, and through cAMP and PKA resulting in a malignant phenotype (Dannenberg, 
Lippman et al. 2005). 
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2.4 Conclusions 
EGFR is over-expressed in MPM. In vitro studies have demonstrated EGFR TKI therapy 
(Gefitinib) can induce cytotoxic effects in MPM cell lines. However, two small Phase II 
trials have shown that EGFR TKIs (Gefitinib and Erlotinib) may not be clinically effective 
in MPM (Govindan, Kratzke et al. 2005; Garland, Rankin et al. 2007). However, both trials 
were Phase II, non-randomised trials with small patient numbers (n=43; n=63) and hence 
definite conclusions cannot be drawn from these trials. The mechanisms of resistance to 
EGFR TKI therapy in MPM could be varied, and may be associated with the absence of 
activating mutations in the TK domain of EGFR. Other resistance mechanisms may include 
loss of the PTEN protein, resulting in persistent activation of PI3K/AKT/MTOR pathway, 
or transactivation of EGFR by COX-2/PGE2. Currently, there are no in vitro or in vivo 
published studies assessing the effect of anti-EGFR mAbs in MPM. The anti-EGFR mAbs 
are not dependent on the presence of activating mutations at the tyrosine kinase domain of 
EGFR and it is yet unknown whether mAbs will have a cytotoxic effect in MPM. However, 
loss of PTEN protein and transactivation of the EGFR by COX-2/PGE2 may induce 
resistance to these mAbs. In vitro studies to investigate the effects of anti-EGFR mAbs in 
MPM are required to assess their cytotoxic effects in MPM. Combination therapy using an 
anti-EGFR mAb with a COX-2/PGE2 inhibitor or an AKT/MTOR inhibitor may show 
enhanced therapeutic potential when compared to single agent mAb therapy. 
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Chapter 3.  PTEN/AKT/MTOR pathway 
in Mesothelioma – Does it have a role to 
play? 
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3.1 PTEN/PI3K/AKT/MTOR pathway  
The PI3K/AKT/MTOR pathway plays an important physiological role in transmitting 
proliferative signals from cell surface growth receptors such as EGFR, Platelet derived 
growth factor receptor (PDGFR), Insulin growth factor receptor (IGFR), Fibroblast growth 
factor receptor (FGFR) and Hepatocyte growth factor (HGF)  to the nucleus via their 
interaction with various other proteins. This signalling results in the control of gene 
expression and protein synthesis thereby controlling growth, proliferation and metabolism 
of the cell. (Wang and Proud 2006; Zhou, Luo et al. 2010). The dysregulation of 
PI3K/AKT/MTOR pathway has shown to play an important role in many tumour types 
(Chiang and Abraham 2007; Guertin and Sabatini 2007). This pathway can be activated by 
stimulation of PI3K by receptor tyrosine kinases in response to growth factor stimuli or by 
loss of tumour suppressor gene PTEN (phosphatase and tensin homolog) resulting in 
hyperphosphorylation and constitutive activation of AKT (Figure 3.1). (Manning and 
Cantley 2007). Phosphorylation of AKT (pAKT) results in activation or inhibition of a host 
of downstream targets resulting in cell survival, cell proliferation and protein synthesis. 
AKT blocks apoptotic proteins such as the BIM, BAX, BAD, FOXO family of 
transcription factors resulting in pro-apoptosis and cell survival. Phosphorylation and 
retention of p27 in the cytoplasm by pAKT causes cell cycle progression  (Fujita, Sato et al. 
2002; Shin, Yakes et al. 2002). The NFkβ pathway is also activated by pAKT resulting in 
cell survival (Nidai Ozes, Mayo et al. 1999; Madrid, Wang et al. 2000). Phosphorylation of 
the tumour suppressor TSC2 by pAKT disrupts the critical balance between TSC2 and 
TSC1 leading to activation of MTOR.  
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Figure 3.1  PI3K/AKT/MTOR signal transduction pathway, feedback inhibition and their 
downstream targets. Growth factors when stimulated by growth factor ligands result in 
enhanced tyrosine kinase activity. Receptor tyrosine kinases activate PI3K by direct 
binding or by phosphorylation of IRS1 which binds to PI3K. PI3K converts PIP2 to PIP3 
resulting in phosphorylation of AKT. PTEN converts PIP3 back into PIP2 thereby 
negatively regulating the phosphorylation of AKT. Phosphorylation of AKT results in 
inhibition of downstream targets such as BIM, BAX, BAD, FOXO, p27 and TSC2 and 
activation of  MDM2 (inhibiting p53), IKKα and NFkβ. Disruption of the critical balance 
between TSC2 and TSC1 leads to activation of MTORC1 which further phosphorylates 
p70S6K and inhibits 3E-BP1. IRS1 is inhibited by p70S6K thereby negatively regulating 
the activation of PI3K/AKT/MTOR pathway. MTORC2 can also phosphorylate AKT 
resulting in activation or inhibition of downstream targets.  
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MTOR can be assembled into two different complexes MTORC1 and MTORC2 (Figure 
3.2) (Guertin and Sabatini 2007). Both the MTOR complexes share the MTOR and 
mLST8/GβL proteins. In addition MTORC1 contains the regulatory associated protein of 
MTOR (Raptor). MTORC2, in addition to MTOR and mLST8/GβL, is constituted of 
Rapamycin insensitive companion of MTOR (Rictor), S1N1 and PROTOR/PRR5 (Vilar, 
Perez-Garcia et al. 2011). MTOR protein is made up of up to 20 tandem HEAT repeats at 
the amino acid terminal and mediates protein-protein interactions (Yang and Guan 2007). 
This is followed by a FAT domain, the FRB domain, kinase domain and the FATC domain 
located at the C-terminus of the protein. The FRB domain provides the docking site for 
Rapamycin- FKBP12 complex and the FAT and FATC modulate the kinase activity. 
Phosphorylation of the kinase domain results in the activation of the downstream effectors 
of MTOR. Rapamycin binds to FKBP12 protein and this Rapamycin- FKBP12 complex 
binds to the FRB domain of MTOR in MTORC1 thereby inhibiting its downstream 
signalling. The exact mechanism of how Rapamycin- FKBP12 acts is currently not known, 
but may be due to inhibition of MTOR autophosphorylation, inhibition of intrinsic kinase 
activity or preventing MTOR protein from interacting with its substrates (Yang and Guan 
2007). However, Rapamycin- FKBP12 complex does not bind to the FRB domain of 
MTOR in MTORC2 thereby making MTORC2 insensitive to the effects of Rapamycin 
(Jacinto, Loewith et al. 2004; Sarbassov, Ali et al. 2004).  
   
 
54 
 
MTOR
MTOR
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Figure 3.2 Structure of MTORC1 and MTORC2 complexes and the structure of MTOR 
protein. Adapted and modified from (Yang and Guan 2007). MTORC1 is made up of 
MTOR, RAPTOR and mLST8/GβL proteins. MTORC2 is made up of MTOR, 
mLST8/GβL, RICTOR and S1N1 and PROTOR proteins. MTOR protein is made up of 
upto 20 tandem HEAT repeats that mediate protein-protein interactions, the FAT domain, 
the FRB domain, the kinase domain and the FATC domain. The FRB domain provides the 
docking site for Rapamycin- FKBP12 complex in MTORC1. 
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Alteration of the critical balance between TSC2 and TSC1 by pAKT results in 
phosphorylation of MTORC1. Activation of MTORC1 phosphorylates downstream targets 
such as 4E-BP1and p70S6K resulting in protein and lipid synthesis and cell survival. Both 
MTORC1 and p70S6K can phosphorylate and degrade IRS1 thereby acting as a negative 
feedback loop to control PI3K/AKT/MTOR pathway activation (Shi, Yan et al. 2005). 
MTORC2 has recently shown to have a critical role to play in the development of prostate 
cancer cell lines that are devoid of PTEN (Guertin, Stevens et al. 2009). MTORC2 
phosphorylates and activates AKT resulting in activation of its downstream targets 
(Sarbassov, Guertin et al. 2005). The presence of PTEN would counteract the stimulatory 
effect of MTORC2 on AKT.   
3.1.1 Over expression of AKT/MTOR and loss of PTEN proteins in MPM 
Immunohistochemical analysis of expression or loss of biomarkers within the 
PI3K/AKT/MTOR pathway has been studied in MPM (Table 3.1). The first study to look 
at loss of PTEN protein and expression of pAKT protein and pMTOR protein was by 
Altomare et al (2005), who demonstrated that PTEN protein was lost in 2/26 tumour 
samples and pAKT protein and pMTOR protein was expressed in 17/26 and 24/26 tumour 
samples respectively when analysed by immunohistochemistry. The PTEN exons 2-8 in 
M43 cells (MPM cell line) was also analysed using single-strand conformation 
polymorphism assay and PTEN gene was found to be absent. Western blot confirmed the 
loss of PTEN protein in the M43 cells (Altomare, You et al. 2005). In another study by 
Garland et al (2007), immunohistochemical analysis showed that PTEN protein was lost in 
3/19 tumour samples and pAKT protein and pMTOR protein was expressed in 16/19 and 
12/19 tumour samples respectively (Garland, Rankin et al. 2007).  A large study of 341 
tumour samples by Opitz et al (2008) demonstrated that PTEN protein was lost in 211/341 
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tumour samples. The loss of PTEN protein strongly correlated with poor median overall 
survival in 129 patients evaluated (PTEN absent 9.7 months versus PTEN present 15.5 
months; log rank test p=0.0001) (Opitz, Soltermann et al. 2008) This association of loss of 
PTEN protein with poor survival was independent of histology (epithelioid vs non 
epithelioid; p=0.003), age (<62 years vs >62 years; p=0.3) and surgery (yes vs no; p=0.09) 
in multivariate cox regression analysis. Another recent study by Watzka et al (2010) 
showed that pAKT protein was expressed in 65/74 tumour samples when analysed by 
immunohistochemistry (Watzka, Setinek et al. 2010).  A tissue microarray of 37 MPM 
samples showed that pAKT protein was expressed in all of them (Wilson, Barbone et al. 
2008). In another study by Suzuki et al (2009) in MPM cell lines, loss of PTEN protein was 
seen in 2/21 cell lines (ACC-MESO-1 and Y-MESO-25) and AKT protein activation was 
seen in 13/21 cell lines (Yutaro Suzuki, Hideki Murakami et al. 2009).  
Despite there being significant variations in the reported frequency of loss of PTEN protein 
in MPM ranging from 8% to 62%, expression of pAKT protein and pMTOR protein has 
been seen in a majority of all tumour samples in the studies conducted. Loss of PTEN was 
shown to be a significant indicator of poor prognosis in the study by Opitz et al (2008) 
(Opitz, Soltermann et al. 2008). Expression of pAKT was not found to be of any prognostic 
significance (Watzka, Setinek et al. 2010). Expression of MTORC2 and the prognostic 
value of MTOR (MTORC1 and MTORC2) in MPM has to be best of our knowledge not 
yet been reported in the literature. 
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Table 3.1  Expression of PTEN/pAKT/pMTOR assessed by Immunohistochemistry. 
Study Protein No of tissue 
samples 
Expression  Prognostic value 
Altomare et al (Altomare, 
You et al. 2005) 
pAKT 26 17 (65%) N/A 
pMTOR 24 (92%) 
PTEN Lost in 2 (8%) 
Garland et al(Garland, 
Rankin et al. 2007) 
PTEN 19 Lost in 3 (16%) N/A 
pAKT 16 (84%) 
pMTOR  12 (74%) 
Opitz et al(Opitz, 
Soltermann et al. 2008) 
PTEN 341 Lost in 211 
(62%) 
Poor prognostic 
(PTEN- 9.7 
months versus 
PTEN+ 15.5 
months; p=0.003; 
n=126)  
Wilson et al (Wilson, 
Barbone et al. 2008) 
pAKT 37 37 (100%) N/A 
Watzka et al (Watzka, 
Setinek et al. 2010) 
PAKT 74 65 (88%) Not prognostic 
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3.1.2 Inhibition of the PTEN/PI3K/AKT/MTOR pathway in MPM 
Various in vitro studies in MPM cell lines have been done looking at the inhibition of the 
PTEN/PI3K/AKT/MTOR pathway. The PTEN/PI3K/AKT/MTOR pathway can be 
manipulated by either counteracting the loss of PTEN or inhibiting over expressed proteins 
such as PI3K, AKT or MTOR. Multi targeted therapies can also be used to target multiple 
proteins within the pathway to enhance the therapeutic effect. 
3.1.2.1  PTEN over expression 
Since loss of PTEN protein results in phosphorylation and activation of AKT, the up 
regulation of PTEN protein may decrease phosphorylation of AKT.  To assess the effect of 
over expression of PTEN protein in MPM, a study transfected two MPM cell lines (REN 
and I-45) with adenovirus type 5 vectors AdPTEN and studied their effects. PTEN gene 
mutation status of both cell lines was unknown and a basal level of PTEN protein was 
present, which on transfection with AdPTEN was significantly increased. Forced over 
expression of PTEN protein resulted in decreased phosphorylation of AKT and increased 
apoptotic death of the cell (Mohiuddin, Cao et al. 2002). In another study, wild type as well 
as mutant PTEN was introduced in PTEN deficient MPM cell line (M43 cell line) using 
adenovirus (Altomare, You et al. 2005). Cells with wild type PTEN and not with mutant 
PTEN disrupted cell cycle progression and reduced AKT phosphorylation.  
3.1.2.2 PI3K / AKT / MTOR inhibition 
In vitro studies looking at the inhibition of the PI3K / AKT /MTOR pathway in MPM cell 
lines and MPM tumour fragment spheroids have been evaluated by various authors (See 
appendix B for list of all drugs and targets for the targeted biological agents used). Tumour 
fragment spheroids are original tumour fragments which are grown in a three dimensional 
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structure thereby maintaining the original characteristics of the tumour.   The PI3K 
inhibitor LY294002 inhibits the ATP binding of the catalytic subunit of PI3K and has been 
used to inhibit the PI3K / AKT pathway in MPM (Figure 3.3). LY294002 has been shown 
to reduce phosphorylation of pAKT in MPM cell lines (M43 cell lines) as well as in tumour 
fragment spheroids (Altomare, You et al. 2005; Wilson, Barbone et al. 2008). Rapamycin 
inhibits MTORC1 by binding to FK-binding protein 12 (FKBP12) and has shown to reduce 
phosphorylation of p70S6K, downstream of MTORC1, in M43 cell lines as well as in 
tumour fragment spheroids (Altomare, You et al. 2005; Wilson, Barbone et al. 2008). 
Inhibition of MTORC1 by Rapamycin has been shown to reduce the negative feedback 
loop exerted via the IRS1/PI3K pathway and thereby increasing the phosphorylation of 
AKT in mesothelioma tumour fragment spheroids (Barbone, Yang et al. 2008). 
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Figure 3.3 Inhibitors of PI3K/AKT/MTOR signal transduction pathway. LY294002 
inhibits PI3K, Rapamycin inhibits MTORC1 and MTOR kinase inhibitors inhibit 
MTORC1 and MTORC2. 
 
Altomare et al (2005) studied the effect of LY294002, and Rapamycin in the M43 cell line 
(Altomare, You et al. 2005). Treatment of M43 cells with LY294002 resulted in 3.3 fold 
rise in sub-G1 cell population and with Rapamycin resulted in increased G1 cell population 
by 30% demonstrating apoptosis and cell cycle arrest at G1 Phase respectively.  
In the study by Kim et al (2005), the effect of potent apoptotic inducer TNF related 
apoptosis-inducing ligand (TRAIL) plus protein synthesis inhibitor Cycloheximide was 
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analysed in MPM monolayer cell lines  (M28, REN, MS-1) and MPM tumour fragment 
spheroids along with the additive effect of LY294002 and Rapamycin (Rapamune Wyeth 
pharmaceuticals) (Kim, Wilson et al. 2005). All tumour spheroids were stained for 
cytokeratin and cleaved caspase 3 after treatment. Cell apoptosis was quantified in the 
tumour spheroids as the percentage of all cytokeratin-positive cells with staining of cleaved 
caspase 3. Cell apoptosis in treated mononuclear cell lines were measured by characteristic 
nuclear morphology compared to the untreated sample. TRAIL plus Cycloheximide 
induced complete apoptosis (treated mean apoptosis score 94%; SEM 6% versus untreated 
mean apoptosis score 6%; SEM 4%) in monolayer MPM cell lines, but MPM tumour 
fragment spheroids demonstrated significant apoptotic resistance (treated mean apoptosis 
score 32%; SEM 4% versus untreated mean apoptosis score 7%; SEM 1%). The addition of 
LY294002 and Rapamycin to TRAIL plus Cycloheximide overcame the resistance to 
apoptosis in tumour fragment spheroids. LY294002 induced apoptosis in tumour fragment 
spheroids on its own and also enhanced the apoptotic effect of TRAIL plus Cycloheximide 
(treated mean apoptosis score 47; SEM 6%). Rapamycin did not have any effect on the 
tumour fragment spheroids on its own but enhanced the apoptotic effect of TRAIL plus 
Cycloheximide (treated mean apoptosis score 50; SEM 17%). In another study by the same 
group, Rapamycin, but not LY294002 (alone and in combination with Rapamycin), 
enhanced the apoptotic effect of TRAIL plus Cycloheximide in tumour fragment spheroids.  
Similar results were seen when Cycloheximide was replaced with Gemcitabine to mimic a 
more clinically relevant setting (Wilson, Barbone et al. 2008). The effect of Rapamycin 
overcoming resistance to apoptosis in tumour fragment spheroids may suggest that the 
resistance may be mediated through the MTOR protein.  
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Rapamycin has also been shown to affect the interaction of MPM cells with the 
extracellular matrix, thereby effecting cell invasiveness and metastasis. Ranzato et al 
(2009) studied the effect of Rapamycin in cell motility of MPM cells (MM98, REN, BR95, 
HMC-htert) on fibronectin and concluded that Rapamycin decreased cell spreading, 
motility and invasion by inhibiting the MTORC1 (Ranzato, Grosso et al. 2009). 
3.1.2.3 Inhibition of multiple targets 
The PI3K inhibitor LY294002 when combined with Cisplatin resulted in enhanced 
inhibition of cell growth in MPM cell lines (M43 and M17) and induction of apoptosis 
(M43 cell line) compared to either agent alone (Altomare, You et al. 2005). In vitro studies 
with ribonuclease enzyme Ranpirnase (Onconase®, Tamir Biotechnology, NJ) (Section 0) )  
in MPM cell lines have shown that Ranpirnase had significant cytotoxic effect on SV40 
negative MPM cell lines by induction of apoptosis (MB cells and MMO cells) but not in 
SV40 positive cell lines (MPP and MCAT cell lines) (Ramos-Nino, Vianale et al. 2005). 
SV40 positive cell lines were found to have increased pAKT compared to SV40 negative 
MPM cell lines. The MB cell line (SV40 negative) and MPP cell line (SV40 positive) were 
treated with LY294002 alone, Ranpirnase alone and in combination. MB cells showed a 
higher response rate to Ranpirnase and a lower response rate to LY294002. However, MPP 
cells showed a higher response rate to LY294002 and a lower response rate to Ranpirnase. 
Survival of both the cell lines was reduced when Ranpirnase and LY294002 were used in 
combination. 
In another in vitro study, the combination of Rapamycin with Cisplatin in MPM cell lines 
(MS257, MS924, MS248, MS589, H2052 and JMN1B) resulted in inhibition of cell 
proliferation and enhanced apoptosis in MS924, MS248, MS589 and JMN1B cells 
compared to either agent alone, but not in MS589 and H2052 cell when analysed using cell 
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proliferation MTS assays ( Section 5.2.2.3) (Hartman, Esposito et al. 2010). MS257, 
MS589, H2052 and JMN1B were more sensitive to single agent Cisplatin compared to 
MS924 and MS248 cells. MS924, MS248 and JMN1B demonstrated loss of cell viability 
when treated with single agent Rapamycin, but not MS257, MS589 and H2052 cells. 
MS589 and H2052 cells which were resistant to the effect of single agent Rapamycin were 
also resistant to the combined effect of Rapamycin and Cisplatin. 
In MPM tumour fragment spheroids targeting multiple targets in the PI3K/AKT/MTOR 
signal transduction pathway by combining LY294002 and Rapamycin did not yield any 
additional benefit compared to Rapamycin alone (Wilson, Barbone et al. 2008). 
3.1.3 Clinical trials with MTOR inhibitors in MPM 
A Phase I study of the Rapamycin rapalog Temsirolimus  (CCI-779, Wyeth 
pharmaceuticals) did not show any response in two patients with MPM (Raymond, 
Alexandre et al. 2004). Currently there are two Phase II trials ongoing which are looking at 
the effect of another Rapamycin rapalog Everolimus  (RAD001, Novartis, Basel) in 
MPM. The first trial is being conducted by the Southwest Oncology Group (Clinical Trials 
Identifier: NCT00770120), which is currently recruiting patients who have progressed on 
first line platinum based chemotherapy and is assessing the effect of Everolimus in patients 
with unresectable MPM. The primary outcome is to measure four month progression free 
survival and the secondary outcomes are to measure response rate, overall survival and 
toxicity.  The second Phase II trial is being conducted by Memorial Sloan-Kettering Cancer 
Centre to assess the effect of Everolimus in patients who have progressed on standard 
chemotherapy in MPM (Clinical Trials Identifier: NCT01024946) . The primary outcome is 
to determine the rate of clinical benefit at 16 weeks. The secondary outcomes are response 
rate and toxicity.  
64 
 
3.1.4 Discussion 
The pAKT and pMTOR proteins are frequently up regulated in MPM (65% to 100%) and 
may induce resistance to apoptosis resulting and cell survival. Targeting the 
PI3K/AKT/MTOR pathway may have a therapeutic effect in MPM, which is otherwise a 
very poor prognostic disease with a fatal outcome. 
In vitro studies looking at inhibiting PI3K as well as MTORC1 in mesothelioma cell lines 
as well as tumour fragment spheroids have at best shown to have a modest response. The 
effect of LY294002 in tumour fragment spheroids is debatable with one study by Kim et al 
(2005) demonstrating some effect but not when repeated by Wilson et al (2008) (Kim, 
Wilson et al. 2005; Wilson, Barbone et al. 2008). This lack of benefit by PI3K inhibitor in 
MPM could be because of AKT activation by other means such as MTORC2.  
The modest response to inhibition of MTORC1 by Rapamycin in MPM, as well as other 
cancers, may be as a result of inhibition of the negative feedback loop of the MTOR 
pathway (MTOR/p70S6K/IRS1/PI3K) resulting in increased activation of AKT which 
stimulates cell survival and proliferation (Chiang and Abraham 2007). One of the potential 
ways to overcome feedback activation of AKT by MTORC1 inhibition would be to block 
MTORC1 as well as PI3K/AKT. However, the combination of PI3K inhibitor LY294002 
and MTORC1 inhibitor Rapamycin did not have any enhanced therapeutic effect when 
tested in mesothelioma tumour fragment spheroids (Wilson, Barbone et al. 2008). One of 
the potential reasons for this may be direct activation of AKT by loss of PTEN and 
presence of MTORC2. Combined inhibition of MTORC1 and MTORC2 may be an 
improved therapeutic strategy. Inhibition of MTORC2 may further limit the feedback 
activation of AKT by MTORC1 inhibition (Gupta, Ansell et al. 2009). Second generation 
MTOR kinase inhibitors have been developed which compete with ATP at the catalytic site 
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of MTOR protein and inhibit both MTORC1 and MTORC2 (Figure 3.2) (Yang and Guan 
2007; Liu, Thoreen et al. 2009). The catalytic domains of MTOR protein and p110  
subunits of PI3K are structurally related. Therefore inhibition of MTOR kinase may also 
inhibit PI3K thereby further reducing the AKT activation produced by MTORC1 
inhibition. Various MTOR kinase inhibitors such as OSI-027 (Osi Pharmaceuticals) and 
AZD-8055 (Astra Zeneca) and dual PI3K / MTOR kinase inhibitors such as NVP-BEZ235 
(Novartis) and XL-765 (Exelisis) are currently in early Phase trials (Vilar, Perez-Garcia et 
al. 2011).  
In vitro studies with PI3K/MTORC1 inhibitors, when combined with chemotherapy, have 
shown to have an enhanced therapeutic potential. PI3K/MTOR inhibitors may overcome 
resistance to apoptosis mediated through the PI3K/AKT/MTOR signal transduction 
pathway thereby sensitising the cells to the cytotoxic effects of chemotherapy resulting in 
an enhanced therapeutic outcome. 
So far there have been no clinical studies reported looking at the therapeutic effect of 
PI3K/MTOR inhibitors as single agents, multi targeted therapies or in combination with 
chemotherapy in MPM. The two clinical trials with Everolimus discussed above are still 
recruiting patients and the outcomes are awaited. Further studies need to be done to better 
understand the role of PI3K/MTOR inhibitors in the clinical setting in MPM. The role of 
MTORC2 in the absence of PTEN in MPM needs to be further delineated and the effect of 
combined inhibition of MTORC1 and MTORC2 needs to be studied. 
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Chapter 4.  Role of Arachidonic acid 
metabolites in MPM 
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Arachidonic acid is a polyunsaturated fatty acid present in the phospholipid of cell 
membrane. It is metabolised by the Cyclooxygenase (COX) and Lipoxygenase (LOX) 
enzymes resulting in the production of prostanoids, Leukotrienes, hydroxyeicosatetraenoic 
acids (HETE) and hydroperoxyeicosatetraenoic acids, which have been implicated in 
inflammation and carcinogenesis. 
4.1 Cyclooxygenases 
Cyclooxygenases, also known as Prostaglandin-endoperoxidase synthases, are a family of 
myeloperoxidases which catalyse the rate limiting step of Prostaglandin biosynthesis from 
Arachidonic acid (Chandrasekharan and Simmons 2004; Sobolewski, Cerella et al. 2010). 
COX’s are present as homodimers.  Each monomer is made up of three different structural 
domains. The amino terminal of the protein contains a single EGF binding domain, which 
functions as a dimerisation domain, followed by four amphipathic helices that anchors the 
protein to the membrane (Chandrasekharan and Simmons 2004). The third domain is the 
catalytic domain involved in the metabolism of Arachidonic acid.   COX’s are normally 
located at the luminal aspect of the endoplasmic reticulum and nuclear membrane. There 
are 3 isoforms of COX’s. COX-1 is a glycoprotein encoded by a gene on chromosome 9. It 
is ubiquitously and constitutively expressed and plays an important role in tissue 
homeostasis, cytoprotection and cell signalling (Smith 1989). COX-2 is also a glycoprotein 
with its primary structure similar to that of COX-1 and is encoded by a gene on 
chromosome 1. It is inducible and is regulated by cytokines and growth factors in 
inflammation and oncogenesis. COX-2 is up regulated in various cancers such as colon, 
lung, breast, stomach, bladder and mesothelioma (Marrogi, Pass et al. 2000; O'Kane, 
Cawkwell et al. 2005). COX-3 is a splice variant of COX-1, present mainly in brain and 
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spinal cord and its function is currently not clear (Sobolewski, Cerella et al. 2010). COX’s 
are bifunctional enzymes with cyclooxygenase (bis-dioxygenase) and peroxidase activity. 
Arachidonic acid is converted to PGG2 by cyclooxygenase activity of COX’s and the 
peroxidase activity reduces PGG2 to PGH2. Both the reactions are coupled and 
functionally interconnected.  
4.1.1 Prostanoid biosynthesis 
Arachidonic acid is released from the membrane phospholipids by Phospholipase A2. Once 
released Arachidonic acid is oxygenated to PGG2 and reduced to PGH2 by COX’s. PGH2 
is then further converted to PGE2, PGF2, PGD2, PGI2 and Thromboxane A2 (TXA2) 
(Figure 4.1). These PG’s then exert their effect by binding to their cell surface receptors in 
an autocrine or paracrine manner. Among these PG’s PGE2 is implicated in carcinogenesis 
(Menter, Schilsky et al. 2010). 
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Figure 4.1 Synthesis of Prostanoids from Arachidonic acid. Adapted from (Smith 1989). 
 
4.1.2 COX-2 / PGE2 and cancer 
PGE2 plays an important role in carcinogenesis and like COX-2, is up regulated in many 
cancers including colon, lung, breast, head and neck cancers and is associated with poor 
prognosis (Wang and Dubois 2010). PGE2 and thus COX-2 can induce tumourogenesis by 
enhancing cell proliferation, survival and metastasis via a variety of cell signalling 
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pathways (Sobolewski, Cerella et al. 2010). Significant cross talk exists between the COX-
2/PGE2 and EGFR pathway resulting in transactivation of EGFR and activation of its 
downstream signalling pathways (Section 2.3 and Figure 2.7) (Dannenberg, Lippman et al. 
2005). Increased EGFR stimulation and subsequent activation of the intracellular MAPK 
result in increased transcription of COX-2, which then produces PG’s including PGE2. 
PGE2 can transactivate EGFR, promoting cell proliferation and migration, and also 
increases expression of amphiregulin, which is a ligand of EGFR. The activation of EGFR 
by COX-2/PGE2 can form a positive feedback loop resulting in increased production of 
COX-2/PGE2, which in turn transactivates the EGFR pathway. 
4.1.3 Role of COX-2 inhibition in MPM 
In MPM, COX-2 protein has shown by immunohistochemistry to be over expressed in 59% 
to 100% of tumour samples (Table 4.1) (Marrogi, Pass et al. 2000; Edwards, Faux et al. 
2002; Baldi, Santini et al. 2004; O'Kane, Cawkwell et al. 2005). The COX-2 inhibitor 
NS398 has been shown to have dose and time dependent antiproliferative activity in the 
mesothelioma cell line (VAMT-1) when compared to a normal mesothelial isolate (CHTN 
18833)  (Marrogi, Pass et al. 2000). COX-2 inhibitor Celecoxib has shown to inhibit MPM 
cell growth (MPP89, H-Meso and Ist-Mes 1) (Catalano, Graciotti et al. 2004). The COX-2 
inhibitor DuP-697 has demonstrated significant cytotoxicity in mesothelioma cell lines 
(MSTO-211H and NCI-H2052) and enhanced the cytotoxic effect of Pemetrexed from 4 to 
26 fold in the cell lines (O'Kane, Eagle et al. 2010). In mice oral administration of 
Rofecoxib significantly reduced the growth of mesothelioma (Table 4.2) (DeLong, Tanaka 
et al. 2003) (See appendix B for list of all drugs and targets for the targeted biological 
agents used).  
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 Table 4.1 COX-2 over expression in MPM assessed by immunohistochemistry. 
Study n = Histological 
subtype 
Antibody used COX-2 
Positive 
Prognostic 
marker 
Marrogi et 
al (Marrogi, 
Pass et al. 
2000) 
30 Epithelial – 23; 
Biphasic – 4; 
Sarcomatoid - 3 
 
C22420; 
(Transduction 
Laboratories, 
Lexington, KY) 
30/30 
(100%) 
Not reported 
Edwards et 
al (Edwards, 
Faux et al. 
2002) 
18 Not reported SC-1745 (Santa 
Cruz) 
18/18 
(100%) 
Yes – poor 
survival 
(p=0.0005) 
Baldi et al 
(Baldi, 
Santini et al. 
2004) 
29 Epithelial – 16; 
Biphasic – 7; 
Sarcomatoid - 6 
SC-1745 (Santa 
Cruz) 
19/29 
(65.5%) 
Yes – poor 
survival 
(p=0.01) 
O’Kane et al 
(O'Kane, 
Cawkwell et 
al. 2005) 
86 Epithelial – 42; 
Biphasic – 28; 
Sarcomatoid - 16 
COX-2, Clone 
33 (BD 
Biosciences, 
CA, USA) 
51/86 
(59%) 
Yes – good 
survival (p= 
0.002) 
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Table 4.2 Cytotoxic effects of COX-2 inhibitors in MPM. 
Study Drugs Samples Methodology Comments 
 
Marrogi et al 
(Marrogi, Pass 
et al. 2000) 
NS398 MPM cell line 
(VAMT-1) 
Cell count and 
FACS 
 
 
 
DeLong et al 
(DeLong, 
Tanaka et al. 
2003) 
Rofecoxib Mouse model  Tumour size in 
mouse 
Only in small 
tumours 
 
 
Catalano et al 
(Catalano, 
Graciotti et al. 
2004) 
Celecoxib; 
NS398; 
Indometacin 
 
MPM cell lines 
(MPP89,H-
Meso,1st-Mes1);  
Mouse model 
Cell 
Proliferation 
Assay (MTS) 
Celecoxib > 
NS398 > 
Indometacin 
 
O’Kane et al 
(O'Kane, Eagle 
et al. 2010)  
flurbiprofen; 
DuP-697;  
MPM cell lines 
(MSTO-211H, 
NCI-H2052, 
NCI-H2452) 
Cell 
Proliferation 
Assay (MTT)  
Potentiates the 
cytotoxic 
effects of 
Pemetrexed 
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4.1.4 Role of combined COX-2 and EGFR inhibition in MPM 
In MPM, both EGFR and COX-2 are over expressed and may have a significant role to 
play in survival and metastasis of this disease. Since significant cross talk exists between 
the two, targeting both the pathways by combining their respective inhibitors may form a 
rationale for the treatment. In MPM cell lines, both EGFR inhibitors Gefitinib (Janne, 
Taffaro et al. 2002; Catalano, Graciotti et al. 2004) and COX-2 inhibitors Celecoxib, 
NS398 and DuP-697 (O'Kane, Eagle et al. 2010) have shown to be cytotoxic when used 
individually. Combined inhibition of five MPM cell lines (NCI-2452, MPP89, Ist-Mes-1, 
Ist-Mes-2 and MSTO-211) with Gefitinib and Rofecoxib showed synergistic effect in only 
the Ist-Mes-2 cell line (Stoppoloni, Canino et al. 2010).  It is yet unknown whether the 
combination of EGFR inhibitors (Monoclonal antibodies and TKIs) and COX-2 inhibitors 
would enhance the cytotoxic effects of either agent when used alone. 
4.2 Lipoxygenases 
Three isoenzymes exist for Lipoxygenase, 5LOX, 12LOX and 15LOX. 5LOX and 12LOX 
have been implicated in carcinogenesis. 
4.2.1 Leukotriene biosynthesis 
Arachidonic acid is converted into Leukotriene (LT) A4 by its interaction with 5LOX and 
5LOX activating protein (FLAP). LTA4 can be converted into 5-HETE, hydrolysed into 
LTB4 or LTC4. LTC4 is then converted to LTD4, which is then converted into LTE4 
(Figure 4.2). Arachidonic acid can also be converted into 12-HETE by its interaction with 
12LOX (Wang and Dubois 2010). The LT’s are produced by leukocytes, epithelial cells 
and endothelial cells and play an important role in mounting an inflammatory response. 
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Figure 4.2 Synthesis of Leukotriene from Arachidonic acid. 
 
4.2.2 LOX and Cancer 
Expression of 5LOX and 12LOX has recently been associated with carcinogenesis of 
various solid tumours. 5LOX and 12LOX are generally absent in normal epithelia, but are 
expressed in various epithelial cancers such as colon, oesophageal, lung, prostate, bladder, 
oral, melanoma, renal and breast (Natarajan, Esworthy et al. 1997; Gupta, Srivastava et al. 
2001; Hennig, Ding et al. 2002; Winer, Normolle et al. 2002; Jiang, Douglas-Jones et al. 
2003; Ohd, Nielsen et al. 2003; Yoshimura, Matsuyama et al. 2003; Chen, Wang et al. 
2004; Matsuyama, Yoshimura et al. 2004; Yoshimura, Inoue et al. 2004; Hoque, Lippman 
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et al. 2005; Li, Sood et al. 2005; Barresi, Grosso et al. 2007).  
LTB4 has been shown to cause cell proliferation and survival in colon cancers. LTB4 
mediated its action via the cell surface receptor BLT1, which activates MAPK pathway. In 
pancreatic cancers LTB4 / BLT1 activates the PI3K-AKT and the MAPK pathway resulting 
in cell survival (Figure 4.3) (Wang and Dubois 2010). 12HETE interacts with the NFkB 
pathway resulting in antiapoptosis and cell survival (Kandouz, Nie et al. 2003). 12HETE 
activates protein kinase C and interact with various growth factors resulting in 
angiogenesis, invasion and metastasis (Honn, Tang et al. 1994).  
4.2.3 Role of LOX inhibition in MPM 
So far there has been only one study published evaluating the role of LOX in MPM cell 
lines.  The three mesothelioma cell lines (created by infecting normal mesothelial cells with 
SV40) expressed both 5LOX and 12LOX when assessed by RT-PCR as opposed to normal 
mesothelial cells which expressed 12LOX only. The 5LOX inhibitor AA-861, the 
generalised LOX inhibitor NDGA and LOX antisense oligonucleotides, significantly 
inhibited mesothelioma cell proliferation in these cell lines (Romano , Catalano et al. 2001).  
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Figure 4.3 Activation of EGFR signalling pathway by LTB4. LTB4 activates BLT1 
receptor and their signal transduction pathway leads to activation of EGFR downstream 
pathway. BLT1 can be activated by its ligand LTB4 resulting in the activation of PI3K and 
MAPK. (Adapted from (Wang and Dubois 2010)). 
 
4.3 Dual COX-2 and 5LOX inhibitors 
Both COX-2 and 5LOX have shown be up regulated in a variety of solid tumours such as 
colon, prostrate, pancreas, oral and oesophageal cancers and combined inhibition of both 
COX-2 and 5LOX have shown to have an enhanced therapeutic effect in in vitro studies 
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(Tucker, Dannenberg et al. 1999; Chen, Wang et al. 2004; Hoque, Lippman et al. 2005; Li, 
Sood et al. 2005; Ye, Wu et al. 2005; Cianchi, Cortesini et al. 2006; Zhi, Wang et al. 2006). 
Currently there are no published studies demonstrating the anti tumour effect of dual COX-
2 and 5LOX inhibitors in MPM. 
4.4 Discussion 
COX-2 plays an important role in carcinogenesis and found to be expressed in many solid 
tumours including MPM. COX-2 inhibitors such as Celecoxib, NS398 and DuP-697 have 
been shown to inhibit proliferation of MPM in cell lines and mouse models. Studies done in 
our laboratory have previously demonstrated that COX-2 inhibitors not only inhibit MPM 
cell lines, but also potentiate the cytotoxic effect of Pemetrexed chemotherapy. Significant 
cross talk exists between the COX-2 and EGFR pathway therefore targeting both the 
pathways simultaneously may form a rationale for the treatment. Combined inhibition of 
COX-2 (Rofecoxib) and EGFR (Gefitinib) has shown synergistic effect in one MPM cell 
line (Ist-Mes-2) (Stoppoloni, Canino et al. 2010). Currently there are no published reports 
evaluating the combination of anti-EGFR monoclonal antibodies and COX-2 inhibitors. 
Further studies are needed to evaluate the anti-tumour effect of EGFR and COX-2 
inhibition.  
The LOX enzymes (5LOX and 12LOX) are expressed in a variety of solid tumours. It is 
currently not known whether the LOX enzyme is expressed in MPM and this needs further 
evaluation. 
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Chapter 5.  Principles of Laboratory 
techniques 
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5.1 Translational research 
Translational research in medicine involves conducting basic research in the laboratory 
(bench) and translating significant findings into clinical practice (bedside). This bench to 
bedside approach is the hallmark of translational research and needs close collaboration 
between the researchers and clinicians to obtain quick and meaningful results. With recent 
advances in molecular technologies, we are now able to study the pathophysiology of 
cancer cells and the effect of drugs on the cells in a much greater detail. There are various 
assays available which can analyse the effect of drugs on cells and the use of methods such 
as proteomics can further enhance our understanding of the mechanism of action of these 
drugs. 
5.2 Cellular assays 
There are various methods by which the effect of drugs in cells can be studied in vitro. 
They can be broadly classified into cytotoxicity assays and cell proliferation assays. When 
assessing the amount of cell lysis or death due to a drug, cytotoxicity assays are preferred 
and when assessing the amount of cell proliferation or reduction in cell proliferation, cell 
proliferation assays are used.  
5.2.1 Cytotoxicity assays 
Cytotoxicity assays are performed to assess the cell killing property of a compound or drug. 
Cell death usually results in alteration of cell membrane permeability resulting in release of 
intracellular substances such as lactate dehydrogenase (LHD) or uptake of extracellular 
substances such as Trypan blue, which would otherwise not take place in viable cells with 
intact cell membrane (Figure 5.1). Trypan blue can be taken up by the damaged cell 
membrane. Individual cells can then be counted using a haemocytometer or flow cytometry 
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to assess the cytotoxic effect of a drug, as the cells stained with trypan blue would be the 
dead cells. As this involves analyzing single cells, it is laborious, time consuming and not 
suitable for high volume assays. LDH is a stable cytoplasmic enzyme that is present in 
most of the cells and is released in the medium when the cell membrane is damaged. This 
LDH can then be quantified using commercially available kits.    
 
 
 
Figure 5.1 Cytotoxicity assays. Alterations in plasma membrane permeability in dead cells 
result in the release of LDH or uptake of Trypan blue which can be measured.  
 
5.2.2 Cell proliferation assays 
Cell proliferation assays are based on measuring the number of viable or healthy cells 
proliferating in a given medium. There are various ways in which cell proliferation can be 
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measured such as clonogenic assays, DNA synthesis assays and mitochondrial activity 
assays.  
5.2.2.1 Clonogenic assays 
Clonogenic assays are cell survival assays which measure the ability of a single cell to form 
a colony which is defined as more than 50 cells. It measures the ability of every cell to 
multiply indefinitely and form colonies. Cells are seeded in appropriate media before and 
after treatment and the colonies counted after 1-3 weeks. This assay is the method of choice 
for analysing dose survival curves for radiation induced cell damage and certain cytotoxic 
drugs (Franken, Rodermond et al. 2006). As this assay relies on counting individual 
colonies, it is time consuming and laborious and it is not practical for high output assays.  
5.2.2.2 DNA Synthesis Assays 
These assays measure the synthesis of DNA as a surrogate marker for cell proliferation as 
DNA replication is a prerequisite for cell multiplication. Prelabelled DNA precursors can 
be added onto the cells, which are taken up by the dividing cells and incorporated into their 
DNA. These precursors can then be quantified and the amount of precursors incorporated 
into the DNA will be directly proportional to the multiplying cells. Thymidine analogue 5-
bromo-2’-deoxy-uridine (BrdU) can in incorporated into the DNA of replicating cells 
instead of Thymidine. The cultured proliferating cells are incubated with BrdU for 
optimum duration during which BrdU is incorporated into the DNA. The incorporated 
BrdU can then be detected using commercially available immunodetection kits, which has 
enzyme, conjugated anti BrdU antibody and can be detected by a substrate reaction and 
quantified by chemiluminescent or colorimetric assays.  
 
82 
 
5.2.2.3 Mitochondrial activity assays 
Viable cells are metabolically active as energy is required for cellular growth and functions. 
Metabolically active cells when incubated with tetrazolium salts are reduced to colored 
formazan and can be quantified using Enzyme linked immunosorbent assay (ELISA) plate 
reader. Since most of the cellular metabolism occurs in the mitochondria, this is a measure 
of mitochondrial activity in viable cells. Dead cells are not metabolically active and do not 
have any effect on the tetrazolium salts. The intensity of the colour change due to the 
production of formazan salts is directly proportional to the number of viable cells in the 
medium. As a result, mitochondrial activity assays can also be used to assess the cytotoxic 
capability of a drug, as cell death would reduce the intensity of the colour change. There are 
various tetrazolium salts commercially available, but the most widely used salts are the 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and MTS salts (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
(Mosmann 1983; Cory, Owen et al. 1991). Certain anti-neoplastic drugs such as Epirubicin, 
Paclitaxel, Doxetaxel, and Cisplatin can directly interact with MTT salts and reduce it to 
Formazan, thereby overestimating the amount of cell proliferation (Rao and Knaus 2008).  
MTT is a water-soluble tetrazole, which is yellow in colour. MTT is reduced by 
mitochondrial reductase enzymes present in metabolically active (viable) cells into 
formazan salt, which is purple in colour and is not soluble in water, hence forming crystals 
(Figure 5.2). These crystals can be solubalised using lysis buffer (40%SDS, 40%DMF, pH 
6.7) and quantified by reading the absorbance spectrophotometrically at wavelength 570 
nm using an ELISA plate reader. 
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Figure 5.2 Chemical reaction demonstrating conversion of MTT to Formazan. 
 
MTS is another alternative colorimetric assay, which uses a different reagent. MTS 
produces formazan in the presence of an electron coupling reagent phenazine methosulfate. 
This formazan is a water-soluble product and can be quantified by reading its absorbance 
spectrophotometrically at a wavelength of 492 nm. 
Use of MTS reagent has various advantages over the use of MTT reagent. Formazan 
products produced as a result of reduction of the MTT reagent are not water-soluble and 
form crystals, which require a lysis buffer to solubilise resulting in cell death.  Due to cell 
death only a single reading at a time point can be taken. However, the MTS reagent in the 
presence of phenazine methosulfate produces water-soluble formazan products. It requires 
fewer steps than the MTT experiment and reduces variability. Also since the use of MTS 
reagent is not cytotoxic, multiple readings at various time intervals can be taken. 
5.3 Discussion 
To analyse the effect of a drug in cell lines both cytotoxic as well as proliferative assays 
can be used. However, for assessing the effect of drugs which act on specific targets, cell 
proliferation assays are better than cytotoxicity assays as these drugs do not necessarily 
induce cell death, but may be cytostatic. Since the cytotoxicity assays rely on alteration in 
cell membrane permeability, it underestimates the cytotoxic effects of some drugs that may 
cause cell death due to its intracellular effect. In our study we would be assessing the 
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cytotoxic effects of drugs that may cause death by inhibiting intracellular signalling 
pathways and may not induce alteration in cell permeability. In view of this, using 
cytotoxicity assays based on alternation is cell permeability was not used in our study.   
For the use of high throughput assays when analyzing the effect of multiple drugs in 
multiple cell lines clonogenic assays are impractical, as they require counting of individual 
colonies making them laborious and time consuming. The use of micro plates containing 96 
wells in each plate is the most widely use format when multiple assays are required. These 
plates have 12 wells placed horizontally in 8 rows. They lend themselves to rapid analysis 
of high sample count and simultaneous assessment of various drugs, multiple dilutions of a 
drug or multiple cell lines. As the use of 96 well plates require a typical reaction volume of 
100 µl to 200 µl per well, it uses significantly less media and drugs making them cost 
effective. The absorbance of the colour change in the media of the plates can be measured 
easily using an ELISA plate reader.   
DNA synthesis assays and the mitochondrial activity assays can be performed using the 
micro plate format for rapid and effective analysis.  For the purpose of our study, the use of 
mitochondrial activity assays is preferred as it can also measure the antiproliferative and the 
cytotoxic capabilities of anti-neoplastic drugs simultaneously as opposed to DNA synthesis 
assays, which are antiproliferative. We preferred MTS assays due to its ease of use and less 
variability in the experiments compared to the MTT assays.   
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5.4 Proteomics 
Once the anti-tumour effect of a certain drugs is identified, it is important to explore the 
mechanism of action of the drug. Novel proteomic platforms can be used to identify the 
molecular mechanism of action of drugs. There are various global analysis methods by 
which a cancer cell can be studied such as genomics, transcriptomics and proteomics 
(Figure 5.3). 
 
 
Figure 5.3  Global analysis methods. Global methods by which a cancer cell can be studied 
at various time intervals depending upon its progression from DNA to functional proteins 
are Genomics, which is based on the study of DNA; Transcriptomics, which is based on the 
study of RNA expression; and Proteomics, which is based on the study of proteins 
expression. 
 
A genome is the entire DNA that is present in an organism and contains all the genes. 
These genes code for all proteins that are required by the organism. The Human Genome 
Project has now identified all the genes present in human DNA. The DNA is transcribed 
into mRNA (messenger ribonucleic acid) that is then translated into proteins, which after 
posttranslational modifications form the functional end result. The genome is relatively 
static and mutations in the genes may not have any functional relevance. Genes can also 
code for more than one protein. The levels of mRNA and proteins are dynamic. The global 
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study of mRNA expression, called transcriptomics, is usually microarray based and used 
for gene expression profiling. This explores the relative levels of mRNA expression from 
genes that are known to be associated with a disease.  However, this does not take into 
consideration any posttranslational modification of the proteins translated or protein 
degradation. The levels of mRNA and protein expression may not correlate at any one time 
point as the mRNA may not be translated into protein or the peak in protein expression may 
lag behind the peak in mRNA production. 
In view of the above drawbacks, the global study of the proteome, called proteomics, may 
provide a more realistic picture of the functional aberrations within a cancer cell. 
Proteomics is a large-scale, global, high throughput, technique for the study of the 
proteome. The study of proteins and its interactions within a cancer cell using proteomic 
techniques is called oncoproteomics. Oncoproteomics can be used in understanding 
complex molecular changes that occur in a cancer cell and help us in identifying 
mechanisms of drug actions, drug resistance and toxicities. It can also be used to identify 
potential new targets for diagnosis and treatment.  They may also be useful to identify 
biomarkers to individualise treatment strategies for patients. 
5.4.1 Antibody Microarray 
Antibody microarray is a technique used in oncoproteomics that can compare protein 
expression profiles in two different samples such as a sample treated with a drug compared 
to its control. An antibody microarray is a collection of antibodies spotted in pairs onto a 
nitrocellulose coated glass microscope slide. It is not however, a global technique as it is 
reliant on the number of antibodies that can be spotted on the slide, but this can be many 
hundreds. The two different protein samples are labelled with different coloured dyes, 
mixed together in equal quantities and incubated with the slide. Depending upon the 
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amount of protein present in each labelled sample, protein expression is detected upon 
competitive binding of the protein to its corresponding antibody on the slide. The amount 
of each dye present on individual antibody is directly proportional to the amount of protein 
present in each sample. The signal intensity can be measured using a fluorescent scanner 
and fold change of the differential expression calculated depending upon the signal 
intensity. A fold change of more than 1.8 is considered significant (Hodgkinson, Elfadl et 
al. 2011). The antibodies spotted onto the slide can relate to a specific biological function 
such as apoptosis or a cell signalling pathway such as EGFR pathway and hence can be 
targeted to analyse a specific outcome. There are various outcomes that can be measured 
such as defining signal transduction pathways, molecular classification of tumours, drug 
sensitivity and resistance, molecular mechanism of action of drugs, etc.  
5.4.2 Data mining 
Depending upon the number of antibodies spotted in antibody microarray experiments, the 
results of the differentially expressed proteins can run into hundreds, which needs to be 
analysed in a logical and scientifically meaningful manner depending upon their biological 
functions, interaction with each other and with other proteins within a specific signalling 
pathway. There are various commercially available software that can enable us to analyse 
the results, such as, Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, 
http://www.ingenuity.com/), STRING (http://string-db.org/), GeneGo MetaCore 
(http://www.genego.com/metacore.php), Ariadne Pathway Studio 
(http://www.ariadnegenomics.com/products/pathway-studio/), etc. Among these, IPA is the 
most widely used software (Muller, Schrotter et al. 2011).  
Ingenuity Pathway Analysis is web-based database launched in 2003. It maintains a 
database of genes and proteins along with their biological and chemical relationships, 
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interactions, pathways, drug targets and biomarkers. This database is called Ingenuity 
pathways knowledge base (IPKB) and is manually curated and regularly updated based on 
published data in scientific literature. The genes of the differentially expressed proteins 
identified by antibody microarray analysis can be analysed depending upon its interaction 
and signalling pathways. This allows for better understanding of the biological functions, 
protein interaction and cell signalling pathways of the differentially expressed proteins 
identified in high throughput proteomic experiments. 
5.5 Identification of individual proteins  
Various antibody based techniques can be used to identify specific proteins of interest in 
cells as well as tissues. Identification of individual proteins can help validate proteins found 
using high throughput proteomic techniques as well as ascertain the expression or absence 
of certain proteins in cell lines or tissue samples. Some of the antibody based techniques 
that are widely used are Western blot, ELISA, Flow cytometry and Immunohistochemistry. 
5.5.1 Western blot 
Western blot can be used to identify proteins which are separated based on their molecular 
weight. The proteins within a sample are separated by electrophoresis based on their 
molecular weight and then transferred onto a nitrocellulose membrane (Figure 5.4). The 
nitrocellulose membrane has a high affinity for protein binding and hence the free protein 
binding sites need to be blocked using non-fat milk or Bovine serum albumin. An antibody 
specific to the protein in question can now be added which would bind to the protein if 
present. This antibody can be tagged with a label or a secondary antibody can be added 
which can be detected using chemiluminescence or fluorescence techniques. To ensure 
equal loading of different proteins in the same membrane, the membrane can be probed 
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using housekeeping proteins such as α tubulin or GAPDH which should demonstrate 
constant level of expression and can act as loading controls. Western blotting is generally 
used for qualitative purposes, but the expressed proteins can then be quantified using a 
densitometer. This will enable identification of proteins that are differentially expressed in 
different samples such as drug treated versus control. Quantification of proteins using a 
densitometer may not be accurate due to various pitfalls in the procedure and at best can be 
considered as a semi-quantitative (Gassmann, Grenacher et al. 2009). Digitalisation of the 
western blot film can alter the signal intensity depending upon the quality and illumination 
of the scanner. Other steps such as colour of the film, background staining and overlapping 
bands can all influence the accuracy of the protein quantification. The accuracy of protein 
quantification can be improved by using appropriate external and internal controls and with 
the creation of standard curves, which can be used to calibrate protein expression levels. 
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Figure 5.4 Schematic diagram of a western blot procedure. Proteins lysate are loaded onto 
a gel and separated by electrophoresis. The proteins are transferred from the gel to a 
nitrocellulose membrane. The membrane is blocked by using non-fat milk and then 
incubated with primary and then subsequently secondary antibody which is tagged and can 
be detected by chemiluminescence technique. The film can then be scanned and analysed 
using a densitometer. 
 
5.5.2 Enzyme Linked Immunosorbent Assay (ELISA) 
In ELISA the specific antibody is immobilised onto a microtitre plate. The protein lysate is 
added onto the plate and the specific protein of interest if present binds to the antibody. A 
secondary antibody coupled with an enzyme can then be added to bind with the fixed 
antibody. A substrate specific to the enzyme is added which then changes colour and can be 
read using a plate reader thereby enabling the identification and quantification of the 
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protein of interest. The intensity of the colour is directly proportional to the amount of 
protein present. 
5.5.3 Flow cytometry 
Flow cytometry measures the optical characteristics of a cell as well as the fluorescent 
characteristics of the fluorescent dyes (fluorochrome) attached to the cell. Fluorochromes 
(eg: R-phycoerythrin) are dyes that can be tagged onto a specific antibody against a protein 
of interest. Flow cytometers are made up of a fluidics chamber, light source and the optical 
and fluorescence detection mirrors (Figure 5.5). The cell population once injected into the 
flow cytometer is arranged into a single file inside a sheath due to the linear flow of fluid 
surrounding the sheath. This enables a single cell to pass through an interrogation point 
where the light source (laser) then intersects the cell. The cells then scatter the light 
depending upon their physical properties such as the size and the granular content. The 
optical mirrors are placed at various positions to absorb the light scatter. One of the mirrors 
is placed in the line of the light source which measures the forward scatter (FSC) based on 
the size of the cell and one perpendicular to the light source which measures the side scatter 
(SSC) based on the granularity of the cell. The fluorescent mirrors detect the fluorescence 
of the fluorochrome attached to the cell.  
If the presence of a particular protein on the cell surface or inside a cell needs to be 
identified, then an antibody specific to the protein of interest, conjugated with a 
fluorochrome, is incubated with the cells forming an antibody-protein complex. When this 
cell is passed through the interrogation point the fluorochrome will be excited upon contact 
with the light source of a particular wavelength due to the light being absorbed by the 
fluorochrome. Some of the energy of the excited fluorochrome is released as heat due to the 
internal conformational change of the fluorochrome. When the fluorochrome returns to its 
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normal resting stage the rest of the energy is released as fluorescence. The wavelength of 
the fluorescence released is longer compared to the wavelength of the lights used to excite 
the fluorochrome due to the loss of some of the energy as heat. The wavelength of the 
fluorescence of the dye emitted can be measured using a variety of fluorescent mirrors and 
filters which allow light of particular wavelengths to pass through. When light comes in 
contact with the fluorescent detectors a small voltage is generated which can be log 
amplified and displayed on a histogram. The data can be quantified depending upon the 
number of cells that are positive for the protein of interest. 
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Figure 5.5  Components of a flow cytometer. The cell suspension is injected into the 
fluidics system containing the sheath with a laminar flow which arranges the cells in a 
single file. The cell is intersected by a light source from a laser. The light source is 
scattered by the cell, passed through the filters and then detected by optical and fluorescent 
detectors. One of the mirrors is placed in the line of the light source which measures the 
forward scatter (FSC) and one perpendicular to the light source which measures the side 
scatter (SSC). 
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5.5.4 Immunohistochemistry 
Immunohistochemistry can be used to identify the presence or absence of proteins in a 
formalin fixed paraffin embedded clinical tissue samples using antibodies against the 
protein of interest (Figure 5.6). The tissue samples are mounted onto a glass slide. 
Formalin cross reacts with proteins present in the tissues and alters the chemical 
characteristics of the proteins. Heating the slides at high temperature (microwave or 
boiling) can hydrolyse the cross link bonds formed between formalin and the proteins. This 
process is call antigen retrieval.  The non specific binding sites on the proteins are blocked 
using casein. The slide is then incubated with the primary antibody specific to the protein of 
interest. The antibody (if optimised) would bind to the protein if present. The slide is then 
incubated with a biotin conjugated secondary antibody against the primary antibody. The 
secondary antibody can be detected using enzyme streptavidin conjugate. Horseradish 
peroxidase (HRP) is a common enzyme used with streptavidin. HRP in the presence of 
Hydrogen peroxide oxidizes water soluable chromogens such as DAB (3,30-
diaminobenzidine tetrahydrochloride) into coloured insoluble precipitates which can be 
seen visually under a light microscope. Significant inter observer variability exists while 
interpreting the slides. This may be as a result of different training and experience between 
the observers, evaluating different regions of a slide, presence of tumour heterogeneity, 
different scoring methods, use of different microscopes, etc. This user variability can be 
minimised by standardizing the scoring methodology, appropriate training of the observers 
and using multiple observers to analyse the slide.  Computerised scanning and assessment 
of the slide may be a more objective and reproducible technique of minimising inter-
observer variability. 
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Figure 5.6 Schematic diagram of Immunohistochemistry protocol. 
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5.6 Aims 
Despite recent advances in chemotherapy, advanced malignant pleural mesothelioma 
(MPM) is associated with poor prognosis. With the administration of Cisplatin/Pemetrexed, 
the median survival of MPM is still only 12 months and currently there is no widely 
approved salvage regimen after failure of first line treatment. There is a need for 
development of newer targeted treatment options in MPM. Epidermal Growth Factor 
Receptor (EGFR), Mammalian target of Rapamycin (MTOR) and Cyclooxygenase-2 
(COX-2) are frequently up regulated in MPM and the potential role of Lipoxygenase 
(LOX) is unclear. The molecular interaction of EGFR, MTOR, COX-2 and LOX are 
detailed in Figure 5.7. 
Currently there are no published studies assessing the effect of anti-EGFR monoclonal 
antibodies such as Cetuximab in MPM. EGFR TKIs such as Gefitinib have previously been 
shown to be cytotoxic to EGF stimulated MPM cell lines, but early Phase clinical trials 
using Gefitinib and Erlotinib  have not shown any benefit for patients (Janne, Taffaro et al. 
2002; Govindan, Kratzke et al. 2005; Garland, Rankin et al. 2007). The presence of 
activating EGFR mutations has a significant positive impact on the response of NSCLC to 
EGFR TKIs. However, the presence of these mutations has not been demonstrated in 
MPM. Similarly the presence of KRAS and BRAF mutations, which induce resistance to 
EGFR monoclonal antibody therapy have so far not been seen in MPM and needs further 
evaluation. There is a modest anti-neoplastic effect seen with MTORC1 inhibition using 
Rapamycin in MPM cell lines, but there are no published studies evaluating the effect of 
combined MTORC1 and MTORC2 inhibition in MPM (Altomare, You et al. 2005). Also 
the effect of combining MTOR inhibition with EGFR inhibition in MPM is currently not 
known. The COX-2 inhibitor DuP-697 has demonstrated cytotoxic effect in COX-2 
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expressing MPM cell lines and also potentiate the inhibitory effect of Pemetrexed in these 
cell lines (O'Kane, Eagle et al. 2010). However, the mechanism of action of DuP-697 is 
currently not well defined. The mechanism of action of DuP-697 needs to be evaluated to 
further enhance our understanding of how COX-2 inhibitors work in MPM and also 
identify new targets which can be therapeutically manipulated. COX-2 inhibitors such as 
Celecoxib and Rofecoxib have been shown to have some anti-tumour effect in MPM and 
Rofecoxib has also shown to have some synergy with Gefitinib in MPM (Catalano, 
Graciotti et al. 2004; Stoppoloni, Canino et al. 2010). The effect of COX-2 inhibition when 
combined with anti-EGFR monoclonal antibodies such as Cetuximab in MPM is currently 
not known. In MPM, various small studies have shown that PTEN protein is rarely absent, 
but a large immunohistochemical study of 341 MPM samples demonstrated that PTEN 
protein was lost in 62% and its loss was associated with poor survival (Opitz, Soltermann et 
al. 2008). This needs further independent validation as it may have significant impact in our 
understanding and choice of targeted treatment option in MPM. 
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Figure 5.7 The EGFR, MTOR, COX-2 and LOX interactions. This figure demonstrates the 
interactions between EGFR, MTOR, COX-2/PGE2 and LOX/LTB4 pathways. Activation 
of EGFR by EGF ligands, including Amphiregulin, results in the activation of 
PI3K/AKT/MTOR pathway and the RAS/RAF/MAPK pathway. MAPK results in 
increased transcription of COX-2 gene thereby increasing the production of COX-2 protein 
which acts on Arachidonic acid to form PGE2. PGE2 activated the EGFR pathway by 
increasing the production of Amphiregulin via its action on cAMP and PKA, by directly 
activating PI3K and by activating the EGFR TK domain via Src. This results in a positive 
feedback loop between COX-2 and EGFR signalling pathways. 5LOX results in the 
increased production of LTB4 which acts on BLT receptors and activates PI3K and MTOR 
resulting in activation of PI3K/AKT/MTOR pathway and MAPK pathway. 
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The specific aims for this project are 
 
 To identify the absence of PTEN protein expression and its prognostic relevance in 
MPM using immunohistochemistry. 
 To demonstrate the expression and prognostic relevance of 5LOXand 12LOX in 
MPM using immunohistochemistry. 
 To evaluate the expression of EGFR and PTEN  proteins and the presence of EGFR, 
KRAS and BRAF mutation in MPM cell lines (NCI-H2052, NCI-H2452, MSTO-
211H) and non small cell lung cancer cell lines (A549).  A549 cell line was used as 
control as it has been extensively evaluated in the literature.  
 To evaluate the effect of EGFR inhibition using Cetuximab and Gefitinib in MPM 
cell lines using the MTS assay. The effect of Cetuximab in MPM has not been 
previously evaluated. 
 To evaluate the effect of MTORC1 and MTORC2 inhibition using Rapamycin 
(MTORC1 inhibitor) and Ku0063794 (MTORC1 and MTORC2 inhibitor) in MPM 
cell lines using the MTS assay. 
 To evaluate the effect of COX-2 inhibition using Celecoxib in MPM cell lines using 
the MTS assay. 
 To identify if the therapeutic effect of anti EGFR inhibition can be enhanced by 
combining Cetuximab and Gefitinib individually with Rapamycin, Ku0063794 and 
Celecoxib in MPM cell lines using the MTS assay. 
 To study the mechanism of action of COX-2 inhibitor DuP-697 using antibody 
microarray, IPA, and western blot. This will also be a pilot study to see if antibody 
microarray can be used to identify mechanism of action of drugs. 
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Chapter 6.  Materials and Methods 
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6.1 Materials 
6.1.1 Cell lines  
The mesothelioma cell lines MSTO-211H (Biphasic, ATCC Number CRL-2081), NCI-
H2052 (epithelial, ATCC Number CRL-5915) and NCI-H2452 (epithelial, ATCC Number 
CRL-5946) were obtained from the American Type Culture Collection (ATCC). The lung 
cancer cell line A549 (catalogue number 86012804) was used as a control was obtained 
from the European Collection of Cell Cultures (ECACC). All cell lines were maintained in 
RPMI 1640 medium (#31870, Invitrogen). RPMI 1640 medium (500 mls)  was 
supplemented with 50 mls of heat inactivated fetal bovine serum (#10106, Invitrogen), 5 
mls of 200 mM L-glutamine (#25303, Invitrogen), 5 mls of 100 U/ml penicillin (#15140, 
Invitrogen) and 5 mls fungizone (#15290, Invitrogen). 
6.1.2 MTS Reagents 
MTS reagent (The CellTiter 96® AQueous One Solution Reagent) was obtained from 
Promega (G3582). The reagent contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and 
an electron coupling reagent phenazine ethosulfate (Section 5.2.2.3) .  
6.1.3 Drugs 
Dimethyl Sulfoxide (DMSO; #D2650, Sigma Aldrich) was used as a drug carrier. 
6.1.3.1 Cetuximab 
Cetuximab was obtained as a Material transfer arrangement from Merck KGaA, Germany 
(see appendix D). 
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6.1.3.2 Mechanism of action 
Cetuximab is a recombinant, chimeric monoclonal antibody directed against the EGFR. It is 
manufactured by ImClone and Bristol-Myers Squibb under the brand name Erbitux®. 
Cetuximab binds to the extracellular domain of the EGFR with an affinity approximately 5-
10 times that of endogenous ligands, thereby preventing activation, dimerisation and 
internalization of the receptor. This may result in inhibition of the EGFR signalling and 
subsequently reduce the EGFR dependent growth of the tumour cells (Figure 2.3) 
Cetuximab also mediates an antibody dependent cell-mediated cytotoxicity towards EGFR-
expressing tumour cells (Kurai, Chikumi et al. 2007). 
Cetuximab has a molecular mass of 145781.6 g/mol (Figure 6.1). 
 
Figure 6.1  3-Dimentional structure of Cetuximab (Image from www.drugbank.ca) 
6.1.3.3 Pharmacokinetics 
Cetuximab when administered intravenously at an initial dose of 400 mg/m2 body surface 
area had a mean volume of distribution of 2.9 l/m
2
 (range; 1.5 to 6.2 l/m2). Cetuximab has 
a long elimination half life of 70 to 100 hours. The mean plasma Cmax was 243 μg /ml 
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(Tan, Moore et al. 2006). The mean steady state peak concentration at FDA approved 
dosing ranges from 168 to 235 μg/mL (Mukohara, Engelman et al. 2005).  
6.1.3.4 Therapeutic indications 
Cetuximab currently has FDA and EMEA approval for the following indications: 
 Patients with EGFR expressing, KRAS wild type metastatic colorectal cancer. 
 Patients with squamous cell cancer of head and neck. 
6.1.3.5 Gefitinib  
Gefitinib was purchased from Tocris Bioscience (catalogue number 3000). 
6.1.3.6 Mechanism of action 
Gefitinib is a small molecule tyrosine kinase inhibitor directed against the tyrosine kinase 
domain of the EGFR (Figure 2.3). It is manufactured by AstraZeneca under the trade name 
Iressa®.  Gefitinib inhibits the EGFR tyrosine kinase domain by binding to the ATP 
binding site and inhibiting EGFR autophosphorylation, thereby subsequently inhibiting the 
EGFR downstream signalling and cellular growth (Kuramitsu, Miyamoto et al. 2009).  
6.1.3.6.1 Molecular structure  
Gefitinib has a molecular mass of 446.9 g/mol and its chemical formula is C22H24ClFN4O3 
(Figure 6.2). 
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Figure 6.2  Chemical Structure of Gefitinib. (Image from www.tocris.com) 
 
6.1.3.6.2 Pharmacokinetics 
Gefitinib is administered orally and peak plasma concentration occurs 3 to 7 hours after 
administration. It has a mean steady state volume of distribution of 1400 litres and 90% is 
plasma protein bound. Gefitinib is metabolised extensively in the liver predominantly by 
cytochrome P450 (CYP) 3A4 and excreted mainly as metabolites via the faeces. 
Concomitant administration of CYP 3A4 inhibitors such as Itraconazole increased the 
Gefitinib plasma levels and administration of CYP 3A4 inducers such as Rifampicin 
reduces the Gefitinib plasma levels (Cohen, Williams et al. 2004). The mean steady state 
peak concentration at FDA approved dosing was 615 ng/ml (Herbst, Maddox et al. 2002).  
6.1.3.6.3 Therapeutic indications 
It is approved by FDA and EMEA for use in metastatic Non small cell lung cancer with 
activating mutations of EGFR-TK domain.  
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6.1.3.7 Rapamycin 
Rapamycin was purchased from Tocris Bioscience (catalogue number 1292). 
 
6.1.3.7.1 Mechanism of action 
Rapamycin (Wyeth, Madison, NJ), manufactured by Wyeth under the trade name 
Rapamune®, acts by forming a complex with cytosolic protein FK-binding protein 12 
(FKBP12) and binding to MTORC1 thereby resulting in inhibition of its downstream 
signalling pathway (Huang, Bjornsti et al. 2003). It was initially approved by FDA for use 
as an immunosuppressant in organ transplant patients for prophylaxis of organ rejection.  
 
6.1.3.7.2 Molecular structure 
Rapamycin has a molecular mass of 914.18 g/mol and its chemical formula is C51H79NO13. 
 (Figure 6.3). 
 
 
Figure 6.3 Chemical Structure of Rapamycin. (Image from www.tocris.com) 
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6.1.3.7.3 Pharmacokinetics 
Rapamycin is administered orally and metabolised in the liver by CYP 3A4 enzyme. At a 
maximum tolerated dose of 6mg per day in patients with solid tumours, the plasma Cmax 
was 27.6 ng/ml and the steady state plasma concentration was 12.7 ng/ml (Jimeno, Rudek 
et al. 2008).  
6.1.3.7.4 Therapeutic Indications 
Rapamycin is indicated for the prophylaxis of organ rejection in patients receiving renal 
transplants. Everolimus (Novartis) is a derivative of Rapamycin, and is approved by FDA 
and EMEA for use in advanced renal cell cancer and progressive neuroendocrine tumours 
of the pancreas. 
6.1.3.8 Ku0063794 
Ku0063794 was purchased from Tocris Bioscience (catalogue number 3725). 
6.1.3.8.1 Mechanism of action 
Ku0063794, synthesised by AstraZeneca, is a MTOR kinase inhibitor and inhibits both 
MTORC1 and MTORC2. It also suppresses cell growth and induces G1-cell cycle arrest. 
(Garcia-Martinez, Moran et al. 2009).  
6.1.3.8.2 Molecular structure 
Ku0063794 has a molecular mass of 465.5 g/mol and its chemical formula is 
C25H31N5O4 (Figure 6.4).  
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Figure 6.4  Chemical Structure of Ku0063794. (Image from www.tocris.com) 
 
6.1.3.8.3 Pharmacodynamics 
Ku0063794 inhibits both MTORC1 and MTORC2 in Human embryonic kidney cells 
(HEK-293) with an IC50 of approximately 10 nM (Garcia-Martinez, Moran et al. 2009). 
6.1.3.8.4 Therapeutic indications 
Ku0063794 is a prototype of the MTOR inhibitor AZD8055 currently in Phase I trial in 
advanced solid tumours (Shimizu, Dobashi et al. 2009). 
6.1.3.9 Celecoxib 
Celecoxib was obtained as a Material transfer arrangement from Pfizer, USA (see appendix 
D). 
6.1.3.9.1 Mechanism of action 
Celecoxib, marketed by Pfizer under the trade name Celebrex® and Onsenal®, is a 
selective COX-2 inhibitor, resulting in inhibition of prostaglandin synthesis. Various 
studies have also shown that Celecoxib may act as an antineoplastic agent by induction of 
apoptosis which may be independent of or dependent on COX-2 inhibition (Hsu, Ching et 
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al. 2000; Han, Leng et al. 2004; Kern, Haugg et al. 2006; Lou, Fatima et al. 2006; 
Schonthal 2007). 
6.1.3.9.2 Molecular structure 
Celecoxib has a molecular mass of 381.37 g/mol and its chemical formula is 
C17H14F3N3O2S (Figure 6.5).  
 
 
 
Figure 6.5  Chemical Structure of Celecoxib. (Image from www.tocris.com) 
 
6.1.3.9.3 Pharmacokinetics 
Celecoxib is administered orally and has a moderate rate of absorption. It is mainly albumin 
bound and is eliminated via excretion in urine and faeces. With an oral dose of 400 mg per 
day, the plasma steady state concentration was found to range from 740 ng/ml to 1000 
ng/ml (Grossman, Olson et al. 2008; Sauter, Qin et al. 2008).   
6.1.3.9.4 Therapeutic indications 
Celecoxib is used as an anti-inflammatory agent. It was initially approved by FDA and 
EMEA for use in patients with Familial adenomatous polyposis to prevent colon cancers 
but its approval has been withdrawn due to lack of long term safety and efficacy data.  
109 
 
6.1.3.10 DuP-697 
DuP-697 was purchased from Tocris Bioscience (catalogue number 1430). 
6.1.3.10.1 Mechanism of action 
DuP-697 is a selective COX-2 inhibitor (Gierse, Hauser et al. 1995). Studies have also 
shown that its action as an antiproliferative agent may be independent of COX-2 inhibition 
and may result in induction of apoptosis via activation of the caspase family (Churchman, 
Baydoun et al. 2007; Peng, Zhang et al. 2008) .  
6.1.3.10.2 Molecular structure 
DuP-697 has a molecular mass of 411.3 g/mol and its chemical formula is C17H12BrFO2S2 
(Figure 6.6).  
 
Figure 6.6  Chemical Structure of DuP-697. (Image from www.tocris.com) 
6.1.3.10.3 Pharmacodynamics 
DuP-697 inhibits COX-2 with an IC50 value of 0.01 µM when compared to COX1 at 
0.8µM in cultured Sf21 insect cells (Gierse, Hauser et al. 1995).  
6.1.3.10.4 Therapeutic indications 
Pre clinical data has shown DuP-697 to have antiproliferative effects in mesothelioma and 
chronic myeloid leukaemia cells (Peng, Zhang et al. 2008; O'Kane, Eagle et al. 2010).   
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6.1.4 Antibodies  
Antibodies for Western blot, Flow cytometry and Immunohistochemistry used are detailed 
in Table 6.1. 
 
Table 6.1 Antibodies for Western blot (WB), Flow cytometry (FC) and 
Immunohistochemistry (IHC). (RT= Room temperature) 
Antibody Company Catalogu
e no 
Mol. 
Wt. 
(kD) 
Host 
species 
Blocking 
agent 
Optimised 
dilution 
Applica
tion 
Anti 
rabbit 
secondary 
 
Santa Cruz SC2030  goat milk 1:1000; 1 
hour; RT 
WB 
Anti 
mouse 
secondary 
 
Santa Cruz SC2031  goat milk 1:1000; 1 
hour; RT 
WB 
Anti alpha 
tubulin, 
loading 
control 
 
Abcam ab 7291 50 mouse milk 1:2500; 2 
hours; RT 
WB 
Anti beta 
actin, 
loading 
control 
 
Abcam ab 8227 40 rabbit milk 1:2500; 2 
hours; RT 
WB 
GAPDH Abcam ab9485 37 rabbit milk 1:2500; 2 
hours; RT 
WB 
Bid Abcam ab32060 22 rabbit milk 1:300; 16 
hours 
WB 
Bcl xL Sigma B9429 27 mouse milk 1:5000; 2 
hours; RT 
WB 
PTEN Abcam ab32199 47 rabbit milk 1:400; 2 
hours; RT 
WB 
p70S6K Abcam ab32359 70 Rabbit Milk 1:1000; 16 
hours; 4
0
C 
WB 
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EGFR Abcam ab2430 170 Rabbit Milk unable to 
optimise  
WB 
EGFR BD 
Pharminogen 
555997  Mouse  Incubate 
in dark for 
30 mins. 
 
FC 
PTEN Abcam ab32199  rabbit Normal 
horse 
serum 
1:50; 2 
hours; RT 
IHC 
5LOX Abcam ab39347  rabbit casein 1:50; 2 
hours; RT 
IHC 
12LOX Abcam ab23678  rabbit casein 1:100; 2 
hours; RT 
IHC 
 
6.2 Methods 
6.2.1 Cell culture 
Cells were cultured in a sterile environment in a class II cell culture hood. All equipment 
including the cell culture hood, incubator and water bath were cleaned with Virkon and 
70% alcohol at regular intervals and the cell culture hood was cleaned prior to every 
experiment. All other equipment used was sprayed with 70% alcohol prior to placing it into 
the cell culture hood. Sterile techniques were maintained throughout the procedure to 
minimise the risk of infection. All cell lines were tested negative for mycoplasma infection. 
6.2.1.1 Thawing of cells 
Cells, which were stored at -80 
0
C in DMSO, were placed in a water bath to be thawed 
quickly. When thawed, the cells were transferred into a screw cap universal tube and 9 mls 
of media per ml of cells (1:10 dilution) was added very slowly (1-2 mins.) to dilute the 
DMSO. The cell suspension was then centrifuged (Sigma 2-5 centrifuge) at 400 x g over 3 
minutes to pellet the cells and remove DMSO, which is toxic to cells. The supernatant was 
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discarded and the pellet resuspended in fresh prewarmed to 37ºC RPMI media (Section 
6.1.1) and incubated into a  T25 (25 cm
2
) or T75 (75 cm
2
) flask depending upon the number 
of cells. The cells were then placed in a humidified incubator at 37ºC with 5% CO2. 
6.2.1.2 Culturing of cells 
Cells were cultured and passaged 3 times a week in T25 or T75 flasks. The flasks were first 
assessed under an inverted microscope for confluency, adherence and infections. In the cell 
culture hood the old media was removed and 3mls of pre-warmed Trypsin (TrypLE Select; 
#12563, Invitrogen) was added to dislodge the adherent cells. Cells were kept in the 
incubator for 3 minutes and tapped gently to dislodge the cells. 7mls of media was added to 
neutralise the action of Trypsin. The cell suspension was then transferred into a screw cap 
universal tube and centrifuged at 400 x g for 3 minutes. The supernatant was discarded and 
cell pellet resuspended in media. The cell suspension was divided depending upon 
confluency and transferred into new flasks.  
6.2.1.3 Freezing cells 
Cells were frozen using freezing media made up of RPMI media containing 10% DMSO. A 
cell pellet was prepared as per section 6.2.1.2 and 1ml of freezing media added to it slowly. 
The cell suspension was then transferred to a cryovial and stored at -80ºC. 
6.2.2 Cell counting 
Cell counting was done using a Neubauer haemocytometer (Figure 6.7). This is a 
microscopic slide with a cell counting chamber of 0.1 mm deep cut into it. This chamber 
has a grid etched into it, which is made up of squares like a graph paper. The main grid is 
1mm X 1mm, medium square is 0.2 mm X 0.2 mm (made of 4 X 4 tiny square) and tiny 
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square is 0.05 mm X 0.05 mm. As the dimensions of the squares are known the volume of 
the square can be calculated. Each 1 mm X 1 mm square will hold a volume of 10
-4
ml. 
 
Figure 6.7  Cell counting using Neubauer haemocytometer. Squares 1,2,3,4 and 5 were 
counted with cell counter and an average of the 5 squares taken. Cells present on the top 
and left lines of the smaller squares were counted to maintain consistency. Square 2 is 
highlighted to show cells. 
 
Cells were harvested, pelleted and diluted in 1-2 mls of media. 25 l of media with 
suspended cells were taken and added to 25 l of Trypan blue (0.4% w/v trypan blue in 
PBS solution) in a 0.5ml eppendorf tube. PBS solution was made up by mixing one tablet 
of PBS (Gibco™ cat no 18912-014, Invitrogen) in 500 mls of dH20 and was sterilised by 
autoclaving at 120 
0
C. Adding the cells to trypan blue facilitated visualization and counting 
of the cells as Trypan blue stains non-viable cells (dead cells) blue. Twenty-five micro 
litres of the above suspension was taken and pipetted onto the V grove of the slide with 
cover slip placed on top. The suspension was sucked in by capillary action and filled up the 
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cell counting chamber. The slide was left for 5 minutes allowing the cells to sediment. Five 
large squares were counted and an average of the 5 squares taken. Cells overlaying the top 
and left boarder of the smaller squares were counted and consistency maintained 
throughout. Each 1mm square should have between 50-150 cells for a more accurate cell 
count.  The average of 5 squares were taken and multiplied by 2 to account for dilution with 
trypan blue. The value X 10
4
 gave the number of cells in 1ml.  
Once the number of cell/ml was known, the amount of suspension needed to determine the 
number of cell required was calculated and made up to 100 l with RPMI media for each 
well in a 96 well plate for MTS assay (Section 6.2.4.1). Depending on the number of wells, 
the amount of cell suspension and media required was calculated first and distributed to the 
wells accordingly. 
6.2.3 Seeding a 96 well plate with cells 
Seeding cells into a 96 well flat-bottomed plate requires a cell count with a Neubauer 
haemocytometer. Once the cell count per ml of suspension is known, the amount of 
suspension to be added into media per well can be calculated.  
Example: 
Cells counted in chamber 1, 2, 3, 4 and 5 were 61, 82, 46, 54 and 58 cells. The average of 
these was 60 cells, which was multiplied by 2 to account for dilution with trypan blue. This 
gave the cell count as 120 X 10
4
 cell per ml or 1200 cells / l. If 10,000 cells per well were 
required in 6 wells then the amount of cell suspension containing 10,000 cells was 
calculated to be 8.3 l (10,000 / 1200 = 8.3 l). If the cells were to be seeded in 6 wells then 
calculations were done for 8 wells to account for wastage. Hence, for 8 wells 8.3 X 8 = 
66.4 l of cell suspension was required. One hundred micro litres of media was required 
per well hence for 8 wells we needed 800 l of media. We needed to add 66.4 l of cell 
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suspension, so the total amount of media required was 800 – 66.4 = 733.6 l. The required 
amount of media (733.6 l) was mixed with 66.4 l of cell suspension to give 80,000 cells 
in 800 l of media.  One hundred micro litres of this cell suspension was added to each well 
to give 10,000 cells / 100 l of media / well. 
6.2.4 Colorimetric Assays 
Colorimetric assays were first described by Mosmann, used in laboratories to measure cell 
viability and proliferation (Mosmann 1983). MTS assay is a colorimetric method for 
determining the number of viable cells in proliferation or cytotoxicity assays (Section 
5.2.2.3). MTS reagent, in the presence of an electron coupling reagent phenazine 
methosulfate, is reduced by mitochondrial reductase enzymes present in metabolically 
active (viable) cells into formazan products. As only the viable cells can reduce the MTS 
reagent, cells that are dead will not form formazan products.  The formazan products can be 
quantified by reading the absorbance spectrophotometrically at wavelength 492 nm using a 
microtitre plate reader. 
6.2.4.1 MTS Assay 
6.2.4.1.1 Protocol 
MTS Assay’s were performed in a 96 well flat-bottomed plate (Figure 6.8). 
Day 1: One hundred micro litres of cell suspension (Section 6.2.3) was added in each well 
and for each drug concentration there were six replicates. One hundred micro litres of 
media was added in each well along the border of the plate. Distilled H2O was added to the 
first well (labelled A1) on the top left hand corner of the plate. Two plates were prepared; 
Plate A for baseline reading on Day 2 and Plate B for dosing with drugs and reading on 
Day 5. Both plates were incubated overnight in 37ºC with 5% CO2 in the incubator.  
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Day 2-4: MTS reagent (20 µl) (G3582; Promega) was added to the cells seeded on Plate A 
and incubated for 3 hours in the incubator. The absorbance of Plate A was then read on Day 
2 spectrophotometrically at wavelength 492nm using a microtitre plate reader (Labsystems 
Multiskan MS, Thermo Electron Corporation). The cells seeded in Plate B were dosed with 
drugs as appropriate on day 2, day 3 and day 4. Media and distilled H2O was changed in all 
wells daily. DMSO was used as a drug carrier for Gefitinib, Rapamycin, Ku0063794 and 
Celecoxib at a final concentration not more than 0.01% diluted in media. Stock solutions 
for Gefitinib (100mM), Rapamycin (500µM), Ku0063794 (1 mM) and Celecoxib (10mM) 
were prepared and stored at -20 ºC. All drugs were freshly diluted in media and stored at    
4 ºC for not more than 3 days. Cetuximab was provided at a concentration of 2mg/ml, 
diluted in 10 mM Sodium Phosphate and 145 mM Sodium Chloride (pH 7.2). Cetuximab 
was stored at 4 ºC and was freshly prepared daily by diluting in media at various 
concentrations as required. 
Day 5: MTS reagent (20 µl) was added into the wells to be read including blanks. The 
experiment was performed in the dark.  The plate was then incubated for 3 hours in 37ºC 
with 5% CO2 in the incubator. The plate was then read spectrophotometrically at 
wavelength 492 nm using a microtitre plate reader and absorbance values obtained.  
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Figure 6.8 MTS assay. This figure demonstrates a 96 well plate showing the layout of 
media (blank), control and treated cells in six replicates. The drugs were added with 
increasing concentration from left to right. Media was added along the borders of the flask 
and distilled water in the top left well.  
6.2.4.2 Calculation of cell proliferation based on MTS reading 
The average values of absorbance from the triplicate wells with cells as well as blanks were 
calculated. The average of the blanks was subtracted from the average value of wells with 
cells, which was then taken as the true absorbance reading for those cells. 
After determining the absorbance values from base line, for control cells and treated cells, 
the increase or decrease in the number of cells was established and expressed as a 
percentage of baseline growth. 
a= baseline absorbance  
b= control absorbance  
c= treated absorbance  
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Absorbance values were calculated as an average (of 6 replicates) – average of blanks (3 
replicates) 
Growth of control cells (d) = (b-a)/a  X 100% 
Growth of treated cells (e) = (c-a)/a  X 100% 
Growth of treated cells as a percentage of control cells (f) = [(e-d)/d] X 100 + 100 
Using the above formulae the growth of cells treated with various drugs were calculated 
and expressed as a percentage of baseline or control cells to ascertain the percentage of 
growth inhibition (see appendix A for an example calculation). 
6.2.4.2.1 Statistical analysis 
The mean of at least two independent experiments were calculated along with the standard 
deviation using Microsoft excel 2007. The average and the standard deviation of the 
percentage of growth inhibition were plotted onto a XY scatter graph. The growth 
inhibition values were on the Y-axis and the drug concentration on the X-axis. A trend line 
was added and the concentration at which 50% of the cells were dead was calculated from 
the equation on the chart.  
For the purpose of drug combinations, the half maximal inhibitory concentration of a drug 
was calculated using GraphPad Prism 5 software (GraphPad Software, Inc, San Diego, 
California). The drug concentration and the percentage of growth inhibition of all three 
independent experiments were uploaded onto the software. The drug concentrations were 
transformed to log scale. The control was set arbitrarily at 2 logs below the lowest drug 
concentration and reflected 100% normal proliferation. The dose response curve was 
calculated for each drug in individual cell line and was characterised by a 4 parametric 
logistic model estimated by a non linear regression analysis. For the purpose of drug 
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combination studies, the primary drug was used at various dilutions and the secondary drug 
was added at a fixed concentration (IC50 value) of the drug obtained in the particular cell 
line. 
6.2.5 Western blot 
6.2.5.1 Protein extraction 
Proteins were extracted from cell lines using Western blot lysis buffer. Western blot lysis 
buffer contained: 
 4ml Distilled water (DH2O) 
 1ml 0.5M TRIS:HCL pH6.8 (Sigma T1503) 
 0.8 ml Glycerol (Sigma G8773) to weigh down the  proteins 
 1.6 ml 10% SDS (Sigma L3771) to denature and negatively charge the proteins 
 200 l 0.05% Bromophenol blue (Sigma B5525) dye to visualise proteins 
To one ml of the above solution the following were added: 
 50 l of 2-Mercaptoethanol (#M-7522, Sigma Aldrich) to denature proteins 
 10 l Phosphatase Inhibitor Cocktail 1 to maintain phosphorylation of proteins  
(#P2850, Sigma Aldrich) 
 10 l Phosphatase Inhibitor Cocktail 2 to maintain phosphorylation of proteins  
(#P5726, Sigma Aldrich)  
 10 l Protease Inhibitor to inhibit protein degradation (#80-6501-23, Amersham 
Biosciences) 
Cells were pelleted as per section 6.2.1.2 and washed with cold PBS three times to ensure 
removal of media. The cells were suspended in 250 l of the western blot lysis buffer and 
vortexed for 5 mins. The suspension was then kept overnight (16 hours) in a cold room at 4 
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o
C on an end-over-end rotator. The suspension was then centrifuged at 10,000 xg for 15 
minutes at 4 
o
C in a microlitres centrifuge. The supernatant was taken and transferred into a 
pre chilled eppendorf and cell debris discarded. The eppendorf was then stored at -80
o
C for 
future use. 
6.2.5.2 Protein quantification 
Proteins were quantified using the RC DC™ (Reducing agent Compatible, Detergent 
Compatible) protein quantification kit (#500-0119 to -0122, Bio-Rad) which is a 
colorimetric assay. RC DC™ kit was used due to its compatibility with the western blot 
lysis buffer.  Standard Bovine serum albumin (BSA) protein dilutions were prepared at 0.2, 
0.5, 0.75, 1 and 1.5 mg/ml using 2mg/ml BSA stock with dH2O in pre labelled eppendorfs. 
Protein extracts that needed to be quantified were diluted with dH2O ranging from 1:2 to 
1:10 dilution to ensure that the concentrations fell within the assay range. To each 
eppendorf, 125 l of RC Reagent I was added, which was then vortexed and incubated at 
room temperature for 1 minute. Then 125 l of RC Reagent II was added, vortexed and 
centrifuged at 15,000 xg for 5 minutes. The supernatant was discarded by inverting the 
eppendorfs onto an absorbent paper to ensure complete removal of liquid and only the 
precipitated protein pellet remained in the tube. Reagent S (20 l) was added to Working 
Reagent A (1 ml) and 127 l of this was added to each eppendorf and vortexed for 5 
minutes or till all precipitate was dissolved. Reagent B (1 ml) was added to each eppendorf 
and incubated at room temperature for 15 minutes. 200 l of all BSA standards and the 
samples were transferred into a 96 well plate in triplicates. A1 well was kept as blank by 
adding dH2O. All air bubbles were removed and the 96 well plate was read 
spectrophotometrically using a microtitre plate reader at a wavelength of 690 nm. The 
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absorbance values of the known proteins are plotted onto a standard curve and the values of 
the unknown protein are calculated from the line equation of that curve. 
6.2.5.3 One-dimensional gel electrophoresis 
Proteins were diluted in Western blot lysis buffer (Section 6.2.5.1) made up to 25 l to 
obtain a protein concentration of 20 g.  
To one ml of Western blot lysis buffer, 50 l of 2-Mercaptoethanol (#M-7522, Sigma 
Aldrich) was added to denature proteins. 
The protein extracts were denatured in a thermo cycler by heating it at 95ºC for 5 minutes 
and subsequently transferred straight to ice to prevent reversal of protein denaturation. The 
proteins were then vortexed and centrifuged at 12,000 xg for 30 seconds. One or two 
(depending upon the number of samples), 12 % Precise Protein Gel (#25222, Thermo 
Scientific) were placed in a tank with a litre of Tris-HEPES-SDS running buffer (#28368). 
Molecular weight marker (10 µl) (Precision Plus Protein WesternC Standard, #161-0376, 
Bio-rad) was loaded onto the first well of the gel and 20 l of each sample was loaded into 
the wells and empty wells filled with 20 l of sample buffer. The gel was then 
electrophoresed at constant voltage of 140V for 40 – 90 minutes (Figure 5.4). 
6.2.5.4 Transfer to Nitrocellulose Membrane 
6.2.5.4.1 Wet transfer 
Transfer buffer and distilled water ice block was stored at -80ºC for 30 minutes.  
Transfer buffer contained: 
 200ml Methanol 
 800ml DH2O  
 3.3g Trizma Base (#93304, Fluka) 
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 14.4g Glycine (#G8898, Sigma Aldrich) 
The gel containing the separated proteins was sandwiched with pre-soaked (in transfer 
buffer) sponge, filter paper and nitrocellulose membrane (#LC2001, Invitrogen) inside a 
cassette in the following order; black side of cassette, sponge, filter paper, gel, membrane, 
filter paper, sponge, transparent side of cassette. The cassettes and ice pack were placed in a 
tank containing a stirrer and 1 litre of transfer buffer was added. It was ensured that the 
black side of the cassette was facing the black section of the tank. Electrophoretic transfer 
was then carried out at a constant current of 400 mA at 4ºC for 1 hour. 
6.2.5.4.2 Dry transfer using iBlot 
Dry transfer of proteins from the gel to the nitrocellulose membrane was done using the 
iBlot transfer system (Invitrogen). The iBlot disposable gel transfer stacks (#IB3010-01, 
Invitrogen) were used. The Bottom Stack was placed on the iBlot machine and then the gels 
were placed on the nitrocellulose membrane contained in the Bottom Stack. If two gels 
were run, then both of them could be placed side by side on the same membrane. Pre-
soaked filter paper (soaked in distilled water) was placed above the gels and air bubbles 
removed using a roller. The Top Stack was then put above the filter paper the electrode 
sponge placed on the lid. The lid was then secured and the iBlot machine ran for 7 minutes 
as per standard manufacturer’s recommendations.  
6.2.5.5 Blocking of binding sites on nitrocellulose membrane 
Once the transfer of proteins occurred from the gel to the nitrocellulose membrane, the 
membrane was then placed in a Nalgene box and blocked with 20 mls of blocking solution 
(either 5 % low-fat Marvel milk powder diluted in TBS Tween-20 or 5% Bovine serum 
albumin). TBS was made up of 121 g Trizma base, 170 g Sodium chloride (#S3014, Sigma 
Aldrich), made to 1 litre with dH2O and pH adjusted to 7.6 with concentrated HCL. TBS 
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Tween-20 was made up of 250 mls of TBS, 4750 mls of dH2O and 2.5 mls Tween-20 
(#P5927, Sigma Aldrich). The box containing the membrane was placed on an orbital 
shaker for 1 hour at room temperature or overnight at 4ºC at a rocking speed of 28 rpm. 
6.2.5.6 Immunoblotting 
The blocking solution was removed from the box containing the membrane and the 
membrane was incubated with 10 mls of primary antibody diluted in blocking solution on 
the orbital shaker. The membrane was then washed three times for five minutes each on the 
orbital shaker with 10 mls of TBS Tween-20 to remove unbound primary antibody. The 
membrane was then incubated with the relevant HRP conjugated secondary antibody 
depending upon the source of the primary antibody on the orbital shaker (see Table 6.1 for list 
of antibodies).  
6.2.5.7 Protein detection 
The membrane was incubated with 8 mls of West Pico Stable Peroxide Solution and 8 mls 
of Supersignal West Pico Luminol Enhancer Solution from the Supersignal West Pico 
Chemiluminescent Substrate Kit (#34078, Thermo Scientific) and gently shaken manually 
for 5 minutes in the dark. The Supersignal West Pico Chemiluminescent Substrate Kit acts 
as a substrate for horseradish peroxidase enzyme present on the secondary antibodies and 
emits chemiluminescent signal that can be captured on a film. The membrane was then 
placed between clean plastic sheets. A CL-XPosure Film (#34090, Thermo Scientific) was 
placed on the plastic sheet containing the membrane and enclosed in a cassette for 
appropriate duration depending upon the antibody. The film was then developed in 250 ml 
of GBX Developer (#P7042, Sigma Aldrich) for approximately 1 minute, followed by 30 
seconds incubation in 250 ml 5 % Acetic Acid, then fixed in 250 ml GBX Fixer (#P7167) 
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for 30 seconds and washed under running water for 30 seconds. The developed films were 
then air dried and analysed. 
6.2.5.8 Loading controls 
Membranes were also probed with loading controls such as GAPDH (ab9485, Abcam), 
Alpha Tubulin (ab7291, Abcam) and Beta Actin (ab8227, Abcam) to assess the accuracy of 
equal protein loading in each well. This allowed for fair comparison between samples in 
each well as the loading controls would normalise loading of samples and give semi-
quantitative assessment of differential protein expression between samples such as drug 
treated versus control using densitometer (Section 2.2.5.10). 
6.2.5.9 Densitometer 
The density of the band in the film is directly proportional to the amount of protein present 
in the sample. This density was quantified and compared between samples. The film was 
scanned using the GS800 Calibrated Densitometer (Bio-Rad) and analysed using Quantity 
One software (Bio-rad). For each sample the test protein band was normalised against the 
respective loading control band. The relative densities of the bands of the proteins in 
question were calculated. Once the values of the relative densities were obtained they were 
compared with each other to assess the fold change between them. 
6.2.6 Immunohistochemistry 
Immunohistochemistry is a laboratory technique used to identify specific antigens in tissues 
or cells based on the principle of specific binding of an antibody to the antigen and its 
visualization by a light microscope (Figure 5.6).  
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6.2.6.1 Tissue samples 
A series of 93 archival MPM tissue samples was available and had been previously 
characterised (O'Kane, Cawkwell et al. 2005). These were formalin-fixed paraffin-
embedded tissue blocks of patients diagnosed with histologically proven MPM within the 
Hull and East Yorkshire Hospitals NHS Trust, UK from 1995 to 2000. Among the 93 tissue 
samples, 48 were epithelioid, 27 were biphasic and 18 were of sarcomatoid histology. 
Survival data was available for all the 93 patients. Local Research Ethics committee 
approval was obtained (see appendix C).  
6.2.6.2 Sample preparation 
Paraffin-embedded 4 µm thick sections of MPM archival tissue samples were cut using a 
microtome onto Super Frost Plus slides (Menzel-Glaser, Germany) and dried overnight at 
37 
o
C in an incubator. Slides were dewaxed by submerging the slides in pre warmed 
Histoclear II (National Diagnostics, Hull, UK) for 10 minutes followed by dipping the 
slides in Histoclear II for 10 seconds each in 2 more pots of Histoclear II. The slides were 
then rehydrated with 100% ethanol for 10 seconds each in three pots. Endogenous 
peroxidase activity of RBC’s was blocked using 30% Hydrogen peroxide (H2O2) in 
methanol for 20 minutes. 
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6.2.6.3 Antigen retrieval 
Antigen retrieval was achieved by boiling slides in 1500 ml dH2O containing 15 mls 
Antigen Unmasking Solution (H-3300, Vector Laboratories Inc., CA, USA), in a pressure 
cooker for 3 minutes at 15 psi. The Antigen unmasking solution is based on a citric acid 
formula and is effective in unmasking antigens at high temperatures.  
6.2.6.4 Blocking non specific sites  
Slides there then transferred to a pot containing TBS and assembled onto a sequenza system 
(Shandon, UK). The  nonspecific staining was blocked by using either 100 µl of 1 X  casein 
(SP-5020, Vector Laboratories Inc., CA, USA) diluted in TBS for 10 minutes or 100 µl pre 
diluted blocking serum (normal horse serum from the Vectastain Quick Kit (#PK-7800, 
Vector Laboratories Inc., CA, USA) for 10 minutes. Slides were then washed with TBS for 
5 minutes each twice. 
6.2.6.5 Immunodetection 
Depending upon the blocking step the antibody was diluted in either 0.2 X casein in TBS 
(if blocked in casein) or 1.5% blocking serum (normal horse serum from the Vectastain 
Quick Kit) to achieve optimum dilution. One hundred microlitres of the diluted antibody 
was added to each slide and incubated at room temperature for 2 hrs (see Table 6.1 for list 
of antibodies). A negative control with 100 µl of 0.2 X casein or 1.5% blocking serum was 
included (depending upon the blocking step) with each batch of slides. Antibody detection 
was carried out using either the StreptABComplex / HRP Duet Mouse/Rabbit kit (#K0492, 
Dako Ltd, Ely, UK) if blocked in casein or the biotin-streptavidin preformed complex 
technology using the R.T.U. Vectastain Quick Kit (#PK-7800, Vector Laboratories Inc., 
CA, USA).  
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6.2.6.5.1 StreptABComplex / HRP Duet Mouse/Rabbit kit 
The slides were incubated with Reagent C (100 µl each slide) from the StreptABComplex / 
HRP Duet Mouse/Rabbit kit containing the biotinylated goat anti mouse/rabbit secondary 
antibody, diluted in TBS (1:100) for 30 minutes. The slides were washed with TBS for 5 
minutes and removed from the sequenza system and stored in TBS.  
6.2.6.5.2 R.T.U. Vectastain Quick Kit 
The slides were incubated with the pre diluted biotinylated pan-specific universal 
secondary antibody (100 µl each slide) from the R.T.U. Vectastain Quick Kit for 20 
minutes (the manufacturer’s recommendation was 10 minutes, but this was found to be sub 
optimal). The slides were washed with TBS for 5 minutes and incubated with streptavidin / 
peroxidase complex reagent from the kit (100 µl) for 10 minutes. The slides were rewashed 
with TBS for 5 minutes and removed from the sequenza system and stored in TBS.  
6.2.6.6 Antibody Visualisation 
Slides were incubated with 0.02% DAB in TBS containing 0.0125% H2O2 for up to 30 
minutes to allow for development of brown stain which could be seen under a light 
microscope. The staining was further enhanced by incubating the slides with Copper 
Sulphate (0.5% copper sulphate in 0.9% saline) for 5 minutes.  
6.2.6.7 Counterstaining, rehydration, clearing and mounting 
Slides were counterstained by prefiltered Harris Haematoxylin stain for 20 minutes. The 
slides were subsequently washed under running water to remove any excess haematoxylin. 
The counter stain was then differentiated in acid alcohol (1% HCL in 70% alcohol) for 10 
seconds and rewashed under running water. Slides were rehydrated in three pots of 100% 
ethanol for 10 seconds each and cleared in three pots of Histoclear II for 10 seconds each. 
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Slides were mounted onto coverslips containing histomount (National Diagnostics, Hull, 
UK). Slides were then left to dry overnight and viewed under a light microscope. 
6.2.6.8 Histological scoring  
Scoring was done by a consultant histopathologist (Dr. Ann Campbell) who is the regional 
expert in MPM.  Since different scoring methods were applied for different proteins, due to 
the nature of their expression, the scoring systems are discussed under the respective 
chapters (Section 7.2.2 and 8.2.2).  
6.2.6.9 Statistical analysis 
Statistical analysis was performed using the SPSS software version 17 and 18 (SPSS, 
Chicago, USA). Univariate survival analysis for protein expression and histological 
subtype was performed using Kaplan Meier curves with log rank analysis. Multivariate 
analysis was calculated using Cox regression to assess the effect of protein expression on 
survival, independent of histological subtype, which has shown to be an independent 
prognostic variable in MPM.  
6.2.7 Flow cytometry 
6.2.7.1 Sample preparation 
All cell lines (NCI-H2052, NCI-H2452, MSTO-211H, A549) were cultured in RPMI 
media, mildly trypsinised, centrifuged and counted in a Haemocytometer after Trypan blue 
staining. Two million cells for each cell line were taken, centrifuged at 400 x g for 3 
minutes and resuspended in 200 µl of PBS/BSA/Sodium Azide solution (PBS 1000ml; 
BSA 2.5grams; Sodium Azide 6.24mls).  
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6.2.7.2 Immunofluorescence staining of cell surface receptors 
Of the 200 µl cell suspension, 100 µl was incubated with 20 µl of EGFR antibody (BD 
Pharminogen; cat No 555997) and the other 100 µl was incubated with an isotype control 
(IgG2b, ) to account for the non specific binding. The EGFR and the isotype control 
antibodies were conjugated with fluorochrome PE (R-phycoerythrin). The cell suspensions 
were then incubated in the dark for 30 minutes. Cells were then washed with one ml of 
PBS/BSA/Sodium Azide solution and centrifuged at 400 X g for 3 minutes 
(Thermoscientific IEC CL3IR multispeed centrifuge). The supernatant was discarded and 
the cells were resuspended in 500 µl of filtered PBS/BSA/Sodium Azide solution.  The 
samples were immediately analysed on the BD FACSAria
TM
 II (BD Biosciences, Oxford, 
UK) using the FACSDiva software.  
6.2.7.3 FACS analysis 
The FACS was set up as per manufacturer’s instructions, FACSDiva software opened and 
start up procedure was followed (Figure 5.5). The cell suspension was acquired and the 
forward scatter (FSC) and the side scatter (SSC) voltages were altered for the isotype 
control to view the cell population in a dot plot (Figure 6.9) (Section 5.5.3). The voltage 
for the fluorochrome PE was set such that the histogram peak was located to the first 
segment of the grid. The cell population was selected and labelled P1 (gated) and the data 
for 10,000 cells were recorded. A marker (P2) was placed on the isotype control histogram 
encompassing ≤1% of the P1 cells (Figure 6.10) which was then subtracted from the 
percentage of cells showing positivity for protein expression. The cell suspension incubated 
with the EGFR antibody was acquired and the location and peak of the histogram recorded.  
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Figure 6.9 Cell acquisition by Flow cytometry. This dot plot demonstrates the A549 
cell population labelled with the isotype control for EGFR antibody and acquired by 
flow cytometry. The voltage settings for the FSC and the SSC were altered to show the 
cell population. The cell population selected to determine the EGFR expression of the 
cell lines was selected (P1). The X-axis demonstrates the FSC and Y-Axis 
demonstrates the SSC. Each dot on the graph represents a cell.  
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Figure 6.10 Histogram plot for isotype control. This figure demonstrates the 
histogram plot using P1 population of the isotype control of the A549 cell line 
(Figure 6.9). The voltage was altered so that the histogram peak was in the first 
segment of the grid. A marker (P2) was inserted (horizontal line on the X axis) to 
ensure ≤1% of the isotype control cells were encompassed by this marker. In a 
positive data set the histogram would fall within the P2 region (on the X axis) when 
the cell suspension incubated with the antibody is analysed. The X-axis demonstrates 
the relative fluorescence and the Y-Axis demonstrates the number of cells analysed. 
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6.2.8 Ingenuity pathway analysis (IPA) 
All proteins identified by antibody microarray were analysed using IPA software. The gene 
name of all the proteins identified was checked against the International Protein Index (IPI) 
and National Centre for Biotechnology Information (NCBI) database and uploaded onto the 
IPA software. The filters and general settings for analysis were as follows: 
 Reference set: Ingenuity Knowledge Base (Genes Only) 
 Relationship to include: Direct 
 Does not Include Endogenous Chemicals 
 Genes were included 
 Molecules per Network: 140 
 Networks per Analysis: 25 
 Data Sources: Select all 
 Species: Human (Relaxed filter) 
 Confidence: Experimentally Observed 
 Tissues and Cell lines: Select all (Relaxed filter) 
Once the genes were identified (ID’s Mapped) analysis of the genes was commenced. 
Ingenuity Pathway Analysis maintains a database of genes and proteins along with their 
biological and chemical relationships, interactions, pathways, drug targets and biomarkers. 
This database is called Ingenuity pathways knowledge base (IPKB) and is regularly 
updated based on published data in scientific literature. Within this IPKB there are various 
types of information which are manually reviewed and updated such as Ingenuity® Expert 
Findings from experimentally-demonstrated information, Ingenuity® ExpertAssist 
Findings from recently published journal abstracts, Ingenuity® Expert Knowledge 
containing signalling and metabolic pathway information developed by Ingenuity experts 
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and Ingenuity® Supported Third Party Information selected from other databases like 
Entrez Gene, Gene Ontology and RefSeq.  The relationship of genes and their products in 
the IPKB is abstracted into a large network called a Global Molecular network. The genes 
of the differentially expressed proteins identified which are also present in the Global 
Molecular network are called focus genes. The focused genes are overlaid into the Global 
Molecular network and the interactions of the focused genes amongst themselves along 
with various other connected genes within the Global Molecular network can be identified. 
Based on the focused genes, multiple networks may be identified and they are all given 
scores based upon the number of focused genes in relation to the total number of genes that 
could have been in the pathway. The higher the score, the increased number of focused 
genes in the network.  
IPA also maintains a library of canonical pathways, which are metabolic and cell signalling 
pathways. Based on the dataset of the focused genes, various canonical pathways are 
identified. All the canonical pathways identified are relayed as a bar chart with the x axis 
showing the pathways and the y axis the ratio of the total number of focused genes in 
relation to the total number of genes that could have been in the pathway. Fisher’s exact 
test was performed by IPA to determine the probability that the association between the 
focused genes and the canonical pathways identified was by chance and was displayed as a 
p-value. 
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Chapter aim 
To identify the absence of PTEN protein expression and its prognostic  
relevance in MPM using immunohistochemistry in a series or  
archival MPM tissue samples. 
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7.1 Introduction 
Phosphatase and Tensin Homolog (PTEN), also known as MMAC or TEP1, is a dual lipid 
and protein phosphatase encoded by the PTEN tumour suppressor gene on chromosome 
10q23 (Li and Sun 1997; Li, Yen et al. 1997; Steck, Pershouse et al. 1997). The PTEN gene 
has been shown to undergo mutations or deletion in various malignancies such as 
endometrial, glioblastoma, prostrate, ovarian, breast, lung etc (Rhei, Kang et al. 1997; 
Risinger, Hayes et al. 1997; Steck, Pershouse et al. 1997; Tashiro, Blazes et al. 1997; 
Bostrom, Cobbers et al. 1998; Feilotter, Nagai et al. 1998; Kohno, Takahashi et al. 1998; 
Suzuki, Freije et al. 1998; Wang, Parsons et al. 1998; Ali, Schriml et al. 1999). Germline 
mutations of the PTEN gene are associated with Cowdens syndrome, which is autosomally 
transmitted and is associated with increased risk of breast and thyroid tumours (Liaw, 
Marsh et al. 1997; Nelen, van Staveren et al. 1997). When cells are stimulated by growth 
factors, PI3K converts Phosphatidylinositol (4,5)-biphosphate (PIP2) into 
Phosphatidylinositol (3,4,5)-triphosphate (PIP3), which phosphorylates AKT and its 
downstream signalling cascade resulting in cell survival and proliferation. The PTEN 
protein negatively regulates phosphorylation of AKT by dephosphorylating PIP3 into PIP2 
(Maehama and Dixon 1998). Loss of PTEN protein may result in increased accumulation of 
PIP3 and constitutive activation of AKT resulting in increased cell survival (Section 3.1). 
 
In MPM, various small studies have shown that PTEN protein is rarely lost, but a recent 
large immunohistochemical study of 341 MPM samples demonstrated that PTEN protein 
was lost in 62% and its loss was associated with poor survival (Opitz, Soltermann et al. 
2008) (Table 3.1). Since there has been only one large study evaluating the expression of 
PTEN protein in MPM, this needs further validation as it may have a significant impact on 
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our understanding of the pathophysiology of MPM and our choice to targeted treatment 
options. In this study we aimed to analyse PTEN protein expression by 
immunohistochemistry in a previously described cohort of 86 samples (O'Kane, Cawkwell 
et al. 2005).  
7.2 Materials and Methods 
7.2.1 Tissue sample collection 
Eighty six archival tissue samples of patients diagnosed with MPM at Hull Royal 
Infirmary, Hull, UK from 1992 to 2000 were obtained. Clinicopathological data for all 
patients were available. Immunohistochemical analysis was performed in all of the 86 
MPM tissue samples (46 epithelial, 24 biphasic, 16 sarcomatoid) to determine the 
expression of PTEN protein. Normal pleura tissue sample was included in the cohort of the 
slides stained to act as a reference slide. 
7.2.2 Immunohistochemistry 
Immunohistochemistry was performed using R.T.U. Vectastain Quick Kit (#PK-7800, 
Vector Laboratories Inc., CA, USA) as detailed in section 6.2.6 with anti- PTEN primary 
antibody (ab32199; Abcam) at a dilution of 1:50.  
All slides were scored by a consultant histopathologist (Dr. Anne Campbell), as detailed in 
section 6.2.6.8. Colorectal tissue samples stained with antibody were used as a positive 
control and slide with antibody omitted as a negative control.  
7.2.3 Statistical Analysis 
Statistical analysis was performed using the SPSS software version PASW statistics 18 
(SPSS, Chicago, USA). Univariate survival analysis for histological subtype and PTEN 
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protein expression was performed using Kaplan Meier curves with log rank analysis. 
Multivariate analysis was calculated using Cox regression analysis. 
7.3 Results 
Mesothelial cells in normal pleura demonstrated positive staining for PTEN protein and 
served as a positive reference (Figure 7.1A). Fibroblasts and endothelial cells were also 
stained with anti-PTEN antibody and served as an internal control (Figure 7.1B). In slides 
where internal control was present, it was taken as a reference along with normal pleura and 
in slides where internal control was not seen normal pleura only was taken as a positive 
reference. 
The staining was recorded as (Figure 7.2) 
 0 - negative (no staining seen) 
 1 -  weak (intensity less than that of normal pleura positive reference slide) 
 2 - strong (intensity equal to or greater than that of normal pleura) 
Staining for PTEN protein in the MPM cells was seen in the cytoplasm as well as the 
nucleus. Cytoplasmic staining was used to calculate the PTEN protein staining score. 
PTEN protein staining score was 0 in 27% (23/86), 1 in 27% (23/86) and 2 in 46% (40/86) 
(Table 7.1). 
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Figure 7.1 Microphotograph of normal pleura and internal control. (A) Normal pleura 
demonstrating positive staining for PTEN protein expression (arrow; score 2). (B) 
Fibroblasts and endothelial cells stained positive and acted as internal control. 
 
Table 7.1  Frequency of PTEN protein expression in all tumour samples along with their 
histological subtypes. PTEN0= protein absent; PTEN1= intensity < normal pleura; 
PTEN2= intensity ≥ normal pleura). 
Samples Total                       PTEN staining Score 
PTEN 0   PTEN 1  PTEN 2  
All Samples  86  23 (26.7%)  23 (26.7%)  40 (46.5%)  
Epithelial  46  10 (22%)  11 (24%)  25 (54%)  
Biphasic  24  7 (29%)  6 (25%)  11 (46%)  
Sarcomatoid  16  6 (37.5%)  6 (37.5%)  4 (25%)  
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Figure 7.2 PTEN protein staining of MPM tissue samples. Figure 7.2A demonstrates 
negative staining in MPM (PTEN score 0). Figure 7.2B demonstrates positive staining, but 
with intensity less than that of the normal pleura (PTEN score 1). Figure 7.2C 
demonstrates strong staining in epithelioid histology with intensity stronger than that of the 
normal pleura (PTEN score 2). Figure 7.2D demonstrates strong staining in sarcomatoid 
histology with intensity stronger than that of the normal pleura (PTEN score 2). 
 
Survival data was available for all 86 patients. Univariate analysis using Kaplan Meier 
survival curves demonstrated that epithelioid histological subtype was associated with 
better prognosis (p<0.001) (Figure 7.3A). The median survival for epithelioid histology 
was 10.3 months (95% CI 12.5 – 21.5 months), biphasic was 5.5 months (95% CI 4.8 – 9.1 
months) and sarcomatoid was 3.4 months (95% CI 2.9 – 6.1 months). Reduced expression 
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of PTEN protein was not associated with poor survival in univariate analysis using Kaplan 
Meier survival curves (p=0.223) (Figure 7.3B). When histological subtype was taken into 
consideration, multivariate Cox regression analysis demonstrated that absence of PTEN 
protein expression was not an independent prognostic variable (HR 0.79; 95% CI 0.61 – 
1.01; p=0.06) (Table 7.2). 
 
 
Figure 7.3 Univariate analysis of PTEN expression. Kaplan Meier survival curves 
demonstrating improved survival with epithelial histological subtype (p<0.001) (A). No 
association between survival and PTEN protein expression was seen (p=0.223) (B). 
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Table 7.2 This table demonstrates multivariate analysis for PTEN expression using 
histological subtype as a confounding factor. 
 HR 95%CI (lower) 95%CI (upper) 
 
P value 
PTEN 1.79 0.61 1.01 0.06 
Histological subtype     <0.001 
Biphasic 0.22 0.12 0.4 <0.001 
Sarcomatoid 0.58 0.3 1.1 0.09 
Epithelial 1.000    
 
7.4 Discussion 
We demonstrated that PTEN protein expression was absent in 27% and reduced in a further 
27% of MPM tissue samples. However, absence of PTEN protein expression was not found 
to be of prognostic significance in univariate analysis.  
A large tissue microarray based study using immunohistochemistry had previously reported 
that PTEN protein expression was absent in 62% (n=341) of MPM tumour samples (Opitz, 
Soltermann et al. 2008) and the absence of PTEN protein expression was associated with 
poor prognosis (n=129; p=0.003), which was independent of histological subtype. This 
difference in the frequency of PTEN protein expression, when compared to our results, 
could be because of different scoring methods. In the study by Opitz et al (2008), the 
scoring was done in tissue microarrays using mouse monoclonal anti-PTEN antibody 
(Novocastra, Sweden) and was scored as 0 (negative), 1 (weak), 2 (moderate) and 3 
(strong) and the staining of the normal pleura was not done. In our study, the scoring was 
done in immunohistochemical slides using rabbit monoclonal antibody (ab32199; Abcam), 
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in reference to normal pleura where, 0 represented negative expression; 1 represented weak 
expression (intensity less than that of normal pleura) and 2 represented strong expression 
(intensity equal to or greater than that of normal pleura). This variation in the technique, 
antibody used and the scoring methodology may account for the difference seen in 
frequency of PTEN protein expression between the two studies. It is important to use 
expression shown in the normal pleura as a comparative reference guide, because the 
absence of PTEN protein cannot be demonstrated unless its presence is initially confirmed 
in normal pleura.  
In our study, we demonstrated PTEN protein expression in both the cytoplasm as well as 
the nucleus. Earlier studies had shown that PTEN protein was localised exclusively to the 
cytoplasm (Li and Sun 1997; Whang, Wu et al. 1998). However, subsequent studies have 
shown that PTEN protein is present in the cytoplasm as well as the nucleus (Salmena, 
Carracedo et al. 2008). Nuclear PTEN protein has important physiological functions 
independent of AKT activation, such as p53 acetylation, induction of apoptosis and cell 
cycle progression (Salmena, Carracedo et al. 2008). 
Absence of PTEN protein may result due to mutations of the PTEN gene on chromosome 
10, promoter methylation, transcription repression, posttranslational modification or 
delocalisation of the PTEN protein (Salmena, Carracedo et al. 2008). Although absence of 
PTEN protein may demonstrate a state of homozygous loss of the PTEN gene, the weak 
staining may demonstrate a heterozygous loss of the PTEN gene which may play an 
important role in cancer initiation and progression (Salmena, Carracedo et al. 2008). In 
mouse models, a heterozygous PTEN gene status in addition to loss of p27 has been shown 
to induce prostate cancers (Di Cristofano, De Acetis et al. 2001). In another study, 
inactivation of one PTEN allele resulted in the occurrence of prostrate epithelial 
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hyperplasia in mice, although homozygous deletion of the PTEN gene was required for the 
induction of advanced prostatic cancer (Trotman, Niki et al. 2003). Gray et al (1998) 
evaluated 37 primary prostate cancers for PTEN allele deletion and single allele deletion 
was seen in 26/37 (70%) of the tumours (Gray, Stewart et al. 1998). Whang et al (1998) 
created ten xenografts from prostate cancer tissues implanted in immune deficient mice. On 
evaluation of the PTEN gene, only one of the ten xenografts was found to have a 
homozygous deletion. Five of the remaining nine xenografts had reduced or absent PTEN 
mRNA or protein expression, but intact PTEN gene suggesting that PTEN inactivation may 
occur at the transcription level (Whang, Wu et al. 1998). This suggests that the reduction of 
PTEN protein expression, either due to loss of a single PTEN allele or due to abnormal 
transcription, may play a role in cancer initiation and progression in addition to the 
homozygous PTEN gene deletion.         
Since the loss of PTEN protein results in activation of AKT and increased cell survival, the 
PTEN protein can be therapeutically manipulated by increasing the expression of PTEN 
protein. To assess the effect of over expression of PTEN protein in MPM, a study 
transfected two MPM cell lines (REN and I-45) with adenoviral vectors AdPTEN and 
studied their effects (Mohiuddin, Cao et al. 2002). PTEN gene mutation status of both the 
cell lines was unknown and a basal level of PTEN protein was present, which on 
transfection with AdPTEN was significantly increased. Forced over expression of PTEN 
protein resulted in decreased phosphorylation of AKT and increased apoptotic cell death of 
the cells. In another study, wild type as well as mutant PTEN was introduced in M43 cell 
line using adenovirus. M43 is a MPM cell line which showed homozygous deletion of the 
PTEN gene and elevated pAKT activity. Cells with wild type PTEN gene reduced AKT 
phosphorylation and decreased cell cycle progression (Altomare, You et al. 2005).  
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In this study we have demonstrated that PTEN protein was either absent or reduced in a 
significant number of MPM tumours when compared with its expression in normal pleura. 
This was however, not associated with survival. Absence or reduction of PTEN protein 
expression may play a significant role in its oncogenic phenotype by activating AKT and be 
an important therapeutic target. Targeting proteins further downstream of the PTEN protein 
such as AKT and MTOR may provide further therapeutic benefit in MPM. In Chapter 10 
we evaluated the PTEN protein expression and the cytotoxic effect of MTOR inhibition in 
MSTO-211H, NCI-H2052, NCI-H2452 and A549 cell lines. 
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Chapter aim 
To demonstrate the expression and prognostic relevance of 5LOX and 12LOX proteins  
in MPM using immunohistochemistry in a series of archival MPM tissue samples. 
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8.1 Introduction 
Arachidonic acid is metabolised by cyclooxygenase (COX) and lipoxygenase (LOX) 
enzymes resulting in the production of prostanoids, leukotrienes (LT), 
hydroxyeicosatetraenoic acids (HETEs) and hydroperoxyeicosatetraenoic acids (HPETEs), 
which have been implicated in inflammation and carcinogenesis (Chapter 4). Our 
laboratory and others (Table 4.1) have previously shown using immunohistochemistry 
(IHC) that COX-2 is over expressed in MPM (O'Kane, Cawkwell et al. 2005) and that the 
specific COX-2 inhibitor DuP-697 can potentiate the cytotoxic effects of Pemetrexed in 
MPM cell lines (O'Kane, Eagle et al. 2010). 
Three isoenzymes exist for lipoxygenase, 5LOX, 12LOX and 15LOX among which 5LOX 
and 12LOX have been implicated in carcinogenesis (Section 4.2.2). The expression of 
5LOX and 12LOX has recently been associated with carcinogenesis in various solid 
tumours. The 5LOX and 12LOX proteins are generally absent in normal epithelia, but are 
expressed in various epithelial cancers including colon (Ohd, Nielsen et al. 2003; Barresi, 
Grosso et al. 2007), oesophageal (Chen, Wang et al. 2004; Hoque, Lippman et al. 2005), 
prostate (Gupta, Srivastava et al. 2001; Matsuyama, Yoshimura et al. 2004), bladder 
(Yoshimura, Matsuyama et al. 2003), oral (Li, Sood et al. 2005), melanoma (Winer, 
Normolle et al. 2002), renal (Yoshimura, Inoue et al. 2004), pancreatic (Hennig, Ding et al. 
2002) and breast (Natarajan, Esworthy et al. 1997; Jiang, Douglas-Jones et al. 2003). To 
our knowledge, this is the first study to investigate the expression of the 5LOX and 12LOX 
proteins using IHC in archival MPM samples. 
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8.2 Materials and methods 
8.2.1 Samples 
Local Research Ethics Committee approval was granted for the study (ref 11/00/212). 
Ninety-three archival tissue samples of patients diagnosed with MPM at Hull Royal 
Infirmary from 1992 to 2000 were obtained, of which 86/93 (92%) patients were male. 
Clinicopathological details for all samples were available. There were 48/93 (51%) 
epithelial, 27/93 (29%) biphasic and 18/93 (19%) sarcomatoid histological subtypes. 
8.2.2 Immunohistochemistry 
All 93 MPM archival tissue samples were analysed by immunohistochemistry as previously 
described in section 6.2.6 to determine 5LOX and 12LOX protein expression. Briefly, 
following antigen retrieval for 3 minutes in a pressure cooker at 15psi containing 1:100 
Antigen Unmasking Solution (#H-3300, Vector Laboratories Inc, CA, USA) non specific 
staining was blocked by using 1x casein (#SP-5020, Vector Laboratories Inc, CA, USA). 
The anti-5LOX antibody (#ab39347, Abcam) was applied at a final concentration of 1:50 
and the anti-12LOX antibody (#ab23678 Abcam) was applied at 1:100. A negative control 
(antibody omitted) and a positive control section (colorectal cancer) were included with 
each batch of slides. Following incubation for 2 hours, antibody detection was carried out 
using the StreptABComplex / HRP Duet Mouse/Rabbit kit (#K0492, Dako Ltd, Ely, UK). 
Positive staining was visualised using DAB as chromogen. All slides were independently 
reviewed by three independent reviewers as discussed in section 6.2.6.8. Positive staining 
was recorded if there was moderately strong staining in at least 25% of malignant cells. 
Negative staining was recorded if less than 25% of malignant cells showed moderately 
strong staining, or if only weak/no staining could be seen. 
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8.2.3 Statistical analysis 
Statistical analysis was performed using SPSS software version 17.0 (SPSS, Chicago, 
USA). Univariate survival analysis for 5LOX and 12LOX protein expression was 
performed using Kaplan Meier curves with log rank analysis. Multivariate analysis was 
calculated using Cox regression analysis to take into consideration histological subtype, 
which has been shown to be an independent prognostic variable in MPM. Co-expression of 
proteins was analysed using Fishers exact test. 
8.3 Results  
8.3.1 5LOX protein expression 
Of the 93 tissue samples, 88 were adequately stained by immunohistochemistry to detect 
5LOX protein expression, with identifiable tumour present. Positive staining of 5LOX 
protein was found predominantly in the nucleus of the malignant cells, with varying 
intensity (Figure 8.1A). Infiltrating lymphocytes also demonstrated positive staining and 
served as an internal positive control. Positive 5LOX protein expression was seen in 65/88 
(73%) of MPM tissue samples (Table 8.1). In univariate analysis, the positive expression 
of 5LOX was associated with improved survival (median survival 8.3 months versus 4.6 
months in 5LOX negative; p=0.006; Figure 8.2). However, when histological subtype was 
taken into consideration, multivariate Cox regression analysis demonstrated that 5LOX 
expression was not an independent prognostic variable (HR 1.58; 95% CI 0.96 – 2.64; 
p=0.074) (Table 8.2).  
8.3.2 12LOX expression 
Eighty-three tissue samples were adequately stained using IHC to detect 12LOX protein 
expression. Positive staining of 12LOX protein was found predominantly in the nucleus 
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and cytoplasm of the malignant cells, with varying intensity (Figure 8.1B). Positive 
12LOX protein expression was seen in 69/83 (83%) of MPM tissue samples (Table 8.1). 
The expression of 12LOX was not associated with survival (p=0.455; Figure 8.3). Co-
expression of 5LOX and 12LOX was seen in 55/82 samples and this was statistically 
significant (p=0.006, Fishers exact, Table 8.3B). 
 
 
Figure 8.1 5LOX and 12LOX protein staining of MPM tissue samples. This figure 
demonstrates MPM tissue samples demonstrating positive staining with (A) anti-5LOX 
antibody (ab39347, Abcam) and (B) anti-12LOX antibody (ab23678, Abcam). 
Magnification X 200. 
 
Table 8.1 Immunohistochemical analysis of 5LOX and 12LOX protein expression 
categorised by histological subtype. 
 Total Epithelial Biphasic Sarcomatoid 
5LOX positive 65/88 (73%) 39/45 (86%) 17/25 (68%) 9/18 (50%) 
12LOX positive 69/83 (83%) 38/44(86%) 21/25 (84%) 10/14 (71%) 
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Figure 8.2 Survival analysis for 5LOX protein expression. Kaplan Meier plot showing 
univariate analysis of 5LOX expression (p=0.006, log rank). The median survival was 8.3 
months in 5LOX-positive cases (green line) versus 4.6 months for 5LOX-negative cases 
(blue line) 
 
Table 8.2 This table demonstrates multivariate analysis for 5LOX expression using 
histological subtype as a confounding factor. 
 HR 95%CI (lower) 95%CI (upper) 
 
P value 
5LOX 1.59 0.96 2.64 0.074 
Histological subtype     <0.001 
biphasic 0.23 0.12 0.42 <0.001 
sarcomatoid 0.57 0.3 1.06 0.075 
epithelial 1.000    
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Figure 8.3 Survival analysis for 12LOX protein expression. Kaplan Meier plot showing 
univariate analysis of 12LOX expression (p=0.455, log rank). The expression of 12LOX 
was not associated with survival. 
8.3.3 Correlations between 5LOX, 12LOX and COX-2 expression 
Using updated survival data, we then correlated previously published COX-2 protein 
expression results from this laboratory (O'Kane, Cawkwell et al. 2005) with the 5LOX and 
12LOX results in the same cohort of 93 patients. Positive expression of the COX-2 protein 
was previously demonstrated in 58/93 (62%) of the samples (O'Kane, Cawkwell et al. 
2005). There was no significant correlation between COX-2 and 12LOX expression (Table 
8.3C). However positive 5LOX expression was significantly more likely in the presence of 
positive COX-2 expression (p=0.002, Fisher’s exact, Table 8.3A). Of the 88 samples which 
were successfully analysed for both 5LOX and COX-2, 47/88 (53%) expressed both 
proteins. In univariate survival analysis the co-expression of 5LOX and COX-2 (n=47) was 
significantly associated with improved prognosis when compared with samples which did 
not express either 5LOX or COX-2 (n=15) with median survival times of 8.6 months versus 
3.4 months (p<0.001, log rank; Figure 8.4). This finding was independent of histological 
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subtype, as demonstrated by multivariate Cox regression analysis (p<0.001). However 
when taken separately in Cox regression analysis, COX-2 status and histological subtype, 
but not 5LOX status, were significantly contributing to survival outcome. Previous findings 
had also revealed COX-2 to be an independent prognostic factor (O'Kane, Cawkwell et al. 
2005). 
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Table 8.3 This table demonstrates the correlations between COX-2 / 5LOX expression (A), 
12LOX / 5LOX expression (B) and 12LOX / COX-2 expression (C). P values were 
calculated based on the Fisher’s exact test. 
A. 5LOX/COX-2 cross tabulation 
Fisher’s Exact Test 
(2 sided) = 0.002  
COX-2   
absent  expressed  Total  
5LOX  absent  15  8  23  
expressed  18  47  65  
Total   33  55  88  
 
B. 12LOX/5LOX cross tabulation  
Fisher’s Exact Test 
(2 sided) = 0.006  
5LOX   
absent  expressed  Total  
12LOX  absent  8  6  14  
expressed  13  55  68  
Total   21  61  82  
 
C.12LOX/COX-2 cross tabulation  
Fisher’s Exact Test 
(2 sided) = 0.227  
COX-2   
absent  expressed  Total  
12LOX  absent  7  7  14  
expressed  22  47  69  
Total   29  54  83  
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Figure 8.4 Survival analysis for combined COX-2/5LOX protein expression. Kaplan Meier 
plot showing univariate analysis of combined COX-2/5LOX expression status (p<0.001, 
log rank). The median survival was 8.6 months in COX-2 positive/5LOX positive cases 
(blue line), 6 months in COX-2 positive/5LOX negative cases (pink line), 4 months in 
COX-2 negative/5LOX positive cases (yellow line) and 3.4 months in COX-2 
negative/5LOX negative cases (green line). 
8.4 Discussion 
In this study both 5LOX and 12LOX proteins demonstrated a significant frequency of over-
expression in MPM and may therefore be considered as possible therapeutic targets. This is 
a similar finding to other reports in various epithelial tumour types such as colon, rectum, 
oesophagus, pancreas, oral, bladder, prostrate, breast, renal and melanoma. We have 
previously shown that COX-2 is over-expressed in MPM and that COX-2 inhibitors may 
have a role to play in MPM therapy (O'Kane, Cawkwell et al. 2005) and we have now 
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demonstrated a positive correlation for 5LOX and COX-2 co-expression. This has 
previously been reported in colorectal cancer where a positive correlation between 5LOX 
and COX-2 expression was demonstrated in a series of 50 adenocarcinomas (Barresi, 
Grosso et al. 2007). This suggests that both the 5LOX and COX-2 metabolic pathways of 
Arachidonic acid are activated in the majority of MPM samples. Individually, the in vitro 
cytotoxic effects of both LOX and COX-2 inhibitors have been demonstrated previously in 
mesothelioma cell lines (Marrogi, Pass et al. 2000; Romano, Catalano et al. 2001; O'Kane, 
Eagle et al. 2010). Inhibiting both the 5LOX and COX-2 pathways simultaneously may 
result in an enhanced therapeutic effect compared to the inhibition of either pathway 
independently. This will need further evaluation in MPM cell lines. 
In this study we also investigated the prognostic significance of 5LOX, 12LOX and COX-2 
protein expression. Neither 5LOX nor 12LOX were found to be independent prognostic 
variables. This is in keeping with the observations made in 61 colorectal tissue samples, 
where 5LOX expression was also not associated with survival (Ohd, Nielsen et al. 2003). 
To date there have not been any other reports on the prognostic value of 5LOX or 12LOX 
in MPM.  
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Multidisciplinary Cancer Congress. Sept 2011, Sweden) 
 
 
Chapter aim 
    To evaluate the expression of EGFR and the presence of EGFR, KRAS and BRAF 
mutation in MPM cell lines (NCI-H2052, NCI-H2452, MSTO-211H) and NSCLC cell line 
(A549). 
 To evaluate the effect of EGFR inhibition using Cetuximab and Gefitinib in MPM cell 
lines and A549 cell line using the MTS assay. 
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9.1 Introduction 
EGFR has been associated with an oncogenic phenotype in many cancers and anti-EGFR 
therapies are now widely used in NSCLC, colon cancers and Head and neck cancers 
(Ciardiello and Tortora 2008). Activation of EGFR by ligand stimulation leads to 
stimulation of a host of intracellular signal transduction pathways resulting in cell 
proliferation, failure of apoptosis, invasion and metastasis (Bogdan and Klambt 2001; 
Hynes and Lane 2005; Citri and Yarden 2006).  The two major pathways stimulated by 
EGFR activation are the PI3K/AKT/MTOR pathway and the RAS/RAF/MAPK pathways 
(Figure 2.2).  
Two groups of anti-EGFR therapies have been developed; monoclonal antibodies against 
the extracellular domain of EGFR, such as Cetuximab and Panitumumab; small molecule 
tyrosine kinase inhibitors (TKI) against the intracellular tyrosine kinase domain of EGFR, 
such as Gefitinib and Erlotinib (Figure 9.1). 
Immunohistochemical studies have shown that EGFR is over-expressed in 44 to 97% of 
MPM tissue samples (Table 2.2) (Dazzi, Hasleton et al. 1990; Govindan, Kratzke et al. 
2005; Destro, Ceresoli et al. 2006; Edwards, Swinson et al. 2006; Garland, Rankin et al. 
2007). Two Phase II clinical trials have shown that EGFR TKIs (Gefitinib and Erlotinib) 
are not effective in MPM (Section 2.2.6). Biomarkers that induce resistance or sensitivity to 
anti-EGFR therapies such as EGFR, KRAS, BRAF and PIK3CA mutations are not 
commonly seen in MPM (Sections 2.2.7, 2.2.8, 2.2.9 and 2.2.10). Currently there are no 
published studies evaluating the EGFR, KRAS and BRAF mutation status of NCI-H2052, 
NCI-H2452 and MSTO-211H cell lines. The MSTO-211H, NCI-H2052, NCI-H2452 and 
A549 cells have previously demonstrated to harbour wild type PIK3CA gene (Janmaat, 
Rodriguez et al. 2006; Yutaro Suzuki, Hideki Murakami et al. 2009). The presence of 
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EGFR activating mutations may have significant anti tumour response to EGFR TKIs and 
the presence of EGFR resistant mutations, KRAS or BRAF mutations may induce 
resistance to anti-EGFR therapy (Section 2.2). 
In this study we aimed to evaluate the expression of EGFR in MSTO-211H, NCI-H2052, 
NCI-H2452 and A549 cell lines and the effect of anti-EGFR inhibitors (Gefitinib and 
Cetuximab) in these cell lines using MTS assays. All cell lines were also evaluated for 
EGFR TK, KRAS and BRAF mutation status.  
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Figure 9.1  The mechanism of action of Cetuximab and Gefitinib. Cetuximab targets the 
extracellular domain of the EGFR and competes with the EGF ligand for binding, thus 
preventing EGFR dimerisation and tyrosine kinase phosphorylation. Gefitinib acts on the 
intracellular component of the EGFR and competes with the ATP at the tyrosine kinase 
domain and inhibit EGFR auto-phosphorylation.  
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9.2 Materials and Methods 
Mesothelioma cell lines MSTO-211H, NCI-H2052 and NCIH2452 were obtained from the 
American Type Culture Collection (ATCC) and the lung cancer cell line (A549) was 
obtained from the European Collection of Cell Cultures (ECACC). All cell lines were 
maintained in RPMI 1640 medium as detailed in Section 6.1.1. 
Anti-EGFR antibody was obtained from Abcam (cat no ab2430) for western blotting and 
from BD Pharminogen (cat No 555997) for flow cytometry (Table 6.1) 
Cetuximab was obtained from Merck KGaA, Germany and Gefitinib (Cat. No. 3000) was 
purchased from Tocris Bioscience (Sections 6.1.3.1 and 6.1.3.5). MTS reagent was 
obtained from Promega (CellTiter 96® AQueous One Solution Cell Proliferation Assay; 
G3582; Promega, Madison, WI).  
9.2.1 Western blot 
Western blotting was performed to analyse the status of the EGFR using anti-EGFR 
antibody (ab2430, Abcam) as described in section 6.2.5.  
9.2.2 Flow cytometry 
Flow cytometry was used to identify EGFR expression in the cell lines as detailed in 
section 6.2.7. One million cells of each cell line was incubated with EGFR antibody (BD 
Pharminogen; cat No 555997) along with an isotype control and analysed on the BD 
FACSAria
TM
 II using the FACSDiva software.  
9.2.3 Mutational analysis 
MSTO-211H, H2052, H2452 and A549 cell lines were analysed for EGFR, KRAS and 
BRAF mutations, as lack of EGFR activating mutations or the presence of EGFR resistant 
mutation, KRAS mutation or BRAF mutation may induce resistance to anti-EGFR 
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therapies. All mutational analysis was performed by the Department of Cellular Pathology, 
Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, 
Birmingham, UK.  
9.2.3.1 EGFR mutation 
EGFR mutational screening was performed using the Amplification Refractory Mutation 
System (ARMS) and Scorpions techniques to identify common mutations using real time 
Polymerase chain reaction (PCR). The EGFR exons 18 to 21 was also sequenced using 
Sanger sequencing (Section 2.2.1.1). 
9.2.3.1.1 Arms-Scorpion PCR  
EGFR mutational screening analysis was performed in MSTO-211H, NCI-H2052, NCI-
H2452 and A549 cell lines using the Therascreen® EGFR RGQ PCR Kit (Qiagen, 
Germany, catalogue number 870111). Among the common mutations identified in the 
EGFR domain (Section 2.2.1.1) the kit enables identification of 29 of the commonest 
mutations in the EGFR gene, including the T790M mutation known to induce resistance to 
EGFR TKIs (Figure 9.2).  
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Figure 9.2  EGFR mutation analysis. This figure demonstrates all the EGFR mutations 
analysed by the Qiagen Therascreen EGFR RGQ PCR Kit. The presence of activating 
mutations is associated with good response to EGFR TKIs and the presence of resistant 
mutations is associated with resistance to EGFR TKIs. (Adapted and modified from 
(Sharma, Bell et al. 2007). 
 
9.2.3.1.2 Sanger Sequencing  
EGFR exons 18 to 21 was sequenced using bidirectional Sanger sequencing with primers 
designed using Primer-3 software. 
9.2.3.2 KRAS mutation 
KRAS mutational screening analysis was performed in MSTO-211H, NCI-H2052, NCI-
H2452 and A549 cell lines using the Therascreen® KRAS Pyro Kit (Qiagen, Germany, 
catalogue number 971460). The Therascreen® KRAS Pyro Kit is a nucleic acid sequence-
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based detection test based on pyrosequencing technique for the quantitative analysis of 
mutations in codon 12, 13 and 61 of the human KRAS gene (Figure 9.3). The kit consists 
of two assays: one for analysis of codon 12 (GGT) and 13 (GGC) which were sequenced in 
the forward direction and the second for codon 61 (CAA) which was sequenced in the 
reverse direction (Section 2.2.1.2 for mutation details).  
 
  
Figure 9.3 KRAS mutation analysis. KRAS mutations identified using the Therascreen 
KRAS Pyro Kit. The presence of KRAS mutations may induce resistance to anti-EGFR 
therapy. 
9.2.3.3 BRAF mutation 
BRAF mutational screening analysis was performed in MSTO-211H, NCI-H2052, NCI-
H2452 and A549 cell lines using the Therascreen® BRAF Pyro Kit (Qiagen, Germany, 
catalogue number 971470). Therascreen® BRAF Pyro Kit, similar to the KRAS kit, is also 
a nucleic acid sequence-based detection test based on pyrosequencing technique for the 
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quantitative analysis of mutations in codon 600 (GTG) of the human BRAF gene and is 
sequenced in reverse direction (Section 2.2.4).  
9.2.4 MTS Assay  
All cell lines were cultured as detailed in section 6.2.1 and cells counted as detailed in 
section 6.2.2.  The optimum number of cells for each cell line (MSTO-211H - 5000 cells 
per well, NCI-H2052 – 1000 cells per well, NCI-H2452 – 1000 cells per well and A549 – 
1000 cells per well) was determined (see appendix A) and seeded onto a 96 well plate as 
detailed in section 6.2.3. MTS assay was performed as detailed in section 6.2.4. In each 
experiment 6 replicate wells were used for each drug concentration and the experiment was 
repeated 3 times. Cells were then exposed to varying concentrations of Cetuximab and 
Gefitinib from day 2 onwards for 72 hours. The drugs and media were replaced daily. 
Media only was used as a control for Cetuximab and 0.01% DMSO diluted in media was 
used as a control for Gefitinib (Section 6.2.4.1.1). The growth of treated cells as a 
percentage of control cells was calculated (see appendix A). The average of the three 
experiments was taken, plotted onto a graph and 50% cell growth inhibition was calculated 
for each drug. The drug concentration of Cetuximab taken for the assay ranged from 100 
nM to 1.75μM. At the FDA approved dosing level of Cetuximab, the mean steady state 
peak concentration ranges from 168 to 235 μg/ml (Mukohara, Engelman et al. 2005). Based 
on the upper limit of 235 μg/ml, the molar concentration calculated for Cetuximab was 1.6 
μM hence 1.75 μM was arbitrarily taken as the maximum concentration in our study. The 
drug concentration of Gefitinib (20nM to 20 μM) was optimised. The concentration of 
Gefitinib calculated based on the mean steady state plasma concentrations (615 ng/ml) at 
the FDA approved dose was 1.4 μM (Herbst, Maddox et al. 2002; Mukohara, Engelman et 
al. 2005). A study by Nutt et al (2009) had demonstrated 50% cell growth inhibition in 
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MSTO-211H cells to Gefitinib at a dose of 18.3 0.7 μM and therefore we extended our 
dose range of Gefitinib to a maximum of 20 μM (Nutt, O'Toole et al. 2009). Drug 
inhibition was considered significant if at least 50% cell growth inhibition was seen 
compared to control.  
9.3 Results 
9.3.1 EGFR expression by Western blot 
Despite using the EGFR antibody in various dilutions (ranging from 1:1000 to 1:200) with 
various incubation periods (2 hours at room temperature and 16 hours at 4 
0
C) we were 
unable to optimise the antibody for use in the cell lines. A549 cells have previously been 
shown to express EGFR by western blotting and hence were used as an external control 
(Tracy, Mukohara et al. 2004).  
9.3.2 EGFR Expression by Flow Cytometry 
All cell lines demonstrated positivity for EGF receptor. Among the 10,000 cells assessed 
for each cell line, 98.6% of A549; 98.4% of MSTO-211H; 98.2% of NCI-H2052 and 
98.2% of NCI-H2452 cells showed positive expression for EGFR (Figure 9.4).  
9.3.3 Mutation analysis 
9.3.3.1 EGFR mutation analysis 
There were no mutations identified in the EGFR gene in MSTO-211H, NCI-H2052, NCI-
H2452 and A549 cell lines using the Arms-Scorpion PCR technique. The whole Exon 
sequenced using the Sanger sequencing did not reveal any known or unknown novel 
mutations in any of the cell lines.  
166 
 
9.3.3.2 KRAS mutation analysis 
A single missense mutation (codon 12 GGT>AGT; protein.Gly12Ser) was identified at 
codon 12 of the KRAS gene in A549 cell line (Figure 9.5). The MSTO-211H, NCI-H2052 
and NCI-H2452 cell lines did not harbour any KRAS mutations. 
9.3.3.3 BRAF mutation analysis 
The MSTO-211H, NCI-H2052, NCI-H2452 and A549 cell lines did not harbour any BRAF 
mutations. 
 
 
Figure 9.4 EGFR expression in MPM cell lines. This is a histogram plot demonstrating 
positive EGFR expression in (A) A549; (B) MSTO-211H; (C) NCI-H2052 and (D) NCI-
H2452 cell lines. Each histogram consists of two regions in the X axis. The region on the 
left is where the cells negative for EGFR expression (including the isotype control) are 
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represented and the region on the right (marked as P2) is where the cells positive for EGFR 
expression are represented.  For each pair of histograms, the graph on the left is a PE 
conjugated isotype control with P2 marker set to contain ≤1% of cells. The histogram on 
the right is PE conjugated antibody against EGFR showing cells within the P2 region 
expressing EGFR. The X-axis demonstrates the relative fluorescence and the Y-Axis 
demonstrates the number of cells analysed. 
 
 
  
Figure 9.5  A549 cell line demonstrating the presence of missense KRAS mutation at 
codon 12. This Figure demonstrates the first peak at A followed by G and then T which 
represents the mutated sequence AGT at codon 12 (wild type sequence GGT).  
9.3.4 MTS Assay 
All cell lines showed 50% cell growth inhibition by Gefitinib at varying concentrations 
(Table 9.1), but at doses higher than 1.4 μM, which was the concentration of Gefitinib 
calculated based on the mean steady state plasma concentrations at the FDA approved dose 
(Figure 9.6). At higher concentration of Gefitinib (>5 μM) the NCI-H2052, NCI-H2452 
and MSTO-211H cells demonstrated growth inhibition values less than 0%. This would 
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indicate that the number of cells was less than that of the control at the starting point, 
thereby demonstrating a cytotoxic effect. Cetuximab showed no significant growth 
inhibition in NCI-H2052, NCI-H2452 and A549 cell lines (Table 9.1), but MSTO-211H 
cells were sensitive to Cetuximab and 50% cell growth inhibition was seen at a 
concentration of 1.6 µM, which was within the clinically relevant dose range (Figure 9.7).  
 
 
 
 
Figure 9.6  The antiproliferative activity of Gefitinib. The data presented is a mean of three 
independent experiments. Each data point is expressed as a percentage of cell growth 
relative to the control (0.01% DMSO) and the error bars indicate standard error of the 
mean.  
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Figure 9.7 The antiproliferative activity of Cetuximab. The data presented is a mean of 
three independent experiments. Each data point is expressed as a percentage of cell growth 
relative to the control (media only) and the error bars indicate standard error of the mean. 
 
Table 9.1  Growth inhibition due to Gefitinib and Cetuximab. This table demonstrates the 
50% cell growth inhibition values achieved in MSTO-211H, NCI-H2052, NCI-H2452 and 
A549 cell lines on incubation with Gefitinib and Cetuximab, for 72 hours and assessed by 
MTS assay. Value in bold is within the clinically relevant dose range. EGFR protein 
expression of the cell lines is also shown. (NA; Not achieved) 
 Gefitinib Cetuximab EGFR 
protein 
NCI-H2052 6 μM NA Expressed 
NCI-H2452 3.7 μM NA Expressed 
MSTO-211H 1.5 μM 1.63 μM Expressed 
A549 13 μM NA Expressed 
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9.4 Discussion 
In this study, flow cytometry analysis demonstrated more than 98% EGFR expression in 
MSTO-211H, NCI-H2052, NCI-H2452 and A549 cell lines. Western blotting was 
unsuccessful in demonstrating the expression of EGFR in the cells lines, including the 
control A549 cell line. The western blot technique is well established in the laboratory. 
Since the flow cytometry demonstrated near universal expression of EGFR in all cell lines 
(including control) the lack of expression in western blotting  likely to be due to an 
unreliable antibody. Other techniques that could have been used to demonstrate expression 
of EGFR proteins are immunocytochemistry and ELISA (Section 5.5). In addition EGFR 
gene amplification and polysomy can be analysed using techniques such as Polymerase 
Chain Reaction and fluorescent in situ hybridization (FISH). A549 has previously been 
shown to express EGFR when analysed by flow cytometry (Janmaat, Kruyt et al. 2003) as 
well as by western blot (Tracy, Mukohara et al. 2004). The NCI-H2052, NCI-H2452 and 
MSTO-211H cell lines have also been shown to express EGFR when analysed by flow 
cytometry (Nayak, Garmestani et al.). Various other authors have also demonstrated 
positive expression of EGFR in A549 and MSTO-2111H cell lines by western blot (Janne, 
Taffaro et al. 2002; Nutt, O'Toole et al. 2009). Western blot analysis of MPM cells (H2461 
and H226) has demonstrated that the treatment of cells with EGF results in phosphorylation 
of EGFR (p-EGFR) and its downstream signalling proteins such as AKT (p-AKT) and 
ERK1/2 (p-ERK) (Janne, Taffaro et al. 2002; Nutt, O'Toole et al. 2009).  
In our study there were no EGFR, KRAS or BRAF mutations identified in NCI-H2052, 
NCI-H2452 and MSTO-211H cell lines. A single KRAS mutation (codon 12 GGT>AGT; 
protein.Gly12Ser) was identified in the A549 NSCLC cell line. Other studies have 
previously identified the same KRAS mutation in the A549 cell line (Krypuy, Newnham et 
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al. 2006). This KRAS mutation may result in constitutive activation of the 
RAS/RAF/MAPK pathway thereby inducing resistance to EGFR inhibition by Cetuximab 
(Sections 2.2.1.2 and 2.2.3). A549 cell line have also shown to have a wild type EGFR TKI 
domain with no activating mutations thereby demonstrating resistance to TKIs (Tracy, 
Mukohara et al. 2004; Krypuy, Newnham et al. 2006). Currently there are no published 
studies evaluating the EGFR, KRAS and BRAF mutation status of NCI-H2052, NCI-
H2452 and MSTO-211H cell lines. 
In our study, 50% cell growth inhibition was induced by Cetuximab in the MSTO-211H 
cell line at the dose of 1.6 μM, which was the upper limit of the mean steady state peak 
concentration achieved in Phase I trials at FDA approved dosing levels (Mukohara, 
Engelman et al. 2005). At the maximum dose of 1.75 μM, NCI-H2052, NCI-H2452 and 
A549 cell lines did not demonstrate any significant antiproliferative effects. Gefitinib 
demonstrated antiproliferative effects in all cell lines, but at doses significantly higher than 
that achieved based on the mean steady state plasma concentrations at FDA approved dose 
levels (Herbst, Maddox et al. 2002; Mukohara, Engelman et al. 2005). To date, there are no 
published studies investigating the anti-proliferative effect of Cetuximab in MPM cell lines. 
Antibodies such as Cetuximab, have various modes of action in vivio, such as receptor 
blockade, down regulation of receptors due to internalization and degradation or by 
activating the host immune system resulting in antibody-dependent cell mediated 
cytotoxicity (Kurai, Chikumi et al. 2007; Chames, Van Regenmortel et al. 2009). Hence, in 
vitro assessments, by means of MTS assays in cell line models for example, may not 
accurately assess the effectiveness of antibody treatments and any interpretation of the 
effectiveness of antibodies may need further confirmation using in vivo studies.   
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The A549 cell line has been show to be resistant to the antineoplastic effects of Cetuximab 
and Gefitinib using the MTT assay (Janmaat, Kruyt et al. 2003). In another study, the A549 
cell line was found to be resistant to the effects of Cetuximab and Gefitinib when analysed 
using the MTS assay (Mukohara, Engelman et al. 2005). Tracy et al (2004) also 
demonstrated lack of effect of Gefitinib in A549 cell line using the MTS assay (Tracy, 
Mukohara et al. 2004).  
In the study by Mukohara et al (2005) the dose of Gefitinib required for antiproliferative 
effect on NSCLC cell lines (HC3255, DFCILU-011 and PC-9) with EGFR TKI activating 
mutation present when analysed using MTS assay, ranged from 10 to 63 nM which was 
significantly less than that seen in our study with any cell line (Mukohara, Engelman et al. 
2005). The A549 cell line with wild type EGFR was resistant to the anti proliferative 
effects of Gefitinib. In our study Gefitinib resulted in 50% growth inhibition only at 
significantly higher doses compared to clinically relevant dose level. This may suggest that 
our MPM cell lines may be resistant to the anti-proliferative effects of Gefitinib, which may 
be due to the presence of wild type EGFR TKI domain or the presence of mutations 
downstream of the EGFR signalling pathway (Figure 2.6).  
There is a paucity of information available in the literature regarding the effect of Gefitinib 
in MPM cell lines (MSTO-211H, NCI-H2052, NCI-H2452). Giovannetti et al (2011) 
studied the effect of Gefitinib and Erlotinib among other drugs in MSHO-211H, NCI-
H2052, NCI-H2452 and NCI-H28 cell lines using the MTT assay. The dose of Gefitinib 
required to inhibit 50% of cells was; MSTO-211H – 4.91 μM; NCI-H2052 – 5.22 μM, 
NCI-H2452 – 4.83 μM and NCI-H28 – 3.99 μM (Giovannetti, Zucali et al. 2011). This was 
roughly similar to dose of Gefitinib required to inhibit 50% of cells our study in NCI-
H2052 (6 μM) and NCI-H2452 (3.7 μM), but not in MSTO-211H (1.5 μM) cells when 
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analysed using MTS assays.  Another study by Janne et al (2002) demonstrated no effect of 
Gefitinib on either A549 or MSTO-211H cell lines with Gefitinib dose up to 10 μM when 
analysed by MTS assay (Janne, Taffaro et al. 2002). In our study the dose of Gefitinib 
required to inhibit 50% of the A549 cells was 13 μM. The study published by Nutt et al 
(2009) demonstrated the effect of Gefitinib among other drugs in MPM cell lines (MSTO-
211H, NCI-H28 and NCI-H226) using a SulphurRhodamine cell proliferation assay. 
Growth inhibition was seen in all cell lines, but the dose required for 50% growth inhibition 
was significantly high (MSTO-211H – 18.3 μM, NCI-H28 – 5.7 μM and NCI-H226 – 20.5 
μM) in comparison to the clinically relevant dose level or to that in our study in MSTO-
211H cells (Nutt, O'Toole et al. 2009).  
9.5 Conclusion 
In this study, we demonstrated for the first time that there are no EGFR, KRAS or BRAF 
mutations identified in MSTO-211H, NCI-H2052 and NCI-H2452 cell lines. A single 
KRAS (codon 12 GGT>AGT; protein.Gly12Ser) mutation was seen in the A549 cell line. 
The role of Cetuximab in MPM had not been previously evaluated. In our study, 
Cetuximab demonstrated an anti-proliferative effect in the MSTO-211H cell line. All other 
cell lines were resistant to the effect of Cetuximab. The resistance to Cetuximab in A549 
cells may be due to the presence of KRAS mutation. Gefitinib did demonstrate cytotoxic 
effect in all of the cell lines, but at dose levels that were significantly higher in comparison 
to the clinically relevant dose level. This lack of cytotoxic effect of Gefitinib may be as a 
result of absence of activating EGFR mutations. The resistance to anti-EGFR therapy may 
be overcome by multi targeted therapy. In Chapter 12 we aimed to overcome anti-EGFR 
therapy resistance by combining Cetuximab and Gefitinib in turn with MTOR inhibitors 
(Rapamycin and Ku0063794) and COX-2 inhibitor (Celecoxib).  
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Chapter 10.  Inhibition of Mammalian 
Target of Rapamycin in malignant pleural 
mesothelioma cells 
 
 
 
Publications and presentations 
Aqarwal V, Lind MJ, Cawkwell L (2011) Growth Inhibition of Mammalian Target of 
Rapamycin (MTOR) in Malignant Pleural Mesothelioma. European journal of cancer 
(Oxford, England : 1990) 47: S140-S141(abstract). Poster - ECCO 17 - 36th ESMO 
Multidisciplinary Congress, Stockholm (September 2011) 
 
 
 
 
 
Chapter aim 
    To evaluate the expression of PTEN protein in MPM cell lines (NCI-H2052, NCI-
H2452, MSTO-211H) and NSCLC cell line (A549). 
 
To evaluate the effect of MTORC1 and MTORC2 inhibition using Rapamycin  
(MTORC1 inhibitor) and Ku0063794 (MTORC1 and MTORC2 inhibitor) in MPM  
cell lines using the MTS assay. 
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10.1 Introduction 
Activation of the PI3K/AKT/MTOR pathway plays an important role in many tumour types 
including MPM. Immunohistochemical analysis of MPM tissue samples has demonstrated 
that the pAKT and pMTOR are over expressed and the tumour suppressor gene, PTEN, is 
lost in a significant proportion of cases (Table 3.1). MTOR can be assembled into two 
different complexes (MTORC1 and MTORC2). MTORC1 is sensitive to the inhibitory 
effects of Rapamycin, whereas MTORC2 is Rapamycin insensitive. 
In this study we aimed to analyse the cytotoxic effect of MTORC1 inhibition using 
Rapamycin and the effect of combined MTORC1 and MTORC2 inhibition using 
Ku0063794 in MPM cell lines using the MTS cell proliferation assay (Figure 10.1). Since 
loss of PTEN results in activation of the MTOR pathway and has been shown to be a poor 
prognostic biomarker, we also assessed the status of PTEN protein in our cell lines using 
Western blotting. To further confirm the subsequent activation of the MTOR pathway as a 
result of loss of PTEN, p70S6K status of the cell lines was also assessed as a surrogate 
marker for MTORC1 activation.  
10.2 Materials and methods 
The MPM cell lines MSTO-211H, NCI-H2052 and NCI-H2452 were obtained from the 
American Type Culture Collection and the lung cancer cell line (A549) were obtained from 
the European Collection of Cell Cultures. All cell lines were maintained in RPMI 1640 
medium as detailed in section 6.1.1. 
The MTORC1 inhibitor Rapamycin (cat no 1292), and the combined MTORC1/MTORC2 
inhibitor Ku0063794 (cat no 3725) were purchased from Tocris Biosciences (Sections 
6.1.3.7 and 6.1.3.8).  
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Figure 10.1 Mechanism of action of Rapamycin and Ku0063794. Rapamycin inhibits 
MTORC1 where as Ku0063794 is a kinase inhibitor and inhibits both MTORC1 and 
MTORC2. 
10.2.1 Western Blot  
Western blotting was performed to analyse the status of the PTEN protein and subsequent 
p70S6K activation as a result of loss of PTEN in the cell lines as detailed in section 6.2.5. 
Protein lysate (20µg) was loaded onto a 12 % Precise Protein Gel (#25222, Thermo 
Scientific) and separated by one dimension gel electrophoresis. The separated proteins were 
transferred onto a nitrocellulose membrane, and incubated with anti- PTEN primary 
antibody (ab32199, Abcam) and anti- p70S6K (phospho T389) antibody (ab32359, Abcam) 
(Table 6.1) 
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10.2.2 MTS Assay 
All cell lines were cultured and counted as detailed in section 6.2.1 and section 6.2.2. The 
optimum number of cells (Appendix A) for each cell line (MSTO-211H - 5000 cells per 
well,  NCI-H2052 – 1000 cells per well, NCI-H2452 – 1000 cells per well and A549 – 
1000 cells per well) was seeded onto a 96 well plate as detailed in section 6.2.3 and MTS 
assay was performed as detailed in section 6.2.4. In each experiment 6 replicate wells were 
used for each drug concentration and the experiment was repeated 3 times. The drug 
concentration of Rapamycin and Ku0063794 taken for the assay ranged from 100 pM to 
1μM. The concentration of Rapamycin calculated based on the mean steady state plasma 
concentrations of 12.7 ng/ml at the maximum tolerated dose of 6 mg per day was 13.9 nM 
(Jimeno, Rudek et al. 2008). The clinically relevant dose range of Ku0063794 is currently 
not known. Control used was 0.01% DMSO. Drug inhibition was considered significant if 
at least 50% cell growth inhibition was seen in the drug treated cells compared to the drug 
carrier control containing 0.01% DMSO. 
10.3 Results 
10.3.1 Western Blot 
PTEN protein was absent in the MSTO-211H cell line, weakly expressed in the A549 cell 
line and strongly expressed in NCI-H2052 and NCI-H2452 cells. The p70S6K protein was 
expressed in MSTO-211H and A549 cells, but not in NCI-H2052 and NCI-H2452 cells 
(Figure 10.2).  
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Figure 10.2 Western blot demonstration of the status of PTEN protein and p70S6K protein. 
Western blot demonstrating absence of PTEN protein expression in the MSTO-211H cells, 
weak expression in the A549 cells and strong expression in NCI-H2052 and NCI-H2452 
cells. The p70S6K protein was present MSTO-211H and A549 cells and absent in NCI-
H2051 and NCI-H2452 cells. The image shows results with anti-PTEN antibody (ab32199, 
Abcam) (1:400 dilution over 2 hours at room temperature) at 47 kDa and anti-p70S6K 
antibody (ab32359, Abcam) (1:1000 dilution over 16 hours at 4 
0
C) at 70 kDa. Alpha 
tubulin (ab7291, Abcam) was used as a loading control at 50 kDa indicating equal loading.  
10.3.2 MTS Assay 
Rapamycin (Figure 10.3) and Ku0063794 (Figure 10.4) demonstrated 50% cell growth 
inhibition in the NCI-H2052, NCIH2452 and A549 cells, but not in the MSTO-211H cells 
(Table 10.1). At concentration of Ku0063794 >800 nM, the NCI-H2052, cells 
demonstrated growth inhibition values of less than 0%. This would indicate that the number 
of cells was less than that of the control at the starting point, thereby demonstrating a 
cytotoxic effect. 
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Figure 10.3 The antiproliferative activity of Rapamycin. The data presented is the mean of 
three independent experiments. Each data point is expressed as a percentage of cell growth 
relative to the control and the error bars indicate standard error of the mean. Despite the 
dose used for Rapamycin ranged from 100 pM to 1μM, the data shown here is up to 1 nM 
as the maximum effect obtained was at this dose level. MSTO-211H did not show 
additional anti proliferative activity up to 1 μM. The maximum clinically relevant dose 
calculated was 13.9 nM. 
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Figure 10.4 The antiproliferative activity of Ku0063794. The data presented the mean of 
three independent experiments. Each data point is expressed as a percentage of cell growth 
relative to the control and the error bars indicate standard error of the mean. Clinically 
relevant dose for Ku0063794 is not known. 
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Table 10.1  Growth inhibition due to Rapamycin and Ku0063794. This table demonstrates 
the 50% cell growth inhibition values achieved in MSTO-211H, NCI-H2052, NCI-H2452 
and A549 cell lines on incubation with Rapamycin and Ku0063794, for 72 hours and 
assessed by MTS assay. Values in bold were within the clinically relevant dose range for 
Rapamycin. Clinically relevant dose range for Ku0063794 is currently not known. PTEN 
protein and p70S6K protein expression of the cell lines is also shown. (NA; Not achieved) 
Cell lines Rapamycin (pM) Ku0063794 (nM) PTEN 
protein  
P70S6K 
protein 
NCI-H2052 610 195 expressed Absent 
NCI-H2452 517 358 expressed Absent 
MSTO-211H NA NA Absent  Expressed 
A549 553 337 weakly 
expressed 
Expressed 
 
10.4 Discussion 
In this study western blot demonstrated that PTEN protein was not expressed in MSTO-
211H cells  and weakly expressed in A549 cells resulting in activation of the MTORC1 
pathway as demonstrated by expression of p70S6K in the MSTO-211H and A549 cell 
lines. The absence of PTEN protein expression in MSTO-211H cells may suggest that 
PTEN/AKT/MTOR pathway may be activated in these cells and may therefore respond to 
MTOR inhibitors.  
Significant inhibition was however seen in the NCI-H2052, NCI-H2452 and A549 cells, 
but not in MSTO-211H cells with Rapamycin. The concentration of Rapamycin calculated 
based on the mean steady state plasma concentrations of 12.7 ng/ml at the maximum 
tolerated dose of 6 mg per day was 13.9 nM (Jimeno, Rudek et al. 2008). In our study, 50% 
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cell growth inhibition in NCI-H2052, NCI-H2452 and A549 cells was seen at 
approximately 500 - 600 pM range, which was significantly below the achievable plasma 
steady state concentration. In a study by Hartman et al (2010), of the six MPM cell lines 
(MS257, H2052, MS589, MS248, MS924 and JMN1B) studied, three MPM cell lines 
(MS248, MS924 and JMN1B) responded to 100 nM of Rapamycin when analysed using 
MTS assay (Hartman, Esposito et al. 2010). Despite NCI-H2052 cells not having shown 
any response in this study, our study demonstrated significant response in NCI-H2052 cells 
to Rapamycin. Rapamycin has also shown to inhibit a MPM cell line (M43) as well as 
enhance the apoptotic effect of various apoptotic regimes in MPM tumour fragment 
spheroids (Section 3.1.2.2).  
Combined inhibition of MTORC1 and MTORC2 in MPM has previously not been 
assessed. In our study, 50% cell growth inhibition using Ku0063794 was seen at 
approximately 200- 350 nM range. Ku0063794 inhibits both MTORC1 and MTORC2 in 
Human embryonic kidney cells (HEK-293) with an IC50 of approximately 10 nM (Garcia-
Martinez, Moran et al. 2009). In another study, Ku0063794 blocked the MTORC1 activity 
at 10 nM as evidenced by dephosphorylation of p70S6K and the MTORC2 activity at 100 
nM as evidenced by dephosphorylation at AKT (Serine 473) in Human vein endothelial 
cells (HUVEC)  (Dormond-Meuwly, Roulin et al. 2011).  
Since the absence of PTEN protein expression and the expression of p70S6K protein was 
seen in the MSTO-211H cells we may have expected a response to MTOR inhibition. 
However, we found that the MSTO-211H cell line was not responsive to either MTORC1 
alone or combined MTORC1 and MTORC2 inhibition. This may be because its oncogenic 
phenotype may be mediated via the AKT pathway further upstream of MTOR in MPM.  
The activation of MTORC1 results in the activation of p70S6K protein which inhibits IRS1 
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and reduces the activation of PI3K and AKT (Figure 10.1) (Shi, Yan et al. 2005). 
Inhibiting the MTORC1 protein may result in activation of AKT by inhibiting the 
p70S6K/IRS1/PI3K negative feedback loop. MPM tumour spheroids on treatment with 
Rapamycin have demonstrated an increase in AKT phosphorylation (Barbone, Yang et al. 
2008). Loss of PTEN protein expression and the inhibition of negative feedback loop may 
have resulted in increased activation of AKT and contributed to the resistance of MSTO-
211H cells to MTOR inhibition. However, this hypothesis will need to be validated in 
subsequent studies.  
Currently there are two early phase clinical trials evaluating the benefit of Rapamycin 
analogues in MPM (Section 3.1.3). There are a few early phase clinical trials evaluating the 
effect of MTOR kinase inhibitors in advanced solid tumours, but none are MPM specific. 
MTOR kinase inhibitors currently undergoing early phase clinical trials are OSI-027 (OSI), 
Phase I; AZD-8055 (AstraZeneca), Phase I/II; AZD-2014 (AstraZeneca), Phase I and 
INK128 (Intellikine), Phase I (Zaytseva, Valentino et al. 2012). 
Combined inhibition of EGFR and MTOR may be an important therapeutic strategy in 
overcoming resistance to either target alone. In epithelioid sarcoma cell lines (VAESBJ and 
Epi544), the combined effect of Erlotinib and Rapamycin was more pronounced compared 
to either drug alone demonstrating strong synergy when analysed using MTS assays as well 
as VAESBJ xenografts grown in mice (Xie, Ghadimi et al. 2011). It is currently not known 
if this combination of anti-EGFR therapy and anti-MTOR therapy may provide additive 
effect compared to either agent alone in MPM. In Chapter 12 we aimed to combine EGFR 
inhibitors (Gefitinib and Cetuximab) with MTOR inhibitors (Rapamycin and Ku0063794) 
to evaluate the additive effect of combined inhibition.  
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Chapter 11.  Inhibition of Cyclooxygenase 
enzyme 2 in malignant pleural 
mesothelioma cells 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter aim 
To evaluate the effect of COX-2 inhibition using Celecoxib in MPM cell lines  
using the MTS assay. 
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11.1 Introduction 
COX-2 is an inducible enzyme which catalyses the conversion of Arachidonic acid to PG in 
response to proinflammatory or mitogenic signals. It is over-expressed in many solid 
tumours and is a potential target for therapeutic intervention (Gasparini, Longo et al. 2003; 
Hull 2005; Rao and Knaus 2008; Ghosh, Chaki et al. 2010). Inhibition of COX-2 has been 
shown to have a significant anti-tumour effect in many solid tumours (Ghosh, Chaki et al. 
2010; Menter, Schilsky et al. 2010). Various studies have demonstrated that COX-2 is 
expressed in MPM tissue samples (Table 4.1). COX-2 inhibitors have significant anti-
neoplastic effect in MPM cell lines as well as mouse models (Table 4.2). 
Previous work at our laboratory has shown that specific COX-2 inhibitor DuP-697 has 
significant anti-proliferative effects when incubated with the mesothelioma cell lines 
(MSTO-211H and NCI-H2052) and the lung cancer cell line (A549) for 72 hours as 
assessed by the MTT assay (O'Kane, Eagle et al. 2010). DuP-697 was also shown to 
potentiate the cytotoxic effect of Pemetrexed by at least 4-fold in MSTO-211H, NCI-
H2052, NCI-H2452 and A549 cell lines. Celecoxib is a specific COX-2 inhibitor that is 
commonly used in clinical practice and is derived from DuP-697 (Figure 11.1) (Blobaum 
and Marnett 2007). In this study we aimed to study the anti-proliferative activity of 
Celecoxib in mesothelioma cell lines. 
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Figure 11.1  COX-2 and EGFR cross talk. This figure demonstrates the complex 
interaction between COX-2 and EGFR with the mechanism of action of Celecoxib. The 
EGFR on activation by its ligand activates the RAS/RAF/MAPK pathway resulting in 
increased production of COX-2 protein which converts Arachidonic acid to PGE2. PGE2 
acts on the EP receptor and activates EGFR via Src, PI3K protein and increases the 
production of Amphiregulin via PKA. Amphiregulin is an EGFR ligand which activates 
EGFR thereby resulting in a positive feedback loop. Celecoxib acts by inhibiting COX-2 
thereby reducing the production of PGE2 (Adapted and modified from (Dannenberg, 
Lippman et al. 2005). 
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11.2 Materials and methods 
The MPM cell lines MSTO-211H, NCI-H2052 and NCI-H2452 were obtained from the 
American Type Culture Collection and the lung cancer cell line (A549) were obtained from 
the European Collection of Cell Cultures. All cell lines were maintained in RPMI 1640 
medium as detailed in section 6.1.1. All cell lines have been previously shown to express 
the COX-2 protein (O'Kane, Eagle et al. 2010). Celecoxib was obtained from Pfizer 
(Section 6.1.3.9). 
11.2.1 MTS Assay 
All cell lines were cultured and counted as detailed in section 6.2.1 and section 6.2.2.  The 
optimum number (see appendix A) of cells for each cell line (MSTO-211H - 5000 cells per 
well,  NCI-H2052 – 1000 cells per well, NCI-H2452 – 1000 cells per well and A549 – 
1000 cells per well) was seeded onto a 96 well plate as detailed in section 6.2.3 and MTS 
assay was performed as detailed in section 6.2.4. In each experiment 6 replicate wells were 
used for each drug concentration and the experiment was repeated 3 times. The drug 
concentration of Celecoxib ranged from 1 μM to 100 μM. Control used was 0.01% DMSO 
diluted in media. The concentration of Celecoxib calculated based on the steady state 
plasma concentrations of 1 μg/ml at the dose of 400 mg per day was 2.6 μM (Grossman, 
Olson et al. 2008). Drug inhibition was considered significant if at least 50% cell growth 
inhibition was seen compared to the drug carrier control containing 0.01% DMSO. 
11.3 Results 
Celecoxib (Figure 11.2) demonstrated 50% cell growth inhibition in the NCI-H2052, 
NCIH2452, MSTO-211H and A549 cell lines, but at doses higher than the maximum 
clinically relevant dose of 2.6 μM (Table 11.1). At higher concentration of Celecoxib (>40 
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μM) all cells demonstrated growth inhibition values less than 0%. This would indicate that 
the number of cells was less than that of the control at the starting point, thereby 
demonstrating a cytotoxic effect. 
 
  
Figure 11.2 The antiproliferative activity of Celecoxib. The data presented is the mean of 
three independent experiments. Each data point is expressed as a percentage of cell growth 
relative to the control and the error bars indicate standard error of the mean.  
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Table 11.1  Growth inhibition due to Celecoxib. This table demonstrates the concentration 
of Celecoxib at which 50% cell inhibition was seen compared to control. Clinically relevant 
maximum dose for Celecoxib is 2.6 μM. COX-2 protein expression of the cell lines is also 
shown (O'Kane, Eagle et al. 2010). 
Cell lines Celecoxib (μM) COX-2 protein 
NCI-H2052 54 expressed 
NCI-H2452 49 expressed 
MSTO-211H 22 expressed 
A549 53 expressed 
 
11.4 Discussion 
Celecoxib showed significant growth inhibition in all cell lines at a concentration of 
approximately 50 μM in NCI-H2052, NCI-H2452 and A549 cell lines and at 22 μM in 
MSTO-211H cell line which where all significantly higher than the clinically relevant dose 
range. Celecoxib has previously shown to inhibit mesothelioma cell lines by Catalano et al 
(2004) (Catalano, Graciotti et al. 2004). The mesothelioma cell lines MPP89, H-Meso and 
Ist-Mes1 and normal mesothelium cells were incubated with Celecoxib for 48 hours and 
cell growth inhibition was assessed using the MTS assay. The study demonstrated 
significant growth inhibition in the mesothelioma cell lines with the mean IC50 value of 
Celecoxib being 35+/- 12 μM. Normal mesothelium did not show any growth inhibition 
(Catalano, Graciotti et al. 2004). Celecoxib demonstrated anti-proliferative effects in A549 
cells (24 hour incubation) at an IC50 value of 73 μM when evaluated using the MTS assay 
(Backhus, Petasis et al. 2005).  
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Schroeder et al (2004) evaluated the effect of Celecoxib in head and neck cancer cell lines 
expressing COX-2 protein (UMSCC-11A/11B, UMSCC-14A, UMSCC-17B, UMSCC-
22B) and those not expressing COX-2 protein (UMSCC-14B, UMSCC-17A, UMSCC-
22A) and was analysed using the MTT assay (Schroeder, Yang et al. 2004). The dose of 
Celecoxib required to inhibit PGE2 production by 89% in COX-2 positive cells (UMSCC-
14A) was 0.1 μM. Celecoxib failed to inhibit PGE2 production in COX-2 negative cells 
(UMSCC-14B). Despite the dose of Celecoxib required to inhibit PGE2 production was 0.1 
μM, the dose required to cause 50% growth inhibition ranged from 25 to 75 μM in all the 
cell lines irrespective of the COX-2 status of the cell lines. This suggests that Celecoxib 
may act as a cytotoxic agent in a manner independent of COX-2 / PGE2 inhibition.  
Studies done at our laboratory have previously demonstrated that COX-2 inhibitors such as 
DuP-697 have significant cytotoxic effect in MPM cells and A549 cells. Celecoxib is 
derived from DuP-697 and is FDA approved for use in clinical practice and has a good 
safety profile. This study demonstrates that Celecoxib, similar to DuP-697, is also effective 
in MPM cells, but at doses higher than clinically achievable. The clinically relevant dose 
range for DuP-697 is currently not known. 
Significant cross talk exists between the COX-2 and the EGFR pathways. Combined 
inhibition of EGFR and COX-2 may therefore enhance the therapeutic effect in comparison 
to single target inhibition. In a single study, five MPM cell lines (NCI-2452, MPP89, Ist-
Mes-1, Ist-Mes-2 and MSTO-211) were incubated with Gefitinib and Rofecoxib to assess 
for synergy.  The Ist-Mes-2 cells, but not the other cells, demonstrated synergistic effect to 
the combination when compared to either drug alone (Stoppoloni, Canino et al. 2010).  It is 
yet unknown whether the combination of EGFR inhibitors (Monoclonal antibodies and 
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TKIs) and Celecoxib would enhance the cytotoxic effects of either agent when used alone 
in MPM cells. In Chapter 12 we aimed to combine EGFR inhibitors (Gefitinib and 
Cetuximab) with Celecoxib to evaluate the additive effect of combined inhibition. 
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Chapter 12.  Overcoming resistance to 
EGFR inhibitors in malignant pleural 
mesothelioma 
 
Publications and presentations 
Agarwal V, Lind MJ, Cawkwell L (2012) Inhibition of EGFR, MTOR and COX pathways 
in mesothelioma cells. Lung Cancer 75: S22 (abstract). Poster - 10th Annual British 
Thoracic Oncology Group Conference, Dublin (January 2012) 
 
 
 
 
 
 
 
 
 
Chapter aim 
To identify if resistance to anti EGFR inhibition can be overcome by combining Cetuximab 
and Gefitinib individually with Rapamycin, Ku0063794 and Celecoxib in MPM cell lines 
using the MTS assay. 
193 
 
12.1 Introduction 
EGFR, MTOR and COX-2 proteins are frequently up regulated in malignant pleural 
mesothelioma (Table 2.2, Table 3.1 and Table 4.1). The results of the relevant protein 
expression and mutation of NCI-H2052, NCI-H2452, MSTO-211H and A549 cells 
obtained in our study are summarised in Table 12.1. The effectiveness of single agent 
Cetuximab, Gefitinib, Celecoxib, Rapamycin and Ku0063794 at clinically relevant dose in 
the cell lines obtained in our study are summarised in Table 12.2. Inhibition of EGFR using 
Cetuximab and Gefitinib has not demonstrated any significant effect in growth inhibition of 
MPM cells (Sections 9.3.4, 10.3.2 and 11.3). Resistance to Gefitinib may be due to lack of 
activating EGFR TK mutations in the MPM cells. Both the KRAS and the BRAF mutations 
were also not seen in MPM cell lines. Due to the absence of KRAS and BRAF mutations, 
we expected some anti-proliferative activity from Cetuximab, which was seen only in 
MSTO-211H cells, but not in NCI-H2052 and NCI-H2452 cells. The A549 cells harboured 
a single KRAS mutation, which may be one of the reasons for Cetuximab resistance in 
A549 cells. This suggests that resistance to Cetuximab may be mediated by downstream 
pathways other than the RAS/RAF/MAPK pathway. The PI3K/AKT/MTOR pathway is 
another downstream signalling pathway of the EGFR and may induce resistance to anti-
EGFR therapy by being activated by other proteins such as PGE2, loss of PTEN or other 
growth factor receptors such as IGF-R and PDGFR. Significant cross talk exists between 
the EGFR, PI3K/AKT/MTOR and the COX-2/PGE2 pathways (Figure 12.1). Anti-EGFR 
therapy resistance may be induced by COX-2/PGE2 or by the activation of the 
PI3K/AKT/MTOR pathway. In this study we aimed to overcome EGFR resistance by 
combining EGFR inhibitors (Cetuximab and Gefitinib) with MTOR inhibitors (Rapamycin 
and Ku0063794) and COX-2 inhibitor (Celecoxib).  
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Table 12.1  Protein expression and mutations status of cell lines. This table demonstrates 
the protein expression and the mutation status of the NCI-H2052, NCI-H2452, MSTO-
211H and A549 cells. The ‘Section’ refers to the paragraph in the text or reference where 
the full details can be obtained from. 
 NCI-H2052 NCI-H2452 MSTO-211H A549 Section 
EGFR protein Expressed Expressed Expressed Expressed 9.3.2 
PTEN protein Expressed Expressed Absent Weakly 
expressed 
10.3.1 
P70S6K 
protein 
Absent Absent Expressed Expressed 10.3.1 
COX-2 protein Expressed Expressed Expressed Expressed O’Kane (2010) 
EGFR TK 
mutation 
Absent Absent Absent Absent 9.3.3.1 
KRAS 
mutation 
Absent Absent Absent Present 9.3.3.2 
BRAF 
mutation 
Absent Absent Absent Absent 9.3.3.3 
PIK3CA Absent Absent Absent Absent Janmaat (2006); 
Suzuki (2009).   
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Table 12.2  Single agent inhibition in cell lines. This table demonstrates the effectiveness 
of single agent Cetuximab, Gefitinib, Celecoxib, Rapamycin and Ku0063794 in NCI-
H2052, NCI-H2452, MSTO-211H and A549 cells at clinically relevant dose. The clinically 
relevant dose of Ku0063794 is currently not known (?). The ‘Section’ refers to the 
paragraph in the text where the full details can be obtained from. 
 NCI-H2052 NCI-H2452 MSTO-211H A549 Section 
Cetuximab Not effective Not effective Effective Not effective 9.3.4 
Gefitinib Not effective Not effective Not effective Not effective 9.3.4 
Celecoxib Not effective Not effective Not effective Not effective 11.3 
Rapamycin Effective Effective Not effective Effective 10.3.2 
Ku0063794 ?Effective ?Effective ?Not effective ?Effective 10.3.2 
 
12.2 Materials and Methods 
12.2.1 MTS assay 
The EGFR and COX-2 positive cell lines MSTO-211H, NCI-H2052, NCI-H2452 
(mesothelioma) and A549 (lung cancer) were utilised. All cell lines were cultured and 
counted as detailed in section 6.2.1 and section 6.2.2.  The optimum number (see appendix 
A) of cells for each cell line (MSTO-211H - 5000 cells per well,  NCI-H2052 – 1000 cells 
per well, NCI-H2452 – 1000 cells per well and A549 – 1000 cells per well) was seeded 
onto a 96 well plate as detailed in section 6.2.3 and MTS assay was performed as detailed 
in section 6.2.4. In each experiment 6 replicate wells were used for each drug concentration 
and the experiment was repeated twice. Cells were incubated with either single agent 
Cetuximab or Gefitinib, and Cetuximab and Gefitinib in turn was combined with 
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Celecoxib, Rapamycin or Ku0063794. A fixed dose of Celecoxib, Rapamycin or 
Ku0063794 was added to a range of concentration of Cetuximab and Gefitinib to see if 
50% growth inhibition could be achieved by the combination at clinically relevant dose of 
Cetuximab (1.6 µM) and Gefitinib (1.4 µM) (Section 9.2.4). 
 
 
Figure 12.1  EGFR pathway interactions. This figure demonstrates the interaction between 
the EGFR, PI3K/AKT/MTOR and the COX-2/PGE2 pathway. The target proteins inhibited 
by Cetuximab, Gefitinib, Rapamycin, Ku0063794 and Celecoxib are also shown. 
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The concentration of Cetuximab used ranged from 100 nM to 1.75 µM and Gefitinib from 
100nM to 10 µM. The maximum concentration for Gefitinib was reduced to 10 µM 
compared to 20 µM used in single agent studies (Section 9.2.4) since the maximum 
concentration of Gefitinib which resulted in 50% cell growth inhibition was 13 µM in A549 
cells (Table 9.1). In MPM cells the dose of Gefitinib required for 50% cell growth 
inhibition was below or equal to 6 µM. To enhance the therapeutic value of Gefitinib by the 
combination, we expected the concentration of Gefitinib to fall below 10 µM.  Cetuximab 
and Gefitinib were then combined with fixed doses of Celecoxib, Rapamycin and 
Ku0063794. The fixed concentrations for Celecoxib, Rapamycin and Ku0063794 were 
calculated based on their half maximal inhibitory concentration of the individual drugs in 
each cell line when used as single agents in Chapter 10 and 11.  
12.2.2 Statistics 
The half maximal inhibitory concentration of Celecoxib, Rapamycin and Ku0063794 for 
each cell line was calculated using GraphPad Prism 5 software (GraphPad Software, Inc, 
San Diego, California) and 50% growth inhibition with the drug combinations were 
analysed as as detailed in section 6.2.4.2.1.  
12.3 Results 
The half maximal inhibitory concentrations of Celecoxib, Rapamycin and Ku0063794 
calculated for MSTO-211H, NCI-H2052, NCI-H2452 and A549 cell lines individually 
based on their anti-proliferative activity as single agents as described in Chapters 10 and 11 
are detailed in Table 12.3.   
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Table 12.3  Inhibitory concentrations of drugs. This table demonstrates the half maximal 
inhibitory concentrations of Celecoxib, Rapamycin and Ku0063794 in MSTO-211H, NCI-
H2052, NCI-H2452 and A549 cell lines using GraphPad Prism 5 software. 
 NCI-H2052 NCI-H2452 MSTO-211H A549 
Celecoxib 50 μM 50 μM 38 μM 42 μM 
Rapamycin 541 pM 228 pM 2.6 nM 278 pM 
Ku0063794 8 nM 40 nM 335 nM 31 nM 
 
To evaluate the clinical implication of EGFR inhibition with Cetuximab and Gefitinib, and 
combination of Cetuximab and Gefitinib in turn with Celecoxib, Rapamycin and 
Ku0063794, we calculated the concentration of the combinations at which 50% cell growth 
inhibition was seen using XY scatter graph using Microsoft excel 2007 as detailed in 
section 6.2.4.2.1. The aim was to potentiate the cytotoxic effect of Cetuximab and Gefitinib 
by reducing the concentration required for 50% cell growth inhibition to less than the 
clinically relevant dose. The maximum clinically relevant concentration of Cetuximab 
calculated was 1.6 μM and Gefitinib was 1.4 μM (Section 9.2.4). In this study MSTO-211H 
cells did not respond to single agent Cetuximab. This was surprising as we had previously 
demonstrated  in section 9.3.4 that single agent Cetuximab had anti-proliferative effect on 
MSTO-211H cells and the dose of Cetuximab required for 50% cell growth inhibition was 
1.63 μM, which was at the upper limit of the clinically achievable dose range. As we were 
unable to replicate the response data we concluded that single agent Cetuximab was not 
effective in MSTO-211H cells.  We found that the combination of Celecoxib and 
Cetuximab reduced the dose of Cetuximab required for 50% cell inhibition to less than the 
maximum clinically relevant dose of 1.6 μM in NCI-H2052 (1.5 μM) , NCI-H2452 (0.4 
199 
 
μM) and A549 (1.1 μM) cells, but not in MSTO-211H cells (Figure 12.2 and Table 12.4). 
The combination of Ku0063794 and Cetuximab reduced the dose of Cetuximab required 
for 50% cell inhibition to less than 1.6 μM in MSTO-211H (1.3 μM) cells but not in NCI-
H2052, NCI-H2452 and A549 cells. No significant growth inhibition to clinically relevant 
dose was seen with Rapamycin and Cetuximab combination. The combination of Gefitinib 
and Celecoxib demonstrated enhanced cytotoxicity in all the cell lines, but the dose of 
Gefitinib required for 50% cell growth inhibition was above the maximum clinically 
relevant dose range of 1.4 μM (Figure 12.3 and Table 12.4). No significant growth 
inhibition to clinically relevant dose was seen with either Rapamycin and Gefitinib 
combination or Ku0063794 and Gefitinib combination.  
 
 
Figure 12.2 The anti-proliferative activity of Cetuximab combinations. The XY scatter 
graphs represent the anti-proliferative effect of Cetuximab (A), Cetuximab and Celecoxib 
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(B), Cetuximab and Rapamycin (C) and Cetuximab and Ku0063794 (D). The concentration 
of Celecoxib, Rapamycin and Ku0063794 used were as detailed in Table 12.3. The control 
used contained media only, hence the control values are disconjugated from the treated 
values.  
 
 
Figure 12.3 The anti-proliferative activity of Gefitinib combinations. The XY scatter 
graphs represent the anti-proliferative effect of Gefitinib (A), Gefitinib and Celecoxib (B), 
Gefitinib and Rapamycin (C) and Gefitinib and Ku0063794 (D). The concentration of 
Celecoxib, Rapamycin and Ku0063794 used were as detailed in Table 12.3. The error bars 
in graph A and D are wide at high Gefitinib doses of 10 μM. This could be as a result of 
having only 2 replicates in the experiments. The control used contained media only, hence 
the control values are disconjugated from the treated values.  
.  
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Table 12.4 Growth inhibition due to Cetuximab and Gefitinib combinations. This table 
demonstrates the concentration of Cetuximab and Gefitinib required for 50% cell growth 
inhibition as single agents and when combined in turn with Celecoxib, Rapamycin and 
Ku0063794. The values in bold are the concentration of Cetuximab below the clinically 
relevant dose of 1.6 μM. The maximum clinically relevant concentration of Gefitinib was 
1.4 μM. 
 NCI-H2052 NCI-H2452 MSTO-211H A549 
Cetuximab alone 
 
Not achieved Not achieved Not achieved Not achieved 
Cetuximab+ 
Celecoxib 
 
1.5 µM 0.4 µM  Not achieved 1.1 µM  
Cetuximab+ 
Rapamycin 
 
Not achieved Not achieved Not achieved Not achieved 
Cetuximab+ 
Ku0063794 
 
Not achieved Not achieved 1.3 µM  Not achieved 
Gefitinib alone  
 
9 μM Not achieved 8.8 μM Not achieved 
Gefitinib + 
Celecoxib 
 
5 μM 4.5 μM 6.4 μM 5.1 μM 
Gefitinib + 
Rapamycin 
 
5.9 μM Not achieved Not achieved Not achieved 
Gefitinib + 
Ku0063794 
7.8 μM Not achieved 9.9 μM Not achieved 
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12.4 Discussion 
In this study we demonstrated that single agent Cetuximab was not effective in MSTO-
211H cells lines in contradiction to our findings in section 9.3.4. We demonstrated that the 
addition of Celecoxib to Cetuximab reduced the concentration of Cetuximab required for 
50% cell growth inhibition to less than 1.6 μM, which was the maximum clinically relevant 
dose was taken in NCI-H2052 (1.5 μM) , NCI-H2452 (0.4 μM) and A549 (1.1 μM) cells.   
An enhanced growth effect was seen in the Cetuximab and Celecoxib combination when 
compared to single agent Cetuximab in one cell line (MSTO-211H) (Figure 12.2). This is 
likely to be an artifact as we could not explain this effect and it was not seen in any other 
cell lines. The combination of Ku0063794 and Cetuximab also reduced the concentration of 
Cetuximab required for 50% cell growth inhibition to less than 1.6 μM in MSTO-211H (1.3 
μM) cells (Figure 12.2).  When Rapamycin and Cetuximab was combined the 
concentration of Cetuximab required to achieve 50% cell growth inhibition was not reached 
at the maximum concentration of 1.75 μM.  
Gefitinib when combined with Celecoxib, Rapamycin or Ku0063794 was unable to 
produce 50% cell growth inhibition within the clinically relevant dose in any of the cell 
lines.   
The study by Stoppoloni et al (2010), in MPM cell lines (MPP89, 1
st
-Mes-1 and 1
st
-Mes-2) 
analysed the cytotoxic effect of Gefitinib and Rofecoxib as single agents and in 
combination (Stoppoloni, Canino et al. 2010). Gefitinib and Rofecoxib reduced the cell 
growth of all MPM cells when the cells were incubated with either Gefitinib or Rofecoxib 
as single agents and analysed using cell proliferation assays. However, when Gefitinib and 
Rofecoxib were combined, synergistic effects were seen only in 1
st
-Mes-2 cells. The 
combination of Gefitinib and Rofecoxib in MPP89 and 1
st
-Mes-1 cells was found to be 
203 
 
antagonistic in nature. In our study the combination of Celecoxib to Cetuximab enhanced 
the cytotoxic effect of Cetuximab in NCI-H2052, NCI-H2452 and A549 cells, but in 
MSTO-211H cells, resulted in a stimulatory effect. The exact reason for this variable effect 
with anti-EGFR therapy and anti-COX-2 therapy combination in MPM cells is currently 
not known and may need further evaluation.  
There are no published studies evaluating the cytotoxic effects of Cetuximab and Celecoxib 
combination in MPM. A phase II clinical trial evaluating the effect of combined EGFR and 
COX-2 blockade using Cetuximab and Celecoxib in chemotherapy refractory metastatic 
colorectal cancers was terminated early due to lack of significant benefit of the combination 
compared to previously published Cetuximab monotherapy data (Chan, Lafleur et al. 2011).  
Chen et al (2008) evaluated the combined effect of Gefitinib and Celecoxib in three 
NSCLC cell lines (A549, GLC82 and SW1573) and demonstrated that the combination has 
additive effect in comparison to either drug alone when analysed using MTT assays (Chen, 
He et al. 2008). Similar additive effect was seen with Celecoxib and Gefitinib combination 
in five head and neck cancer cell lines (Tu177, Tu212, 212LN, 686LN and 886LN) when 
compared to either agent alone (Chen, Zhang et al. 2004).  This is in keeping with our 
finding of significant enhanced cytotoxic effect when Celecoxib was combined with 
Gefitinib in A549 cells compared to single agent Gefitinib. Clinical studies in NSCLC have 
however failed to demonstrate the additive benefit of Celecoxib and Gefitinib combination 
compared to single agent Gefitinib (Gadgeel, Ruckdeschel et al. 2007; Agarwala, Fisher et 
al. 2008). One of the reasons for lack of anti-proliferative effect of Celecoxib and Gefitinib 
combination at clinically relevant doses in MSTO-211H, NCI-H2052, NCI-H2452 and 
A549 cells may be due to lack of EGFR TK activating mutations (Table 12.1). Gadgeel et 
al (2007) treated EGFR TK mutation positive lung cancer cell lines (H3255 and H1650) 
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and wild type EGFR TK lung cancer cell line (H1781) with Gefitinib, Erlotinib or 
Celecoxib alone and the combination of Gefitinib or Erlotinib with Celecoxib and analysed 
the outcome using MTT assays (Gadgeel, Ali et al. 2007). The study demonstrated that 
Celecoxib significantly enhanced the cytotoxic effect of Gefitinib and Erlotinib in the 
mutation positive cell lines, but not in the cells with wild type EGFR.   
Buck et al (2006) evaluated the synergistic effect of EGFR inhibitor Erlotinib and 
Rapamycin in 22 cell lines of a wide variety of cancers (NSCLC, pancreatic, colon, and 
breast cancer) (Buck, Eyzaguirre et al. 2006). Of the 22 cell lines 12 of them demonstrated 
significant synergism with the Rapamycin and Erlotinib combination. Among the 22 cell 
lines, five cell lines harboured PI3K or PTEN mutations and all the cell lines harbouring the 
PI3K or PTEN mutations demonstrated synergism to the Rapamycin and Erlotinib 
combination. In our study the combination of Cetuximab and Ku0063794 resulted in 
significant growth inhibition and the addition of Ku0063794 to Cetuximab reduced the 
dose of Cetuximab required for 50% cell growth inhibition to within clinically relevant 
dose in MSTO-211H cells. Single agent Ku0063794 has failed to demonstrate any 
significant activity in MSTO-211H cells (Table 10.1). MSTO-211H cells have 
demonstrated loss of PTEN protein expression and expression of p70S6K protein by 
western blot (Table 12.1). The inhibition of MTORC1 protein may result in feedback 
stimulation of AKT by inhibiting the p70S6K/IRS1/PI3K negative feedback loop (Figure 
10.1) thereby inducing resistance to single agent Ku0063794 (Shi, Yan et al. 2005). 
Complete inhibition of AKT may be required by inhibiting the p70S6K/IRS1/PI3K 
negative feedback loop. The addition of Cetuximab to Ku0063794 may inhibit this 
feedback loop by inhibiting PI3K resulting in complete blockade to AKT. Other studies 
have demonstrated that the addition of Erlotinib can suppress Rapamycin induced 
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activation of AKT (Wang, Hawk et al. 2008).  The molecular mechanism hypothesised will 
need to be validated in subsequent studies as no significant growth inhibition was seen with 
Cetuximab and Rapamycin combination or Gefitinib and Rapamycin / Ku0063794 
combinations. 
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Chapter 13.  Proteomic exploration of the 
molecular mechanism of action of the 
specific COX-2 inhibitor DuP-697 
Acknowledgment 
This part of the study was kindly supported by Yorkshire Cancer Research. 
 
Contributions 
Dr. Gina Eagle (PhD) - cell treatment and protein extraction 
Dr. Victoria Hodgkinson (PhD) - antibody microarray analysis 
Dr. Vijay Agarwal – Data mining and validation 
 
Publications and presentation 
Agarwal V, Hodgkinson VC, Eagle GL, Scaife L, Lind MJ, Cawkwell L. 
Proteomic (antibody microarray) exploration of the molecular mechanism of action 
of the specific COX-2 inhibitor DuP 697.  
International Journal of Oncology. (In Press) 
 
Agarwal V, Hodgkinson VC, Eagle GL, Scaife L, Lind MJ, Cawkwell L (2010) 
Proteomic analysis of the mechanism of action of DuP-697 in mesothelioma cells. 
Oral presentation - The 10th International Conference of the International 
Mesothelioma Interest Group, Kyoto, Japan (August 2010). 
 
 
 
 
Chapter aim 
To study the mechanism of action of COX-2 inhibitor DuP-697 using antibody  
microarray, IPA, and western blot. This will also be an initial pilot study to see if  
antibody microarray can be used to identify mechanism of action of drugs. 
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13.1 Introduction 
Previous work in our laboratory had demonstrated that COX-2 is over expressed in 59% 
(51/86) of archival malignant pleural mesothelioma tissue samples, a finding supported by 
similar studies (Marrogi, Pass et al. 2000; Edwards, Faux et al. 2002; Baldi, Santini et al. 
2004; Cardillo, Spugnini et al. 2005; O'Kane, Cawkwell et al. 2005). The cytotoxic effect 
of COX-2 inhibitors has been demonstrated in mesothelioma cell lines (Marrogi, Pass et al. 
2000; Catalano, Graciotti et al. 2004) and recently we reported that specific COX-2 
inhibitors, including DuP-697, induce anti-proliferative effects in mesothelioma cell lines 
that the cytotoxic effect of Pemetrexed chemotherapy can be enhanced by the addition of 
DuP-697  (O'Kane, Eagle et al. 2010). Several COX-2 inhibitors which are currently used 
in clinical practice, including Celecoxib and Rofecoxib, are derived from DuP-697 
(Blobaum and Marnett 2007).  
DuP-697 is therefore worthy of further clinical investigation. However the molecular 
mechanism of action of DuP-697 has not been widely studied. In normal proliferating 
human umbilical vein endothelial cells (HUVECs) expressing low levels of COX-2, DuP-
697 was shown to induce apoptosis and this was associated with the upregulation of 
caspase 3, 8 and 9 (Churchman, Baydoun et al. 2007). In the K562 chronic myeloid 
leukaemia cell line, DuP-697 induced G1-S cell cycle arrest and apoptosis with 
upregulation of caspase 8 (Peng, Zhang et al. 2008). These hypothesis-driven studies 
suggest that the mechanism of cytotoxic action of DuP-697 may be via induction of 
apoptosis. We aimed to explore, using a novel proteomic platform, the molecular 
mechanism of action of this compound using cell lines derived from solid tumours. This 
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was a preliminary pilot study to see if antibody microarray technique can be used to 
identify mechanism of action of drugs. 
13.2 Materials and Methods 
13.2.1 Cell line treatments and protein extraction 
The cell treatment and protein extraction was performed by Dr. Gina Eagle (PhD). DuP-697 
was previously demonstrated to have a cytotoxic effect in the COX-2 positive 
mesothelioma cell line MSTO-211H and in the lung cancer cell line A549, which was 
originally selected as a COX-2 positive control cell line (O'Kane, Eagle et al. 2010). In 
order to induce a visible cytotoxic effect in DuP-697 treated cells (50% reduction in cell 
numbers compared to untreated control), MSTO-211H and A549 cells were treated with 
31.7 µM and 50 µM DuP-697 (#1430, Tocris Bioscience) respectively, for 72 hours. Drug 
carrier (dimethyl sulfoxide; DMSO) only was added to control (untreated) cells. Protein 
extraction from control cells and cells treated with DuP-697 was performed for subsequent 
antibody microarray and western blot analysis. This was achieved by suspending cells in 1 
ml of ‘Buffer A’, which is a lysis buffer provided in the antibody microarray kit, incubating 
on an end-over-end rotator for 5 minutes at 4 °C, and subsequent centrifugation, to yield a 
minimum of 1 mg protein in a total volume of 1 ml. Protein concentration was determined 
by the Bradford Assay (#B6916, Sigma Aldrich). For western blot, protein extraction was 
performed as described in section 6.2.5.1.  
13.2.2 Antibody microarray analysis  
The antibody microarray analysis was performed by Dr. Victoria Hodgkinson (PhD). The 
Panorama XPRESS Profiler725 antibody microarray Kit (Sigma Aldrich #XP725) was 
used for antibody microarray which consists of 725 antibodies, spotted in duplicate, onto a 
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nitrocellulose-coated glass microscope slide (see appendix E for list of antibodies). The 
expression of a wide variety of proteins was analysed, including those involved in 
apoptosis, cell cycle, signalling, proliferation and cell adhesion. Protein labelling, protein 
binding and image analysis were carried out in low-light conditions, using the method 
previously described (Smith, Watson et al. 2006; Hodgkinson, Elfadl et al. 2011). 
13.2.2.1 Protein Labelling 
Proteins were labelled with Cy3 (PA23001, GE Healthcare) [control] and Cy5 (PA25001, 
GE Healthcare) [treated] fluorescent dyes, according to manufacturer’s instructions.  
13.2.2.2 Protein Binding 
Prior to protein binding, dye-to-protein molar ratios were determined for each sample to 
ensure successful labeling of proteins. These were calculated as specified in the antibody 
microarray kit protocol, and as recommended, samples were only used if the ratio was >2.  
Equal amounts of protein from each sample (50-150 µg) were mixed with array incubation 
buffer (supplied) then incubated with the slide for 45 minutes, protected from the light. 
13.2.2.3 Image Acquisition and Analysis 
The slide was scanned (GenePix Personal 4100A Microarray Scanner, Axon Instruments) 
and analysed using GenePix Pro (Axon Instruments) and Acuity software (Axon 
Intruments). Normalisation, based on the Lowess method, was performed within Acuity 
software to identify differentially expressed proteins (DEPs). For optimum quality control, 
spot criteria were applied to only include spots with <3 % saturated pixels, those which 
were not flagged as absent and those that had ‘relatively uniform intensity’ and were 
detectable above the background. Experiments which showed ‘percentage substance 
matched’ values  90 % were carried forward, to ensure only slides of good quality were 
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accepted for further analysis. Differentially expressed proteins were considered significant 
with a fold change ≥ 1.8, whilst fold changes ≥ 1.5 were also recorded for each experiment 
for use as supporting data (Figure 13.1) (Hodgkinson, Elfadl et al. 2011).  
 
 
Figure 13.1 Antibody microarray slide demonstrating upregulation (red) of Bcl-xL in 
duplicate spots in MSTO-211H cells. Downregulated proteins would have been 
demonstrated as a green spot in duplicate and equal expression demonstrated as yellow 
spots in duplicate.  
13.2.3 Ingenuity Pathway Analysis 
Gene identifiers which corresponded to the DEPs were identified from the Ingenuity  
Knowledge Base and the dataset was analysed through the use of Ingenuity Pathway 
Analysis (IPA; Ingenuity  Systems, www.ingenuity.com) as detailed in section 6.2.8. The 
dataset containing gene identifiers of the DEPs was uploaded into the application and each 
identifier was mapped to its corresponding object in the Ingenuity  Knowledge Base. 
Canonical Pathways Analysis was used to identify pathways from the IPA library that were 
most significant to the dataset.  
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13.2.4 Western blotting 
Validatory dye-swap experiments were not performed during the antibody microarray 
analysis due to cost and sample availability. Therefore western blotting was used to 
determine and confirm the direction of protein expression change. Western blotting was 
carried out as detailed in section 6.2.5. In brief, proteins were extracted in Laemmli buffer 
(62.5 mM Tris-HCl [pH 6.8], 10% glycerol, 2% SDS, 5%  β-mercaptoethanol, 1% protease 
inhibitor mix and 0.00125% bromophenol blue) and 20 ug was electrophoresed on a 12% 
Precise gel (#25222, Pierce) at a constant voltage of 140 V for 40 minutes. Proteins were 
transferred using the iBlot dry transfer system (#IB3010-01, Invitrogen) onto nitrocellulose 
membrane. The membrane was blocked in 5% non fat dry milk dissolved in tris buffered 
saline containing 0.05% Tween 20. A primary antibody against BCL2L1 (Bcl-xL; #B9429, 
Sigma Aldrich) was applied at 1:5000 for 2 hours (Table 6.1). A primary antibody against 
BID (#ab32060, Abcam) was applied at 1:300 for 16 hours. As loading control, a primary 
antibody against alpha tubulin (#ab7291, Abcam) was applied at 1:2500 for 2 hours. The 
relevant secondary antibody (#SC-2030 or #SC-2031, Santa Cruz Biotechnology) was 
applied at 1:1000 for 1 hour and bands were detected using the Supersignal West Pico 
Chemiluminscent Substrate Kit (#34078, Pierce). Films were scanned using a GS800 
calibrated densitometer (Bio-Rad) with Quantity One software (Bio-Rad). Following data 
normalisation against the loading control, differential expression between samples was 
calculated. 
13.3 Results 
Antibody microarray analysis identified 32 unique proteins, which demonstrated  1.8-fold 
difference in expression in at least one cell line, when comparing DuP-697 treated versus 
control (drug carrier only) cells (Table 13.1).  
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Of these, 20 DEPs demonstrated  1.8-fold difference in 2/2 cell lines. The dataset of 32 
DEPs was submitted to IPA and the top relevant canonical pathway was “Apoptosis 
Signalling”, which involved 5 DEPs: BCL2L1 (Bcl-xL), BID, CHUK (IKK), FASLG and 
RAF1 (Figure 13.2).  
 
Table 13.1 List of DEPs identified by antibody microarray. A total of 32 unique DEPs 
identified using antibody microarray analysis following DuP-697 treatment of MSTO-211H 
mesothelioma cells and A549 lung cancer cells. Significant expression fold change (  1.8) 
is indicated in bold. For proteins which show  1.8-fold change in expression in one cell 
line, supporting data from the second cell line is shown upward of 1.5-fold and non 
significant values (below 1.5-fold) are indicated “---“. Highlighted protein targets were 
selected for western blot analysis. Downregulated proteins are demonstrated as minus 
values.   
Ab # (Sigma 
Aldrich) 
Protein target Gene 
identifier 
A549 MSTO-211H 
P0084 Pinin PNN 7.67 7.32 
Z0377 Zxyin ZYX -4.39 -4.74 
C1862 Coilin COIL -4.6 -3.46 
A5968 AP-1 JUN 2.49 2.97 
B3183 tBID BID 2.42 2.54 
C7736 Centrin CETN1 2.51 2.04 
S5446 SUMO-1 SUMO1 2.44 2.09 
C6219 Connexin-43 GJA1 2.44 2.01 
M0445 MDMX MDM4 2.13 2.39 
A0844 AP-2a TFAP2A 
 
2.37 2.28 
A7107 AP2 -2.06 -2.04 
I6139 IKKa CHUK 2.37 1.99 
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E8526 E2F4 E2F4 2.37 1.96 
S1190 SLIPR / MAGI-3 MAGI3 2.15 1.92 
B9429 Bcl-xL BCL2L1 2.13 2.24 
S9809 Sp1 SP1 2.13 1.95 
F3648 Fibronectin FN1 1.99 2.12 
F2051 Fas Ligand FASLG 1.81 2.14 
V7881 Vitronectin VTN 1.99 1.82 
H9912 Hsnf5 / INI1 SMARCB1 1.96 1.84 
A7833 ATF-1 ATF1 1.83 1.84 
R8274 RIP Receptor Interacting 
Protein 
RIPK1 2.11 1.74 
T5942 14-3-3 theta/tau YWHAQ -1.64 -2.22 
T1075 Tal LRSAM1 2.05 1.72 
C3470 Connexin-32 GJB1 2.04 1.76 
R1151 c-Raf pSer621 RAF1 1.78 1.99 
R4904 Reelin RELN 1.95 1.67 
S3934 Smad4 (DPC4) SMAD4 1.87 1.61 
R3529 Rnase L RNASEL -1.59 -1.82 
A5044 alpha Actinin ACTN1 1.82 1.66 
E8767 c-erbB-3 ERBB3 1.82 --- 
C3956 c-Myc MYC 1.81 --- 
L1538 LIN-7 LIN7A 1.8 1.57 
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Figure 13.2  Apoptosis signalling pathway.  Apoptosis Signalling canonical pathway from 
IPA (Ingenuity  Systems, www.ingenuity.com) showing BCL2L1 (Bcl-xL), BID, CHUK 
(IKK), FASLG and RAF1 which were identified by antibody microarray analysis. 
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The BCL2L1 (Bcl-xL) and BID proteins were selected for further analysis using western 
blotting. The anti-apoptotic BCL2L1 (Bcl-xL) protein was down regulated by 2.48 fold in 
the MSTO-211H cell line when treated with DuP-697 (Figure 13.3). The anti-tBID 
antibody (B3183), which was present on the antibody microarray, proved to be unreliable 
in the western blot application. However full length BID was found to be down regulated in 
both the MSTO-211H and A549 and the cell lines by a fold change of 10.16 and 14.52 
respectively, following treatment with DuP-697 (Figure 13.4).  
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Figure 13.3 Western blotting image demonstrating expression of BCL2L1.Western blotting 
demonstrated a significant decrease (2.48-fold) in expression of BCL2L1 (Bcl-xL) in the 
MSTO-211H cells following treatment with DuP-697. The BCL2L1 (Bcl-xL) protein could 
not be detected in the A549 cell line. The primary antibody against BCL2L1 (Bcl-xL) used 
here (#B9429, Sigma Aldrich) is expected to detect a band size of approximately 27 kD. 
Alpha tubulin (#ab7291, Abcam) is included as a loading control. 
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Lanes Normalised Ratio
A549 69.7 14.52
A549 DuP 697 4.8
MSTO-211H 86.4 10.16
MSTO-211H DuP 697 8.5
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Figure 13.4 Western blotting image demonstrating expression of BID. Western blotting 
demonstrated a significant decrease in expression of full length BID in the MSTO-211H 
and A549 cells following treatment with DuP-697. The primary antibody against full length 
BID used here (#ab32060, Abcam) is expected to detect a band size of approximately 22 
kD. Alpha tubulin (#ab7291, Abcam) is included as a loading control. 
13.4 Discussion 
We have previously confirmed that COX-2 is over-expressed in MPM samples which 
suggests that novel anticancer therapies targeted at this pathway may be useful in 
mesothelioma patients (O'Kane, Cawkwell et al. 2005). In addition, we have demonstrated 
that the COX-2 inhibitor DuP-697 enhanced the cytotoxic effect of Pemetrexed in 
mesothelioma cell lines, including MSTO-211H (O'Kane, Eagle et al. 2010). It is important 
to understand the molecular mechanism of action of novel agents before possible clinical 
testing and DuP-697 has not been widely researched. Two previous studies have suggested 
a role in inducing apoptosis via the caspase pathway (Churchman, Baydoun et al. 2007; 
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Peng, Zhang et al. 2008). In the present study we have explored the molecular mechanism 
of action of DuP-697 using an antibody microarray proteomic platform. We have identified 
32 unique differentially expressed proteins which were associated with DuP-697 treatment 
for 72 hours. Of these, 20 proteins demonstrated significant (  1.8-fold) differential 
expression in both the MSTO-211H mesothelioma and A549 lung cancer cell lines. Using 
some of the data from these, and other, experiments we have recently described Zyxin as 
the commonest repeatedly identified DEP (RIDEP) when using this proteomic platform 
(Hodgkinson, Elfadl et al. 2011) and therefore the selection of proteins for further analysis 
must be carefully considered. The analysis of the 32 DEPs using IPA indicated that 5 
proteins, BCL2L1 (Bcl-xL), BID, CHUK (IKK), FASLG and RAF1, were associated with 
the Apoptosis Signalling canonical pathway. Following a positive signal for apoptosis, 
activated caspase 8 cleaves inactive, cytosolic, full length BID into active truncated BID 
(tBID), which localises to the mitochondrial membrane (Danial 2007; Song, Chen et al. 
2010; Strasser, Cory et al. 2011). The anti-apoptotic proteins BCL-2 and BCL2L1 (Bcl-xL) 
block the escape of cytochrome C from the mitochondria, by preventing Bax from forming 
channels in the mitochondrial membrane, until activated tBID is localised to the membrane 
(Danial 2007; Song, Chen et al. 2010; Strasser, Cory et al. 2011). The caspase pathway of 
apoptosis has previously been implicated as the in vitro mechanism of action for DuP-697 
(Churchman, Baydoun et al. 2007; Peng, Zhang et al. 2008). The onset of apoptosis may be 
associated with decreased levels of full length BID, due to its cleavage into tBID, and 
decreased levels of the anti-apoptotic protein BCL2L1 (Bcl-xL). Our western blot data 
would support these suggested protein changes following administration of DuP-697 for 72 
hours. 
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The caspase pathway of apoptosis has previously been implicated as the in vitro mechanism 
of action for DuP-697, with upregulation of caspase 3, 8 and 9 being observed in 
hypothesis-driven experiments in normal proliferating endothelial cells or leukaemia cells 
(Churchman, Baydoun et al. 2007; Peng, Zhang et al. 2008). At the 72 hour time-point, 
which we examined here, we did not identify differential expression of caspase 3, 4, 5, 6, 7, 
8, 9, 10, 11, 12 or 13 or pro-caspase 8 in either MSTO-211H or A549 cells. However this 
may be due to the return of these proteins to basal levels within 72 hours since the 
upregulation of caspase 3, 8 and 9 was noted within 8 hours in HUVECs (Churchman, 
Baydoun et al. 2007). 
COX-2 is a key enzyme involved in the metabolism of Arachidonic acid resulting in the 
production of PG, particularly PGE2, which plays an important role in tumour progression. 
COX-2 inhibitors may act by inhibition of COX-2, but the exact mechanism of how COX-2 
inhibitors exert an anti-neoplastic effect is currently unknown. Indeed, several studies have 
suggested that COX-2 inhibitors may act independently of COX-2 (Kern, Haugg et al. 
2006; Lou, Fatima et al. 2006; Pang, Zhou et al. 2007; Schonthal 2007). In our antibody 
microarray experiments, differential expression of COX-2 was not observed in either cell 
line after treatment with DuP-697 for the duration selected (72 hours). In future work, the 
expression of COX-2 and the individual proteins within the apoptosis signalling pathway, 
which we have implicated here, could now be examined over a time-course of treatment 
with DuP-697. 
We have demonstrated that the antibody microarray proteomic platform can be used to 
explore the molecular mechanism of a COX-2 inhibitor. This will prove useful in gaining a 
more thorough understanding of novel agents which may have clinical applications. 
Specific COX-2 inhibitors, such as DuP-697, may have a future therapeutic role in MPM. 
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Our proteomic analysis suggests that the anti-proliferative effect of DuP-697, which was 
previously seen in mesothelioma cell lines, may be exerted via the induction of apoptosis. 
DuP-697, or other COX-2 inhibitors such as Celecoxib or Rofecoxib, may act as an 
effective apoptosis sensitiser when combined with chemotherapy drugs such as Pemetrexed 
and further studies are required to test this hypothesis. 
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Chapter 14.  Conclusions 
In summary, this study has demonstrated that  
 PTEN protein expression is undetectable in 27% of archival MPM tissue samples 
and is reduced in another 27% of MPM tissue samples as analysed by 
immunohistochemistry.  
 Both the 5LOX and 12LOX proteins were up regulated in 73% and 83% of archival 
MPM tissue samples respectively.  
 EGFR protein was expressed in MSTO-211H, NCI-H2052, NCI-H2452 and A549 
cells as analysed by flow cytometry.   
 PTEN protein expression was absent in MSTO-211H cells, weakly expressed in 
A549 cells and strongly expressed in NCI-H2052 and NCI-H2452 cells as analysed 
by western blot. 
 Our study is the first to evaluate the EGFR, KRAS and BRAF mutation in NCI-
H2052, NCI-H2452 and MSTO-211H cells. NCI-H2052, NCI-H2452, MSTO-211H 
and A549 cells harboured wild type EGFR TK domain and there was no BRAF 
mutations seen. A549 cells demonstrated a single KRAS mutation. No KRAS 
mutations were seen in H2052, NCI-H2452 and MSTO-211H cells.  
 We demonstrated that EGFR inhibitors (Cetuximab and Gefitinib) were not very 
effective as single agents in MPM cells. Our study is the first to evaluate the 
cytotoxic effect of Cetuximab in MPM.  
 The COX-2 inhibitor (Celecoxib) did demonstrate cytotoxicity, but at doses 
significantly higher than those that can be achieved therapeutically.  
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 MTOR inhibitors (Rapamycin and Ku0063794) demonstrated significant 
cytotoxicity in NCI-H2052, NCI-H2452 and A549 cells, but not in MSTO-211H 
cells. Our study is the first to evaluate the cytotoxic effect of MTOR kinase 
inhibitor (Ku0063794) in MPM.  
 Combined inhibition of Cetuximab and Gefitinib with Celecoxib, Rapamycin and 
Ku0063794 demonstrated enhanced inhibition in NCI-H2052, NCI-H2452 and 
A549 cells when Cetuximab was combined with Celecoxib and in MSTO-211H 
cells when Cetuximab was combined with Ku0063794 cells.  
 We successfully carried out a pilot study using antibody microarray as a novel 
platform to identify mechanism of action of COX-2 inhibitor (DuP-697) and 
demonstrated that DuP-697 may cause cytotoxicity by activating apoptosis.  
 
14.1 Implications of using in vitro cell line models 
Our cytotoxicity studies are based on cell lines grown in monolayer which is a simple and 
convenient way of demonstrating the effectiveness of drugs in cancer cells. There are 
several advantages to using cell lines as they are easy to grow, store and handle. They are 
homogenous and available in unlimited amount. However, culturing the cells over 
prolonged duration may alter their morphology and genotype (Bahia, Ashman et al. 2002; 
Burdall, Hanby et al. 2003; Watson, Bahia et al. 2004). Under normal circumstances a 
tumour microenvironment is made up of cancer cells, inflammatory cells, cytokines, 
extracellular matrix (containing stromal fibroblasts and epithelial cells), blood vessels and 
endothelial cells (Bissell and Radisky 2001). Significant interactions take place within 
different cells via cell-cell cross talk and cytokines. This complex tumour 
microenvironment plays an important role in the morphology and phenotype of cancer 
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initiation and progression. Cell lines grown as monolayers are immortalised cells derived 
from cancer tissues and lack the extracellular matrix, inflammatory cells, blood vessels and 
endothelial cells significantly altering the tumour microenvironment. In vivo experiments or 
cells grown in a three dimensional model may represent the phenotype and the morphology 
of cancer cells more accurately as there is less alteration of the tumour microenvironment 
(Smalley, Lioni et al. 2006).  Barbone et al (2008) grew MPM cells in a three dimensional 
multicellular spheroid model and demonstrated that the spheroids acquired resistance to a 
variety of apoptotic stimuli such as TRAIL, ribotoxic stressors, HDAC1 and proteosome 
inhibitors, which were highly effective in cells grown as monolayers (Barbone, Yang et al. 
2008). As a result, validation of the MTS assays in our study may need to be done using 
three dimensional spheroid models or by using in vivo models such as mouse xenografts.  
14.2 Is this the end of EGFR inhibition in MPM? 
Preclinical studies, including our study, have demonstrated that EGFR TKI such as 
Gefitinib have no significant cytotoxic effect in MPM cell lines at clinically relevant doses 
(Janne, Taffaro et al. 2002; Nutt, O'Toole et al. 2009). Clinical studies evaluating the effect 
of Gefitinib and Erlotinib (first generation EGFR TKIs) have demonstrated lack of clinical 
benefit in early phase trials in MPM (Govindan, Kratzke et al. 2005; Garland, Rankin et al. 
2007). The likely reason for the lack of benefit from EGFR TKI may be as a result of lack 
of activating EGFR mutations in MPM. Various authors have failed to demonstrate the 
presence of EGFR TK activating mutations in MPM (Section 2.2.7) (Cortese, Gowda et al. 
2006; Destro, Ceresoli et al. 2006; Okuda, Sasaki et al. 2008). Our study has demonstrated 
that EGFR mutations are not seen in MPM cell lines. The second generation EGFR TKIs 
irreversibly inhibit the TK activity of the EGFR resulting in longer and more potent 
inhibition of the receptor. The second generation EGFR TKIs  such as Afatinib (BIBW 
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2992, Boehringer Ingelheim) and Dacomitinib (PF-00299804, Pfizer)  have shown to be 
anti-neoplastic in EGFR mutation positive NSCLC (Ou 2012) (See appendix B for list of 
all drugs and targets for the targeted biological agents used). In a Phase II trial in NSCLC, 
Dacomitinib when compared to Erlotinib has shown to improve PFS in patients with wild 
type EGFR and KRAS (11.1 weeks versus 8 weeks; p= 0.047) (Ou 2012). The Phase III 
trial (ARCHER 1009; ClinicalTrials.gov Identifier: NCT01360554) comparing 
Dacomitinib to Erlotinib in advanced NSCLC patients with wild type EGFR is currently 
ongoing. If second generation irreversible EGFR TKIs demonstrate better efficacy 
compared to first generation reversible EGFR TKIs in tumours with wild type EGFR, then 
their evaluation in patients with MPM (with wild type EGFR) may demonstrate a 
therapeutic potential. 
To date there have not been any studies evaluating the effect of EGFR monoclonal 
antibodies such as Cetuximab in MPM. Biomarkers of Cetuximab resistance such as KRAS 
and BRAF mutations are not seen in MPM (Sections 2.2.8 and 2.2.9). Our study has 
demonstrated that KRAS and BRAF mutations are not seen in MPM cell lines. Given that 
KRAS and BRAF mutations are not seen in MPM and that EGFR is expressed in MPM, we 
expected to find significant anti-proliferative activity with Cetuximab in MPM cell lines. 
This was however not seen in our study. The current role of other anti-EGFR monoclonal 
antibodies such as Panitumumab and Matuzumab® (EMD 72000, Merk Serono) in MPM 
are currently not known. Given that Cetuximab has so far been not very effective in MPM 
cells in our study, the benefit of other similar anti-EGFR monoclonal antibody may be 
doubtful in cell line models, but will need further evaluation in in vivo models. One of the 
mechanisms of resistance to anti-EGFR therapy may be that the downstream signalling 
pathways are activated by other pathways such as COX-2/PGE2 pathway or co-activation 
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of other growth factor receptors may mediate the activation of PI3K/AKT/MTOR pathway 
(Figure 14.1). HGF/MET, IGF-1R and VEGFR are frequently up regulated and activated 
along with EGFR in MPM and the HGF/MET, IGF-1R and VEGFR inhibitors have 
demonstrated significant activity against MPM cells (Mukohara, Civiello et al. 2005; 
Jagadeeswaran, Ma et al. 2006; Whitson and Kratzke 2006; Kai, D'Costa et al. 2009; Nutt, 
O'Toole et al. 2009; Brevet, Shimizu et al. 2011). Inhibition of multiple targets in 
combination with EGFR may overcome anti-EGFR therapy resistance induced as a result of 
the activation of other growth factor receptors.  
The studies done to date evaluating the incidence of KRAS, BRAF and PIK3CA in MPM 
are very few and with small number of tissue samples and cell lines and this needs further 
evaluation with a larger number of MPM tissue samples.    
EGFR is the most common growth factor expressed in MPM and its role as a target for 
anti-cancer therapy is not the end,  but a modest, albeit a frustrating beginning. The 
complex molecular interaction of EGFR with other growth factors, its downstream 
signalling pathways, complicated feedback inhibitions and the role played by activating and 
resistant mutations of the EGFR and its other downstream signalling proteins make this an 
extremely difficult target to understand and manipulate for therapeutic advantage. Further 
work is required to understand the role played by EGFR in the pathogenesis of MPM and 
its mechanism of resistance. Inhibition of multiple targets, along with EGFR, may be of 
benefit and should be the next phase of the study. The suggested targets to co inhibit would 
be pan EGFR inhibition along with EP receptor, MET, IGFR and VEGFR in various 
combinations and also in combination with PI3K/AKT/MTOR pathway inhibition which 
plays an important and a central role in the oncogenic phenotype of MPM. In clinical 
practice inhibition of various targets is associated with toxicities which may be generic or 
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specific to the target inhibited (Widakowich, de Castro et al. 2007). Our ability to 
appropriately combine multiple target inhibitors is likely to be limited due to the varied and 
increased toxicity profile of the drug and target combinations. 
 
 
Figure 14.1  Interaction between cell surface receptors. This figure demonstrates the 
interaction between EGFR family and other cell surface receptors PGE2/EP, HGF/MET, 
IGF-1R and VEGFR and the likely mechanism of resistance to EGFR. Figure adapted and 
modified from (Doebele, Oton et al. 2010).  
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14.3 MTOR pathway and MPM – There is still work to do. 
We have demonstrated that NCI-H2052, NCI-H2452 and A549 cells were sensitive to the 
cytotoxic effects of the MTORC1 inhibitor Rapamycin at clinically relevant doses and the 
MTOR kinase inhibitor Ku0063794. Various other studies have demonstrated significant 
inhibitory effects of Rapamycin in MPM cell lines as well as MPM spheroids (Altomare, 
You et al. 2005; Kim, Wilson et al. 2005; Barbone, Yang et al. 2008; Wilson, Barbone et 
al. 2008). However, inhibition of MTORC1 may result in inhibition of the inhibitory 
feedback loop via the p70S6K/IRS1/ PI3K pathway resulting in activation of AKT and 
increased cell survival. Inhibition of MTOR kinase may overcome this effect by inhibiting 
MTORC2 which is an activator of AKT. In our study Ku0063794 has demonstrated 
significant cytotoxic effects in NCI-H2052, NCI-H2452 and A549 cells for the first time.  
There are various MTOR kinase inhibitors undergoing early phase clinical trials such as 
OSI-027 (OSI), Phase I; AZD-8055 (AstraZeneca), Phase I/II; AZD-2014 (AstraZeneca), 
Phase I and INK128 (Intellikine), Phase I (Zaytseva, Valentino et al. 2012). The inhibitory 
effect of these MTOR kinase inhibitors will need further evaluation in MPM at clinically 
relevant doses. MTOR inhibition can also be combined with other targeted drugs such as 
PI3K inhibitors (XL-147 (Exelixis) and BKM120 (Novartis)) to overcome the inhibitory 
effects of the p70S6K/IRS1/ PI3K negative feedback loop and enhance its therapeutic 
effect. The newer MTOR kinase inhibitors also inhibit the p110α, β and γ isoforms of PI3K 
thereby completely blocking the effect of PI3K / AKT signalling. Some of the dual MTOR 
kinase / PI3K inhibitors currently undergoing clinical trials are NVP-BEZ235 (Novartis), 
Phase I/II; XL765 (Exelixis/Sanofi-Aventis), Phase I/II; SF1126 (Semafore), Phase I; 
GSK2126458 (GlaxoSmithKline),  Phase I;  BGT226  (Novartis),  Phase I/II; GDC0980 
(Genentech),  Phase I; PF-04691502  (Pfizer),  Phase I/II and PF-05212384 (PKI-587, 
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Pfizer), Phase I (Zaytseva, Valentino et al. 2012). The effect of dual (MTOR kinase / PI3K) 
kinase inhibitors will need further evaluation in MPM.  
In our study the combined inhibition of EGFR and MTOR failed to demonstrate any 
significant therapeutic advantage at clinically relevant doses except in MSTO-211H cells 
where the combination of Ku0063794 and Cetuximab enhanced the cytotoxic effect of 
Cetuximab. One of the reasons for resistance to EGFR inhibition could be that the growth 
factor mediating the MTOR signalling pathway in NCI-H2052, NCI-H2452 and A549 may 
be independent of EGFR. Significant co activation of IGF-1R, VEGF and MET/HGF along 
with EGFR has been seen in MPM and inhibition of these growth factors in combination 
with MTOR inhibition using multiple kinase inhibitors may enhance the therapeutic effect 
when compared with inhibition of any single target alone. The next phase of this 
translational research should involve the evaluation of MTOR dual kinase inhibitors in 
MPM cells, initially as single agents and subsequently in combination with multiple growth 
factor receptor inhibitors (Figure 14.2). 
Since there was a significant inhibition in MPM cell lines by Rapamycin at clinically 
relevant doses, the next phase would be to trial this in a clinical setting, either a single 
agents after failure of chemotherapy or in combination with chemotherapy. Currently there 
are two Phase II clinical trials ongoing which are evaluating the benefits of the Rapamycin 
rapalog Everolimus in patients with MPM (Section 3.1.3). The outcome of these trials will 
provide significant information on the importance of inhibiting MTOR in patients with 
MPM. 
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Figure 14.2 MTOR and Growth factor receptor inhibitors. This figure demonstrates the 
extent of inhibition of growth factor receptor and the PI3K/AKT/MTOR pathway using 
various MTOR and growth factor receptor inhibitors. 
14.4 Arachidonic acid metabolism in MPM 
Arachidonic acid metabolizing enzymes COX-2 and 5LOX are upregulated in MPM 
suggesting that both the metabolic pathways may be active (Section 8.3.3, Figure 4.1, and 
Figure 4.2). Since the metabolism of Arachidonic acid by COX-2 and 5LOX are 
interrelated, there is a likely possibility that inhibiting either enzyme may shift and increase 
the metabolic activity to the other enzyme resulting in neoplastic activity. In a study by 
Duffield-Lillico et al (2009), healthy volunteers when treated with Celecoxib demonstrated 
a reduction in the level of urinary PGE-M (metabolite of PGE2 secreted in urine) levels, but 
an increase in the urinary LTE4 levels, demonstrating a shift in the metabolism of 
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Arachidonic acid from the COX-2 pathway to the 5LOX pathway (Duffield-Lillico, Boyle 
et al. 2009).  In colon cancer cell lines (Caco-2 and HT29) treatment with Celecoxib 
resulted in significant reduction of PGE2 production, but an increase in the production of 
cysteinyl Leukotriene (5LOX metabolite) demonstrating a shift in the metabolic activity 
(Cianchi, Cortesini et al. 2006). Similarly treatment of the colon cancer cells with a 5LOX 
inhibitor (MK886) resulted in a reduction in the production of cysteinyl Leukotriene and an 
increase in the production of PGE2. Combined inhibition with Celecoxib and MK886 
resulted in the reduction of both PGE2 and cysteinyl Leukotriene in both the cell lines. 
Similar additive effect of COX-2 and 5LOX inhibition has been demonstrated by other 
studies in colon cancer, oral cancer and oesophageal cancers (Chen, Wang et al. 2004; Li, 
Sood et al. 2005; Ye, Wu et al. 2005; Shi, Lv et al. 2011) In MPM, COX-2 inhibitors  and 
5LOX inhibitors have independently demonstrated cytotoxic effect in MPM cell lines 
(Marrogi, Pass et al. 2000; Romano , Catalano et al. 2001; DeLong, Tanaka et al. 2003; 
Catalano, Graciotti et al. 2004; O'Kane, Eagle et al. 2010). Inhibiting both the 5LOX and 
COX-2 pathways by using both COX-2 and 5LOX inhibitors simultaneously or dual COX-
2/5LOX inhibitor (Licofelone , Merckle GmbH, Germany), may target the shift of 
metabolic pathways resulting in an enhanced therapeutic benefit and needs further 
evaluation. 
In MPM, COX-2 inhibition with Celecoxib has demonstrated significant cytotoxic effect, 
but at doses significantly higher than those achieved clinically. The exact mechanism of 
action of Celecoxib is currently a focus of investigation and various studies have suggested 
that the mechanism may be independent of COX-2/PGE2 inhibition  (Tegeder, Pfeilschifter 
et al. 2001; Maier, Schilling et al. 2004; Pyrko, Soriano et al. 2006; Tong, Wu et al. 2006). 
In our study we used antibody microarray as a pilot to evaluate the mechanism of action of 
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the COX-2 inhibitor DuP-697 and a similar study may be required to identify the 
mechanism of action of Celecoxib in MPM and identify further targets that may be 
therapeutically manipulated. 
14.5 Research in MPM 
There is a significant paucity of research in MPM. In the UK in 2008, there were 1,967 
patients diagnosed with mesothelioma, 47,693 patients diagnosed with breast cancer, 
17,960 patients diagnosed with lung cancer and 17,894 patients diagnosed with colorectal 
cancer (http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/ accessed 
20/03/2012).  A brief survey conducted in Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/) 
on 20/02/2012 and searching the tumour type under the heading of Title/abstract and 
deducting any review articles, showed that the total number of manuscripts in MPM was 
1450, in comparison to breast cancer (124,478), lung cancer (64,419) and colorectal cancer 
(37,940). Using the same search criteria in clinicaltrials.gov (http://clinicaltrials.gov/), the 
total number of clinical trials in MPM were 97, in comparison to breast cancer (4,606), lung 
cancer (3,877) and colorectal cancer (2,421). This suggests that MPM is proportionately (in 
relation to the incidence)  significantly under researched and needs more research input to 
better understand the pathophysiology of the disease and identify important targets that can 
be therapeutically manipulated to benefit patients.  
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Appendix A (MTS Optimization) 
Estimation of duration of exposure to MTS reagent 
MSTO-211H cell lines were seeded in a 96 well plate at cell density of 5000cells per well, 
10000 cells per well and 20000 cells per well in triplicates. After 4 days of incubation, 
MTS reagent was added to each well and colorimetric reading taken after 1hr, 2 hrs and 3 
hrs interval. Manufacturer’s recommendation was to read the plate between 1 to 4 hours 
(Table A.1). 
Table A.1 Table showing true absorbance values after adding MTS reagent at 1hr, 2 hrs 
and 3 hrs interval.  
MSTO-211H cells 1 hr reading  2 hrs reading  3 hrs reading  
5000 cells 0.33 0.56 0.7 
10000 cells 0.58 0.88 1.07 
20000 cells 0.73 1.08 1.34 
 
The best readings were observed after 3 hrs and hence that was taken forward.  
 
Optimal cell seeding density for cell growth 
NCI-H2052, NCI-H2452, MSTO-211H and A549 cell lines were seeded in a 96 well plate 
at cell density of 5000cells per well, 10000 cells per well and 20000 cells per well in 
triplicates with and without 0.01% DMSO (drug carrier) and incubated for 4 days (Table 
A.2). Growth of the cells was calculated at the end of 4 days by MTS assay read at 3 hrs. 
The aim was to achieve maximal growth without exceeding 80% confluence at the end of 4 
days to avoid growth inhibition due to cell-cell interaction, competing for nutrients and 
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space. Confluence was estimated by directly visualizing the total area occupied by cells in 
relation t othe total area of the well by light microscopy (magnification 20X). Maximal 
growth was seen in MSTO-211H cell line at 5000 cells per well with 70-80% confluence. 
Growth was also seen in NCI-H2052 and A549 cell lines, at seeding density of 5000cells 
per well, but the confluence of these cells were nearing 100%. NCI-H2452 cell lines did not 
show significant growth at seeding density of 5000 cells per well. The experiment was 
repeated for NCI-H2052, NCI-H2452 and A549 cell lines with a seeding density of 1000, 
2500 and 5000 cells per well. Maximal growth was seen in 1000 cell per well for NCI-
H2052, NCI-H2452 and A549 cell lines. Confluence was seen to be 70% to 80% in the cell 
lines at this seeding density. There was no cytotoxic effect of 0.01% DMSO noted. 
 
Calculation of percentage of growth inhibition 
An example of a single calculation of A549 cell line treated with 50μM Celecoxib is shown 
in Table A.3. All subsequent calculations done to estimate the growth response curve were 
based on this template. 
Once the growth of treated cell as a percentage of control cells was calculated the average 
of the three independent experiments were taken and Average of the three experiments was 
calculated along with the standard error of mean. The average reading of all the doses was 
taken an plotted onto a XY scatter plot in Microsoft excel work sheet along with the error 
bars to denote the standard error of mean. Growth inhibition (50%) was calculated after 
adding the trend line equation on the graph.  
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 Table A.2 This table demonstrates the % of cell growth and the effect of 0.01% DMSO in 
cell lines depending upon their seeding density. 
 
 
 
 
 
Cell lines Cell seeding density % Growth  % Growth with 0.01% DMSO 
NCI-H2052 1000 218.40 263.47 
2500 141.75 161.28 
5000 27.22 22.42 
5000 186.9 167.68 
10000 92.37 94.89 
20000 76.65 81.65 
NCI-H2452 1000 165.54 166.65 
2500 35.53 41.30 
5000 10.95 9.84 
5000 52.18 58.33 
10000 17.78 17.22 
20000 8.65 10.16 
MSTO-211H 5000 127.41 171.08 
10000 96.95 115.95 
20000 68.05 79.93 
A549 1000 405.67 414.45 
2500 128.96 120.92 
5000 44.34 32.29 
5000 106.28 96.38 
10000 15.06 12.45 
20000 5.15 4.32 
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Table A.3 Example calculation of the growth of treated cell as a % of control cells. 
A549 cells with 50μM Celecoxib 
      
D2 reading      
Blank 
0.13 0.13 0.11 
 Average= 0.12 
      
Baseline reading 
0.49 0.52 0.53 
  
 
0.54 0.40 0.39 
 Average= 0.48 
      
True Baseline reading (a) =(Baseline reading [0.48]– blank [0.12])  0.35 
      
D5 reading      
      
Blank 
0.13 0.11 0.14 
 Average=0.13 
      
      
Control absorbance 
2.15 2.46 2.45 
  
 
2.12 2.21 1.96 
 Average=2.23 
      
True Control absorbance (b)=(control absorbance [2.23]-blank [0.13]) 2.1 
      
Treated absorbance 
0.82 0.88 0.78 
  
 
0.76 0.89 0.90 
 Average=0.84 
      
True Treated absorbance (c)=(Treated absorbance [0.84]-blank [0.13]) 0.71 
      
      
Growth of control cells (d) = [(b-a)/a]*100 = [(2.1-0.35)/0.35]*100 494.15% 
      
Growth of treated cells (e) = [(c-a)/a]*100 = [(0.71-0.35)/0.35]*100 100.71% 
      
Growth of treated cells as a % of control cells (f) =  
(((e-d)/d)*100)+100 = (((100.71-494.15)/494.15)*100)+100 
20.38% 
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Appendix B (List of Drugs and Targets) 
Table B.1 List of targeted drugs used in text. 
Drug  Alternative 
names 
Manufacturer Drug Targets 
AA-861 SC-200570   5LOX 
AG1024     IGF-1R Tyrosine Kinase 
AZD-8055   Astra Zeneca MTORC1, MTORC2 
AZD-2014   Astra Zeneca MTORC1, MTORC2 
Bevacizumab Avastin  Genentech Inc VEGF 
BGT226  Novartis MTORC1, MTORC2, PI3K 
BIBW 2992 Afatinib  Boehringer 
Ingelheim 
Irreversible EGFR Tyrosine 
Kinase (2
nd
 Generation) 
BKM120  Novartis PI3K 
Cediranib AZD2171 Astra Zeneca VEGF Tyrosine Kinase 
Celecoxib Celebrex , 
Onsenal  
Pfizer COX-2 
Cetuximab IMC-C225, 
Erbitux  
ImClone Systems 
Incorporated 
EGFR 
DuP-697     COX-2 
Everolimus   RAD001 Novartis MTORC1 
GDC0980  Genentech MTORC1, MTORC2, PI3K 
Erlotinib OSI-774, 
Tarceva  
OSI 
Pharmaceuticals 
Reversible EGFR Tyrosine 
Kinase (1
st
  Generation) 
Flurbiprofen     Non selective COX 
Gefitinib ZD1839, Iressa  AstraZeneca Reversible EGFR Tyrosine 
Kinase (1
st
  Generation) 
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GSK2126458  GlaxoSmithKline MTORC1, MTORC2, PI3K 
Indomethacin     Non selective COX 
INK128   Intellikine MTORC1, MTORC2 
Ku0063794   AstraZeneca MTORC1, MTORC2 
 
Lapatinib GW572016, 
Tyverb  
GlaxoSmithKline EGFR, HER2 
ML3000 Licofelone  Merckle GmbH COX-2, 5LOX 
LY294002     PI3K 
Matuzumab EMD 72000 Merck Serono EGFR 
MK886   FLAP (5LOX activating 
protein) 
NDGA     Non selective LOX 
NS398     COX-2 
NVP-AEW541   Novartis IGF-1R Tyrosine Kinase 
NVP-BEZ235   Novartis MTORC1, MTORC2, PI3K 
OSI-027   Osi 
Pharmaceuticals 
MTORC1, MTORC2 
Panitumumab ABX-EGF, 
Vectibix  
Amgen EGFR 
PF-00299804 Dacomitinib  Pfizer Irreversible EGFR Tyrosine 
Kinase (2
nd
 Generation) 
PF-04691502    Pfizer MTORC1, MTORC2, PI3K 
PF-05212384 PKI-587 Pfizer MTORC1, MTORC2, PI3K 
Ranpirnase Onconase  Tamir 
Biotechnology 
Ribonuclease enzyme 
Rapamycin Rapamune  Wyeth MTORC1 
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Pharmaceuticals 
Rofecoxib Vioxx ,Ceoxx  Merck COX-2 
Semaxanib SU5416 SUGEN VEGF Tyrosine Kinase 
SF1126  Semafore MTORC1, MTORC2, PI3K 
Sorafinib Nexavar  Bayer VEGF Tyrosine Kinase, 
PDGFR Tyrosine Kinase, Raf 
kinases 
SU11274     c-MET Tyrosine Kinase 
Temsirolimus CCI-779 Wyeth 
Pharmaceuticals 
MTORC1 
Thalidomide     VEGF 
Valproic acid     HDAC 
Vatalanib PTK787, 
PTK/ZK 
Bayer & Novartis VEGFR, PDGFR, c-kit 
Vorinostat Zolinza  Merck HDAC 
XL-147 SAR245408 Exelixis PI3K 
XL-765 SAR245409 Exelixis MTORC1, MTORC2, PI3K 
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Appendix E (List of antibodies in antibody microarray kit) 
Table E.1 List of antibodies in Panorama XPRESS Profiler725 antibody microarray Kit 
(Sigma Aldrich #XP725) 
ANTIBODY SIGMA No. 
14-3-  T5942 
Acetylated Protein A5463 
Actin A5060 
Actin A3853 
Actin, α-Smooth Muscle A5228 
β-Actin  A1978 
β-Actin  A2228 
-Actinin  A5044 
Actopaxin A1226 
AP2 A7107 
β1 and β2-Adaptins  A4450 
I-Afadin A0349 
AFX A8975 
AFX (FOXO4) A5854 
AKR1C3 A6229 
Aly A9979 
β-Amyloid  A8354 
Amyloid Precursor Protein, C-Terminal  A8717 
Amyloid Precursor Protein, N-Terminal  A8967 
Amyloid Precursor Protein, KPI Domain  A8842 
Androgen Receptor  A9853 
Annexin V  A8604 
Annexin VII  A4475 
Anti Cy3+Cy5 C0992 
AOP1  A7674 
AP-1 A5968 
AP-  A0844 
AP Endonuclease A2105 
Apaf1, N-Terminal  A8469 
Apoptosis Inducing Factor (AIF) A7549 
APRIL, Extracellular Domain A1726 
APRIL, Extracellular Domain 2 A1851 
ARC, C-Terminal  A8344 
ARNO (Cytohesin-2)  A4721 
 A5601 
ARP2 A6104 
ARP3 A5979 
ARTS A3720 
ARTS     A4471 
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ASAP1/Centaurin β4  A4227 
ASC-2 A5355 
ASPP1 A4355 
ASPP2 A4480 
ATF-1 A7833 
ATF2 A4086 
phospho-ATF-2 (pThr
69,71
)  A4095 
ATM A6093 
Anti Cy3+Cy5 C0992 
ATM A6218 
Aurora-B A5102 
BACE-1 B0806 
BACH1 B1310 
BAD B0559 
BAF57 B0436 
BAK B5897 
BAP1 B9303 
Bax B3428 
Bax B8429 
Bax B8554 
Bax B9054 
Bcl-10 B7806 
Prion protein P0110 
Bcl-10 B0431 
Seladin S4697 
Bcl-2 B9804 
Bcl-2 B3170 
Bcl-x B9304 
Bcl-xL  B9429 
BID B4305 
BID B3183 
Bim B7929 
Anti Cy3+Cy5 C0992 
CDK5 C6118 
Bmf, N-Terminal  B1684 
Bmf, C-Terminal  B1559 
BNIP3 B7931 
BOB.1/OBF.1 B7810 
Brg1/hSNF2β  B8184 
BTK, C-Terminal  B0811 
BTK, N-Terminal B0686 
BUB1 B0561 
BUBR1 B9310 
c-Abl  A5844 
c-Cbl   C9603 
c-erbB-2 E2777 
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c-erbB-3 E8767 
c-erbB-4 E5900 
phospho-c-Jun (pSer
63
) J2128 
phospho-c-Jun (pSer
73
)  J2253 
c-Myc M4439 
c-Myc C3956 
Uvomorulin/E-Cadherin  U3254 
N-Cadherin  C2542 
N-Cadherin  C2667 
Pan Cadherin C1821 
Anti Cy3+Cy5 C0992 
Calbindin-D-28K  C7354 
Calcineurin ( -Subunit) C1956 
Caldesmon C6542 
Calmodulin C7055 
Calnexin C4731 
Calponin    C2687 
Calreticulin C4606 
Calretinin C7479 
Claspin C7867 
CaM Kinase IV (CaMKIV)  C2851 
 C7099 
CaM Kinase IIα (CaMKIIα) C6974 
CaM Kinase IV (CaMKIV) C9973 
CASK/LIN2  C4856 
Casein Kinase 2β  C3617 
Caspase 2 C7349 
Caspase 3 C9598 
Caspase 3, Active C8487 
Caspase 4 C4481 
Caspase 4     C3392 
Caspase 5     C6979 
Caspase 6 C7599 
Caspase 7 C7724 
Anti Cy3+Cy5 C0992 
Caspase 7 C1104 
Caspase 8 C3101 
Caspase 8  C2976 
Caspase 8      C4106 
Pro-Caspase 8 C7849 
Caspase 9 C7729 
Caspase 9       C4356 
Caspase 10 C8351 
Caspase 10     C1229 
Caspase 11 C1354 
Caspase 12     C7611 
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Caspase 13 (ERICE) C8854 
Catalase C0979 
α-E-Catenin  C8114 
-N-Catenin C8239 
 C2081 
β-Catenin  C7207 
β-Catenin  C7082 
phospho-β-Catenin (pThr41) C8616 
phospho-β-Catenin (pSer33/pSer37)  C4231 
phospho-β-Catenin (pSer45) C5615 
phospho-β-Catenin (pSer33) C2363 
δ-Catenin/NPRAP  C4864 
Anti Cy3+Cy5 C0992 
Cathepsin D    C0715 
Cathepsin L C2970 
Caveolin-1 C3237 
CD40 C5987 
Cdc14A  C2238 
Cdc25c         C0349 
Cdc25A  C9479 
Cdc27         C7104 
Cdc6          C0224 
Cdc7 Kinase C6613 
Cdh1          C7855 
Cdk1
p34cdc2
 C4973 
Negative Control NA 
Cdk4    C8218 
Cdk6    C8343 
Cdk-7/cak   C7089 
TBP T1827 
CENP-E C7488 
Centrin C7736 
Chk1    C9358 
Chk2 C9108 
Chk2     C9233 
Chondroitin Sulfate  C8035 
Anti Cy3+Cy5 C0992 
Ciliated Cell Marker  C5867 
CIN85 C8116 
Casein Kinase 2α  C5367 
Clathrin Light Chain C1985 
Clathrin Heavy Chain C1860 
CNPase C5922 
Cofilin C8736 
Coilin C1862 
Collagen, Type IV C1926 
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Connexin 32 C3470 
Negative Control NA 
Connexin- 32  C6344 
Connexin- 43 C8093 
Connexin- 43 C6219 
β-COP    G6160 
Cortactin  C6987 
Corticotropin Releasing Factor  C5348 
COX II C9354 
Crk-L C0978 
Crk II C0853 
Csk  C7863 
CtBP1, N-Terminal  C9491 
CtBP1, C-Terminal  C8741 
Anti Cy3+Cy5 C0992 
CUG-BP1 C5112 
Cyclin A C4710 
Cyclin B1 C8831 
Cyclin D1  C5588 
Cyclin D1  C7464 
Cyclin D2  C7339 
Cyclin D3  C7214 
Cyclin H C5351 
Cystatin A       C3095 
Cytohesin-1  C8979 
Cytokeratin peptide 4 C5176 
Cytokeratin CK5  C7785 
Cytokeratin peptide 7 C6417 
Cytokeratin 8.12 C7034 
Cytokeratin 8.13 C6909 
Cytokeratin peptide 13 C0791 
Cytokeratin Peptide 17  C9179 
Cytokeratin peptide 18 C1399 
Cytokeratin peptide 19 C6930 
Pan Cytokeratin C2931 
DAPK           D2178 
phospho-DAPK  (pSer
308
) D4941 
DAP Kinase 2 D3191 
Anti Cy3+Cy5 C0992 
Daxx D7810 
DcR1 D3566 
DcR2 D3188 
DcR3 D1814 
DEDAF D3316 
Desmin D1033 
Desmosomal Protein D1286 
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Destrin/ADF  D8940 
Dnase I D0188 
Dnase II D1689 
DNMT1 D4567 
DNMT1 D4692 
DOPA Decarboxylase D0180 
DP2 D7438 
DR3 D3563 
Negative Control NA 
DR4 D3813 
DR5 D3938 
DR6 D1564 
DRAK1 D1314 
Dystrophin D8168 
Dystrophin  D8043 
E2F1 E9026 
Anti Cy3+Cy5 C0992 
E2F1 E8901 
E2F2 E8776 
E2F3 E8651 
E2F4 E8526 
E6AP E8655 
EGF receptor   E3138 
ERK5 (Big MAPK-BMK1) E1523 
Elastin E4013 
ELKS E4531 
Endothelial Cell Protein C Receptor  E6280 
Endothelial Cells  E9653 
Endothelin E0771 
Epidermal Growth Factor  E2520 
Episialin (EMA) E0143 
ERP57 E5031 
Estrogen Receptor  E0521 
Estrogen Receptor  E1396 
Exportin T E1531 
Ezrin E8897 
F1A F3428 
FADD F8053 
Focal Adhesion Kinase (pp125
FAK
)  F2918 
FAK Phospho (pSer
772
) F9051 
Anti Cy3+Cy5 C0992 
phospho-FAK Phospho (pSer
910
) F9301 
phospho-FAK (pTyr
397
) F7926 
phospho-FAK (pTyr
577
) F8926 
Falkor/PHD1  F5303 
Fas (CD95/Apo-1) F4424  
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Fas Ligand F2051  
Fas Ligand F1926  
FBI-1/PAKEMON F9429 
Fibroblast Growth Factor-9 F1672 
Fibronectin F0791 
Fibronectin F3648 
Fibronectin    F7387 
Filamin F1888 
Filensin F1043 
FKHR (FOXO1a) F6928 
FKHRL1 (FOXO3a) F2178 
FKHRL1 (FOXO3a) F1304 
FLIPγ/δ, C-Terminal  F9925 
FOXC2 F1054 
FOXP2 F6304 
FANCD2 F0305 
FXR2 F1554 
FRS2 (SNT-1)  F9052 
Anti Cy3+Cy5 C0992 
G9a Methyltransferase G6919 
Glutamic Acid Decarboxylase 65 (GAD 
65)  
G4913 
Glutamic Acid Decarboxylase 65 (GAD 
65)  
G5038 
Glutamic Acid Decarboxylase (GAD65/67) G5163 
GADD 153 (CHOP-10) G6916 
GAP1
IP4BP
 G6666 
GAPDH G8795 
GATA-1 G0290 
Gelsolin G4896 
Gemin 2 G6669 
Gemin 3 G6544 
GFAP (Glial Fibrillary Acidic Protein)  G9269 
GFAP (Glial Fibrillary Acidic Protein)  G3893 
Growth Factor Independence-1 (GFI) G6670 
Glutamate receptor NMDAR 2a G9038 
Glutamine Syntethase G2781 
Glycogen Synthase Kinase-3β (GSK-3β)  G7914 
Glycogen Synthase Kinase-3 (GSK-3) G4414 
Glycogen Synthase Kinase-3 (GSK-3) G6414 
Granzyme B G1044 
Grb-2 G2791 
GRK 2 G7670 
GRP1 G6541 
Anti Cy3+Cy5 C0992 
GRP 75 G4170 
GRP78/BiP  G8918 
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GRP94 G4420 
hABH1 A8103 
hABH2 A8228 
hABH3 A8353 
hBRM/hSNF2α  H9787 
HAT1 ( Histone acetyltransferase 1) H7161 
HDAC-1  H3284 
HDAC-1  H6287 
HDAC-2 H3159 
HDAC-2 H2663 
HDAC-3 H6537 
HDAC-3 H3034 
HDAC-4 H9411 
HDAC-4  H9536 
Negative Control NA 
HDAC-5 H4538 
HDAC-5 H8163 
HDAC-6 H2287 
HDAC-7 H2537 
HDAC-7 H6663 
HDAC-8 H6412 
Anti Cy3+Cy5 C0992 
HDAC-10 H3413 
HDAC-11 H2913 
HDRP/MITR H9163 
Heat Shock Factor 1  H4163 
Heat Shock Factor 2  H6788 
Heat Shock Protein 25  H0148 
Heat Shock Protein 27  P1498 
Heat Shock Protein 27/25  H2289 
Heat Shock Protein 70     H5147 
Heat Shock Protein 90   H1775 
Heat Shock Protein 110  H7412 
Heat Shock Protein 110  H7287 
Acetyl Histone H3 (Ac-Lys
9
) H9286 
Acetyl Histone H3 (Ac-Lys
9
) H0913 
Acetyl- & phospho-Histone H3 (Ac-Lys
9
, 
Ser
10
) 
H9161 
Acetyl- & phospho-Histone H3 (Ac-Lys
9
, 
Ser
10
) 
H0788 
Dimethyl Histone H3 (diMe-Lys
4
) D5692 
Dimethyl Histone H3 (diMe-Lys
9
) D5567 
methyl-Histone H3 (Me-Lys
9
) H7162 
phospho-Histone H2AX (pSer
139
)  H5912 
phospho-Histone H3 (pSer
10
)  H6409 
phospho-Histone H3 (pSer
28
)  H9908 
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phospho-Histone H3 (pSer
10
)  H0412 
Anti Cy3+Cy5 C0992 
SUV39H1 Histone Methyl Transferase S8316 
HMG-1 H9537 
hMps1 M5818 
hnRNP-A1  R4528 
hnRNP-A1  R9778 
hnRNP-A2/B1  R4653 
hnRNP-C1/C2  R5028 
hnRNP-K/J  R8903 
hnRNP-L R4903 
hnRNP-Q  R5653 
hnRNP-U R6278 
hnRNP M3-M4         R3777 
hPlk1  P5998 
hPlk1  P6123 
hSNF5/INI1 H9912 
iASPP A4605 
IFI-16  I1659 
 I0505 
 I6139 
ILK I0783 
ILK I1907 
ILP2 I4782 
Negative Control NA 
Anti Cy3+Cy5 C0992 
Importin-  I9658 
Importin-  I9783 
Importin-  I9908 
INCENP I5283 
ING1 I3659 
-Internexin  I0282 
JAB 1 J3395 
JAB 1 J3020 
JAK 1 J3774 
c-Jun N-Terminal Kinase  J4500 
JNK, Activated (Diphosphorylated JNK) J4750 
KCNK9 (TASK-3) K0514 
Kaiso K4263 
KIF17 K3638 
KIF3A K3513 
KSR      K4261 
Ku Antigen  K2882 
L1CAM L4543 
l/s-Afadin  A0224 
Laminin L9393 
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Laminin- -2 Chain) L0663 
LAP2 (TMPO) L3414 
Leptin L3410 
Anti Cy3+Cy5 C0992 
LIM Kinase 1 L2290 
LIN-7 L1538 
LIS1 L7391 
LKB1 L7917 
LDS1 L4793 
Mad1 M8069 
Mad2 M8694 
MADD M5683 
MAFF M8194 
MAGI-1 M5691 
MAGI-2 M2441 
MAP Kinase, 
Activated/Monophosphorylated 
(Phosphothreonine ERK-1&2) 
M7802 
MAP Kinase, Monophosphorylated 
Tyrosine  
M3682 
MAP Kinase, Activated (Diphosphorylated 
ERK-1&2)  
M9692 
MAP Kinase, Monophosphorylated 
Threonine  
M3557 
MAP Kinase (ERK-1)  M7927 
MAP Kinase (ERK1+ERK2) M5670 
MAP Kinase Activated Protein Kinase-2 
(MAPKAPK-2)  
M3550 
MAP Kinase Phosphatase-1 (MKP-1) M3787 
MAPK non phosphorylated ERK M3807 
MAP Kinase 2 (ERK-2)  M7431 
MAP Kinase Kinase (MEK, MAPKK)  M5795 
MAP2 (2a+2b) M2320 
Anti Cy3+Cy5 C0992 
MAP1 M4278 
MAP1 (Light Chain) M6783 
MAP1b M4528 
MAP2 M9942 
MBD1 M6569 
MBD2a M7568 
MBD2a,b M7318 
MBD4 M9817 
MBDin/XAB1  M1944 
MBNL 1 M3320 
MCH M8440 
Mcl-1 M8434 
MDC1 M2444 
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MDM2 M8558 
MDM2 M4308 
MDM2   M7815 
MDMX M0445 
MeCP2 M9317 
MeCP2 M7443 
MeCP2 M6818 
MEKK4 M7194 
Melanocortin-3 Receptor  M4937 
MGMT M3068 
Anti Cy3+Cy5 C0992 
Mint2 M3319 
LRRK2 (PARK8) L3044 
MRP1 M9192 
MRP2 M3692 
-MSH  M0939 
MSH6 M2445 
MSH6 M2820 
MSK-1 M5437 
MTA 2 M7569 
MTA1 M1320 
MTA1 M7693 
MTA2/MTA1L M7818 
MTA3L M0819 
MTBP M3566 
mTOR T2949 
Munc-18-1 M2694 
Munc-13/1 M6194 
MyD88 M9934 
Myosin M1570 
Myosin Iβ (Nuclear)  M3567 
Myosin IIA M8064 
Myosin IX/Myr5  M5566 
Negative Control NA 
Anti Cy3+Cy5 C0992 
Myosin Light Chain Kinase M7905 
Myosin Va M4812 
Myosin Va  M5062 
Myosin VI  M0691 
Myosin VI  M5187 
NBS1 (Nibrin) N9287 
NBS1 (Nibrin) N3037 
NBS1 (Nibrin) N3162 
Nck-2 N2911 
Nedd 8     N2786 
Nerve Growth Factor-β  N3279 
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Nerve Growth Factor Receptor N5408 
Nerve growth factor receptor (NGFR p75) N3908 
Neurabin I  N4412 
Neurabin II (C-terminal)  N5037 
Neurabin-II  N5162 
Neurofibromin N3662 
Neurofilament 160  N2787 
Neurofilament 200 N4142 
Neurofilament 200 N0142 
Neurofilament 200  N5389 
Neurofilament 68  N5139 
Neurofilament 160/200 N2912 
Anti Cy3+Cy5 C0992 
NF-  N8523 
-Activating Kinase)  N2661 
NG2  N8912 
Nicastrin N1660 
Nitric Oxide Synthase, Brain (b-NOS)  N2280 
Nitric Oxide Synthase, Brain (b-NOS)  N7155 
Nitric Oxide Synthase, Endothelial ( e-
NOS) 
N9532 
Nitric Oxide Synthase, Endothelial ( e-
NOS) 
N3893 
Nitric Oxide Synthase, Endothelial ( e-
NOS) 
N2643 
Nitric Oxide Synthase, Inducible (i-NOS)  N7782 
Nitric Oxide Synthase, Inducible (i-NOS)  N9657 
Notch1 N6786 
Nitrotyrosin N0409 
NTF2         N9527 
Nuf2  N5287 
O-GlcNAc Transferase  O6264 
OP-18/Stathmin  O0138 
Ornithine Decarboxylase (ODC) O1136 
p115/TAP  P3118 
p120
ctn
 P1870 
p130
CAS
 C0354 
p14
 arf 
  P2610 
p16
INK4a/CDKN2
      P0968 
Anti Cy3+Cy5 C0992 
p19
INK4d
 P4354 
p21WAF1/Cip1 
 
 P1484 
p300/CBP P2859 
p34
cdc2  
 C3085 
p35 (Cdk5 Regulator) P9489 
p38 MAP Kinase, Non-Activated  M8432 
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p38 MAPK M0800 
p38 MAPK activated (diphosphorylated 
p38)  
M8177 
Negative Control NA 
p53 P5813 
p53 P6874 
phospho-p53 (pSer
392
)  P8982 
p53DINP1/SIP P4868  
p53R2l P4993 
p53 BP1 B4561 
p53 BP1 B4436 
p57
kip2     
 P2735 
p63 P3362 
p63         P3737 
PABP P6246 
PAD14 P4749 
phospho-PAK1 (pThr
212
) P3237 
Par-4 (Prostate Apoptosis Response-4) P5367 
Anti Cy3+Cy5 C0992 
 P5746 
Parkin P6248 
PARP P7605  
Paxillin P1093 
PCAF  P7493 
Proliferating Cell Nuclear Antigen (PCNA) P8825 
PDK 1 P3110 
Pen-2  P5622 
Peripherin P5117 
Peroxiredoxin 3 P1247 
PERP P5243 
Phospholipase A2 group V P5242 
Phosphoserine     P5747 
Phosphothreonine   P6623 
Phosphotyrosine    P1869 
 P8104 
PhosphatidylSerine Receptor (PSR)  P1495 
Negative Control NA 
PIAS-x  P9498 
Negative Control NA 
PINCH-1 P9371 
 P2482 
 P1601 
Anti Cy3+Cy5 C0992 
phospho-PKB (pSer
473
) P4112 
phospho-PKB (pThr
308
) P3862 
Protein Kinase C (PKC)  P5704 
305 
 
 P4334 
Protein Kinase Cβ1  P3078 
Protein Kinase Cβ1  P6959 
Protein Kinase Cβ2  P3203 
Protein Kinase Cβ2  P2584 
 P8083 
Protein Kinase Cδ  P8333 
Protein Kinase Cε  P8458 
Protein Kinase Cζ  P0713 
Protein Kinase Cη  P8090 
Protein Kinase D P3987 
PKR P0244 
 P8087 
Platelet-Derived Growth Factor Receptor β  P7679 
Plectin P9318 
PML P6746 
Presenilin-1 (S182) P7854 
Prion Protein  P5999 
PRMT1 P6871 
PRMT1 P6996 
Anti Cy3+Cy5 C0992 
PRMT2  P0748 
PRMT3 P9370 
PRMT4 P4995 
PRMT5 P0493 
PRMT6 P6495 
PRMT6 P2996 
Proliferating Cell Protein Ki-67  P6834 
 P7979 
 P7607 
 P8998 
Protein S P4555 
Protein Tyrosine Phosphatase PEST  P9109 
PSF P2860 
PTEN P7482 
PTEN  P3487 
PUMA/bbc3, C-Terminal P4618  
PUMA/bbc3, N-Terminal P4743  
Pyk2 P3902 
AP2 beta  
phospho-Pyk2 (pTyr
579/580
) P6989 
  
Negative Control NA 
Rab5 R7904 
Anti Cy3+Cy5 C0992 
Rab 7 R8779 
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Rab9 R5404 
RAD1 R5029 
Rad17 (C-terminal)  R8029 
Raf-1/c-Raf  R2404 
Raf-1 R5773 
phospho-c-Raf (pSer
621
) R1151 
RAIDD, Internal Domain  R9775 
RAIDD R5275 
RALAR R8529 
Ran            R4777 
PIASy P0104 
RAP1 R8154 
RbAp48/RbAp46  R3779 
Reelin R4904 
Retinoblastoma R6775 
phospho-Retinoblastoma (pSer
795
)  R6878 
RhoE R6153 
RICK, C-Terminal  R9650 
RIP (Receptor Interacting Protein) R8274 
RNase L R3529 
ROCK-1 R6028 
ROCK-2 R8653 
Anti Cy3+Cy5 C0992 
Rsk1             R5145 
S-100 S2644 
S- -Subunit) S2407 
S-100 (β-Subunit)  S2532 
S-Nitrosocysteine  N5411 
S6 Kinase  S4047 
SAPK3        S0315 
β)  S3396 
Serine/Threonine Protein Phosphatase 2 
A/A  
P8109 
Serine/Threonine Protein Phosphatase 1β  P7484 
 P7609 
Serine/Threonine Protein Phosphatase 2 
 
P5359  
Serine/Threonine Protein Phosphatase 2 
A/B′ pan2  
P8359 
Serine/Threonine Protein Phosphatase 2C 
 
P8609 
AP2 gamma A3108 
SGK  S5188 
SH-PTP2 (SHP-2)      S3056 
Siah2  S7945 
Sin3A, N-terminal  S4445 
Sin3A, C-Terminal  S6695 
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Sir2 S5313 
-1)  S1311 
Sirt1  S5196 
Anti Cy3+Cy5 C0992 
SKM1 (Skeletal Muscle Type 1) S9568 
Beta tubulin III (neuronal)  
SLIPR/MAGI-3  S1190 
SLIPR/MAGI-3 S4191 
Smad4 (DPC4)  S3934 
SMC1L1 S6446 
SMN  S2944 
-SNAP, C-terminus  S9444 
SNAP-23  S2194 
SNAP-25 S9684 
SNAP- 29 S2069 
Sos1    S2937 
Sp1 S9809 
Spred-2 S7320 
Striatin S0696 
Substance P Receptor  S8305 
SMAC/Diablo S0941 
SUMO-1 S8070 
SUMO-1 (C-terminal) S5446 
Survivin  S8191  
Synaptotagmin S2177 
Synaptopodin S9442 
Synaptopodin  S9567 
Anti Cy3+Cy5 C0992 
SynCAM S4945 
 S4688 
 S4813 
Syntaxin S0664 
Syntaxin 6 S9067 
Syntaxin 8 S8945 
-Synuclein  S3062 
Negative Control NA 
Tal  T1075 
Tal  T1200 
TAP T1076 
Tau  T9450 
phospho-Tau (pSer
199/202
)  T6819 
Tau T5530 
Tenascin T2551 
Thimet Oligopeptidase 1 T7076 
TIS7 T2576 
Tumor Necrosis Factor Soluble T1815 
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Receptor II  
Tob T2948 
TOM22 T6319  
Topoisomerase-I  T8573 
TRAIL T3067 
TRAIL T9191 
Anti Cy3+Cy5 C0992 
Transforming Growth Factor-β, pan  T9429 
Transportin 1 T0825 
TRF1        T1948 
Tropomyosin T2780 
Tropomyosin (Sarcomeric) T9283 
Tryptophane Hydroxylase T0678 
TSG101 T5826 
 T6074 
 T6199 
-Tubulin T5201 
β-Tubulin I T7816 
-Tubulin I+II T8535 
-Tubulin III T5076 
β-Tubulin IV  T7941 
 T5326 
 T3559 
-Tubulin T3320 
ε-Tubulin  T1323 
Tubulin, Polyglutamylated  T9822 
Tubulin, Tyrosine T9028 
Tumor Necrosis Factor-  T8300  
Tumor Necrosis Factor-  T2824 
Nanog N3038 
Anti Cy3+Cy5 C0992 
TWEAK Receptor/Fn-14  T9700 
Tyrosin hydroxylase T2928 
U2AF
65
 U4758 
Ubiquitin U0508 
Ubiquitin C-terminal Hydrolase L1  U5133 
Ubiquitin C-terminal Hydrolase L1  U5258 
Pinin P0084 
Vanilloid Receptor-1 V2764 
VDAC/Porin V2139 
Vascular Endothelial Growth Factor 
Receptor-1 (VEGFR-1)  
V4762 
Vesicular GABA Transporter  V5764 
VGLUT 1 V0389 
VGLUT 2 V2639 
Vimentin V6389 
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Vinculin V4505 
Vitronectin V7881 
WAVE W0392 
WSTF  W3516 
Y14 Y1253 
ZAP-70  Z0627 
Zip Kinase  Z0134 
Zyxin Z0377 
GAPDH G8795 
Anti Cy3+Cy5 C0992 
 
